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Abstract
The synthesis of alpha-aryl, -alkenyl, and -alkynyl esters and amides has been extensively investigated over the
past decade because of the prevalence of these substructures within the cores of molecules of biological
instance, namely non-steroidal anti-inflammatory drugs (NSAIDs) and analgesics. New methods were
developed that employ potassium organotrifluoroborate salts to overcome the drawbacks of previously
reported approaches, such as lack of functional group compatibility and the necessity for an organometallic
species that must be formed under low temperature, inert conditions. Optimization was carried out to
determine ideal catalysts, ligands, bases, and solvents for each of the desired transformations, leading to the
development of conditions for the cross-coupling of 2-chloroacetates and 2-chloroacetamides with aryl-,
heteroaryl-, alkenyl-, and alkynyltrifluoroborates. The developed methods boast enhanced functional group
compatibility and expand the scope of the electrophilic components compared to previous protocols.
Significant interest has recently emerged in the synthesis of sp2-sp3 bonds involving non-aromatic
heterocyclic structures. Interestingly, while sp2-sp3 coupling methods are known, many of the existing
protocols are either completely ineffective or extremely low-yielding for secondary alkyl substrates containing
heteroatoms. Conditions were developed that allowed a variety of substituted aryl and heteroaryl bromides to
be cross-coupled reductively with piperidinyl, tetrahydropyranyl, pyrrolidinyl, tetrahydrofuranyl, azetidinyl,
and oxetanyl bromides. The developed method utilizes bench-stable components under conditions that are
tolerant of numerous functional groups, which is compatible with late-stage incorporation of saturated
heterocyclic structures into larger molecules of interest. The reductive protocol was expanded to allow alkyl
tosylates of nonaromatic heterocyclic systems to participate as coupling partners with aryl and heteroaryl
bromides. This development allows the use of bench stable, crystalline solids that can be prepared from
inexpensive, commercially available alcohols.
2,1-Borazaronaphthalenes have received a significant amount of attention because of their potentially
impactful properties in the fields of pharmaceuticals and materials science. Based on conditions established
for the reductive coupling of non-aromatic heterocyclic bromides with aryl bromides, the cross-coupling of
non-aromatic heterocyclic halides with 2,1-borazaronaphthalenes was explored. Conditions were developed
that allow reductive cross-coupling of alkyl iodides with a variety of 3- bromo-2,1-borazaronaphthalenes. This
method provides a valuable, direct route to alkylated, functionalized azaborine systems.
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ABSTRACT 
 
CROSS COUPLING OF SP3 CENTERS VIA TRADITIONAL 
AND REDUCTIVE METHODS 
Kaitlin M. Traister 
Gary A. Molander 
 
          The synthesis of α-aryl, α-alkenyl, and α-alkynyl esters and amides has been 
extensively investigated over the past decade because of the prevalence of these 
substructures within the cores of molecules of biological instance, namely non-steroidal 
anti-inflammatory drugs (NSAIDs) and analgesics. New methods were developed that 
employ potassium organotrifluoroborate salts to overcome the drawbacks of previously 
reported approaches, such as lack of functional group compatibility and the necessity for 
an organometallic species that must be formed under low temperature, inert conditions. 
Optimization was carried out to determine ideal catalysts, ligands, bases, and solvents for 
each of the desired transformations, leading to the development of optimized conditions 
for the cross-coupling of 2-chloroacetates and 2-chloroacetamides with aryl-, heteroaryl-, 
alkenyl-, and alkynyltrifluoroborates. The developed methods boast enhanced functional 
group compatibility and expand the scope of the electrophilic components compared to 
previous protocols. 
 
 
vii 
   
          A great deal of interest has recently emerged in the synthesis of sp2-sp3 bonds 
involving non-aromatic heterocyclic structures. Interestingly, while sp2-sp3 coupling 
methods are known, many of the exisiting protocols are either completely ineffective or 
extremely low-yielding for secondary alkyl substrates containing heteroatoms. 
Conditions were developed that allowed a variety of substituted aryl and heteroaryl 
bromides to be cross-coupled reductively with piperidinyl, tetrahydropyranyl, 
pyrrolidinyl, tetrahydrofuranyl, azetidinyl, and oxetanyl bromides. The developed method 
utilizes bench-stable components under conditions that are tolerant of numerous 
functional groups, which is compatable with late-stage incorporation of saturated 
heterocyclic structures into larger molecules of interest. The reductive protocol was 
expanded to allow alkyl tosylates of nonaromatic heterocyclic systems to participate as 
coupling partners with aryl and heteroaryl bromides. This development allows the use of 
bench stable, crystalline solids that can be prepared from inexpensive, commercially 
available alcohols.  
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          2,1-Borazaronaphthalenes have received a significant amount of attention because 
of their potentially impactful properties in the fields of pharmaceuticals and materials 
science. Based on conditions established for the reductive coupling of non-aromatic 
heterocyclic bromides with aryl bromides, the cross-coupling of non-aromatic 
heterocyclic halides with 2,1-borazaronaphthalenes was explored. Conditions were 
developed that allow the reductive cross-coupling of alkyl iodides with a variety of 3-
bromo-2,1-borazaronaphthalenes. This method provides a valuable, direct route to 
alkylated, functionalized azaborine systems.  
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Chapter 1: Metal-Catalyzed C-C Bond Formation  
 
1.1 Introduction to Traditional Metal-Catalyzed Cross-Coupling Reactions 
          Although for many years after its initial discovery in 1802, palladium was not 
considered valuable,1 the metal has transformed catalytic chemistry over the past century. 
By the early 1900s, copper and cobalt were beginning to be used for carbon-carbon bond-
forming reactions, although their use in a catalytic fashion was not widespread. It was not 
until the 1960s that palladium was used for coupling chemistry, and even then, its 
applications were seemingly limited to Heck-type couplings2–4 and hydrogenations of 
unsaturated compounds.5 In the mid-1970s, palladium began to emerge as a transition-
metal catalyst capable of effecting various carbon-carbon bond-forming processes.  
 Various types of organometallic reagents were explored in palladium-catalyzed 
cross-coupling reactions over the next several decades. Development of the Kumada,6,7 
Negishi,8,9 and Stille reactions10,11 highlighted the use of catalytic palladium in cross-
couplings involving organomagnesium, organozinc, and organostannane reagents, 
respectively. Each of these couplings illustrated carbon-carbon bond formation between 
an organic halide and a pregenerated organometallic reagent (Scheme 1.1). Although the 
development of these Pd-catalyzed protocols represented significant advancements in the 
realm of cross-coupling, the organometallic reagents were typically quite sensitive to air 
and moisture.12 
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Scheme 1.1: Pd-Catalyzed Cross-Coupling Reactions  
 
 
Soon after the discovery of Pd-catalyzed cross-couplings of Mg, Zn, and Sn 
reagents, it was discovered that organoborons were able to serve as partners in a similar 
transformation. In 1979, Suzuki and Miyaura reported the first cross-coupling of an 
alkenylboron reagent with an aryl halide in the presence of catalytic palladium (Equation 
1.1).13  
 
Equation 1.1:  
 
 The discovery of organoborons as suitable cross-coupling partners under Pd-
catalysis spurred the preparation of myriad organoboron compounds that addressed 
several limitations persistent in coupling chemistry, such as air-sensitivity of 
organometallic reagents and toxicity concerns associated with waste disposal.  
R1 + R2
Pd(0)
R1 R2
M = Mg, Kumada (1975)
    = Zn, Negishi (1976)
    = Sn, Stille (1976)
X M
n-Bu
B Br
n-Bu
O
O +
98% yield
Pd(PPh3)4 (1 mol %)
NaOEt/EtOH
benzene
4 h, reflux
 
 
3 
 Although each of the aforementioned Pd-catalyzed cross-coupling reactions 
utilizes a different organometallic reagent, all go through a common catalytic pathway 
(Figure 1.1).14 The catalytic cycle begins with a Pd(0) species, which can be generated 
from reduction of a Pd(II) species in situ. An aryl halide undergoes oxidative addition to 
the ligated Pd(0) to generate an Ar-Pd-X species. The organometallic reagent then 
participates in a transmetalation event, in which the organic portion is transferred to the 
Pd(II) complex to generate a ligated Ar-Pd-R species, where R can be an aryl, alkenyl, 
alkynyl, or alkyl group. Reductive elimination from Pd(II) generates the C-C bond of the 
product and reduces the catalyst back to Pd(0), which can re-enter the catalytic cycle.  
 
 
Figure 1.1: General Catalytic Cycle for Pd-Catalyzed Cross-Couplings 
Pd(0)
Ar-X
LnPd
R-M
Ar
X
LnPd
Ar
R
M-X
Ar-R
oxidative addition
transmetalation
reductive elimination
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Each type of cross-coupling reaction requires optimization of various parameters 
to ensure productive catalytic turnover. Challenges arise because of conflicting electronic 
and steric requirements for each step of the cycle. Oxidative addition proceeds most 
readily with electron-deficient arenes, whereas electron rich organic moieties undergo 
transmetalation most easily. The reductive elimination step is promoted by steric bulk 
around the Pd center, but this can also serve to hinder the transmetalation.  As a result, 
the choice of ligand can be quite important for the fine-tuning of challenging couplings, 
as can the choice of base and solvent.  
 
1.2 Development and Advances of Suzuki-Miyaura Cross-Couplings 
Boron reagents that were employed in early examples of Suzuki-Miyaura cross-
couplings were those that could be accessed from hydroboration of alkynes, namely 
alkenylboranes and alkenyl catechol boronates.13,15 A commonly used borane reagent for 
cross-couplings, 9-BBN (9-borabicyclo[3.3.1]nonane) (Figure 1.2, 1) suffers from the 
same major drawbacks as other BR3 species, which include instability in air and 
propensity toward protodeboronation.16 Boronic acids represent a class of boron reagents 
bearing two hydroxyl groups on the boron atom (Figure 1.2, 4). These substrates can 
typically be handled in air, but protodeboronation can occur slowly over time, depending 
on the nature of the R group. These reagents have excellent atom economy, but because 
they lack any sort of protecting group, they are entropically driven to exist in an 
anhydrous trimeric form (boroxine), making their stoichiometry often unpredictable.  
 
 
5 
Boronates are structures of the formula R1B(OR2)2, where R2 is typically a cyclic 
hydrocarbon; two commonly utilized subclasses are catechol- and pinacol-boronates 
(Figure 1.2, 2 and 3).  Electron rich alkyl groups on boronates allow greater donation of 
electron density from the oxygen atoms into the empty p orbital on boron, adding to the 
stability of these structures. Boronates possess an advantage over boronic acids in their 
stability to column chromatography and predictable monomeric form.  
 
 
Figure 1.2: Organoboron Reagents Employed in Cross-Coupling Reactions 
 
 Alternative boron reagents have been developed that have tetrahedral geometry as 
a result of an additional bond or coordination to the boron atom. Organotriolborates17 and 
MIDA boronates18 (Figure 1.2, 5 and 7) possess added stability compared to their 
corresponding boronic acids and are crystalline solids that can be handled in air without 
decomposition. Both of these classes of compounds can undergo cross-coupling under 
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aqueous conditions, which serve to unmask a reactive boron species. Unfortunately, these 
reagents display poor atom economy, because unveiling of the trivalent boron species 
requires waste of a rather large protecting group in both cases.  
A class of reagents that embodies both increased stability compared to boronic 
acids as well as favorable atom economy is that of potassium organotrifluoroborates 
(Figure 1.2, 6). These tetracoordinate salts are air- and moisture-stable, free-flowing 
powders that can be stored indefinitely on a bench without decomposition. Boronic acids 
or boronates can be readily converted to potassium trifluoroborate salts through treatment 
with aqueous KHF2 (Scheme 1.2).19 Additionally, a more recently developed protocol for 
the preparation of organotrifluoroborate salts uses tartaric acid and KF to avoid etching of 
glassware.20 Although organotrifluoroborates suffer from the limitation of not being 
stable to column chromatography, they can be isolated through crystallization techniques, 
which is desirable for large-scale preparation.  
 
Scheme 1.2: Conversion of Boronic Acids and Esters to Potassium 
Organotrifluoroborates  
 
 
OH
B
OH
R BR
O
O
or
aq. KHF2 (4.5 M, 3.3 equiv)
MeOH
or
R BF3KKF (4 equiv)
tartaric acid (2.05 equiv)
MeCN, THF, H2O
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 Because of their stability to a variety of reaction conditions, potassium 
organotrifluoroborates remain intact through many organic transformations, allowing 
their orthogonal reactivity within a substrate. Under basic, aqueous conditions, 
organotrifluoroborates are slowly hydrolyzed to their corresponding boronic acids. Rates 
of this hydrolysis are substrate-dependent, and significant exploration into the fine-tuning 
of this process has taken place.21–23 In a cross-coupling catalytic cycle, the rate of  
“deprotection” of an organotrifluoroborate to a species capable of transmetalation must 
be carefully controlled to minimize concentrations of unstable boron species. 
Extensive research has been carried out to determine the transmetalation pathway 
for organotrifluoroborates in the Suzuki-Miyaura reaction.24,25 Although it had been 
determined that basic, aqueous conditions are effective for the hydrolysis of an 
organotrifluoroborate to the corresponding acid, the role of base was determined to play a 
more complex role within the Suzuki-Miyaura reaction. Experiments have illustrated that 
even after the hydrolysis to the boronic acid is complete, the presence of hydroxide is 
necessary for the cross-coupling to occur. A ligated Ar1-Pd-X complex was isolated and 
stirred with an arylboronic acid in DMF at room temperature in both the presence and 
absence of hydroxide (Scheme 1.3). The coupled product was only observed in the 
presence of excess base, leading to the conclusion that hydroxide is required for the 
formation of cross-coupled product.  
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Scheme 1.3: Base Dependence of Transmetalation of Arylboronic Acids to a Pd 
Complex 
 
 
 
 To explore this phenomenon further, a ligated Ar1-Pd-OH complex was isolated 
and exposed to an arylboronic acid in the absence of excess base. In this case, the desired 
biaryl coupling product was observed. However, preparation of a ligated Ar1-Pd-Ar2 
complex did not undergo reductive elimination in the absence of base (Scheme 1.4).  
 
Scheme 1.4: Transmetalation and Reductive Elimination Experiments for 
Arylboronic Acids in the Presence of a Pd Complex 
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 These experiments led to the hypothesis that the hydroxide ion  plays several 
distinct roles in the Suzuki-Miyaura reaction: (1) formation of Ar-Pd-OR from Ar-Pd-X, 
which aids in transmetalation because of the favored oxophilicity of boron, (2) hydrolysis 
of the organotrifluoroborate to the corresponding R-B(OR)2, and (3) promotion of 
reductive elimination from Ar1-Pd-Ar2 by formation of a pentacoordinate complex. It was 
observed that transmetalation did not occur in the presence of a large excess of 
hydroxide, suggesting an additional role of base is the formation of a tetracoordinate 
boron species that is unreactive within the catalytic cycle.  
Although four different possibilities were initially considered for the 
transmetalation of arylboron species to Pd (Figure 1.3), several can be ruled out from the 
experimental findings. Because excess base inhibited the coupling by removing the 
arylboron moiety from the catalytic cycle as an inactive species, both (3) and (4) were 
ruled out as possible pathways for the transmetalation. Because the arylboronic acid did 
not react with a preformed Ar-Pd-X species in the absence of base, pathway (1) was also 
ruled out. It is therefore presumed that the transmetalation proceeds through pathway (2). 
In this scenario, transmetalation occurs through a four-membered transition state from a 
trivalent R-B(OR’)2 species to an Ar-Pd-OR complex.22 
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Figure 1.3: Possible Scenarios for the Transmetalation of an Arylboronic Acid to a 
Pd Complex 
 
 The catalytic cycle for the Suzuki-Miyaura cross coupling of an 
organotrifluoroborate is depicted in Figure 1.4. Beginning with an organotrifluoroborate, 
aqueous, basic conditions convert the trifluoroborate salt into a trivalent boron species. 
The resulting boron species transmetalates onto an Ar-Pd-OH complex. The presence of 
hydroxide allows the formation of a pentacoordinate Pd complex, from which reductive 
elimination can readily occur to generate the product and regenerate Pd(0).  
 
 
Figure 1.4: Suzuki-Miyaura Cross-Coupling Catalytic Cycle  
Ar1Pd X
Ar2 B
OH
OH
Ar1Pd OH
Ar2 B
OH
OH
Ar1Pd OH
Ar2 B
OH
OH
Ar1Pd X
Ar2 B
OH
OH
OH OH
(1) (2) (3) (4)
R BF3K
H2O, baseR B(OR)2
Pd(0)
Ar-X
LnPd
Ar
X
LnPd
Ar
R
Ar-R
oxidative addition
transmetalation
reductive elimination
LnPd
Ar
OH
B(OR)3
hydrolysis
PdAr
R
L L
OH
via
 
 
11 
 The investigation into the mechanism of Suzuki-Miyaura cross-couplings has 
been paramount in the understanding of base optimization for this class of reactions. It is 
now clear that the addition of base under aqueous conditions is essential, but the addition 
of a significant excess can directly hinder reaction progress by removing one of the 
coupling partners from the reactive catalytic cycle. The base must be carefully optimized 
to allow the formation of an R-Pd-OH complex without forcing hydrolysis of the 
organotrifluoroborate to the corresponding boronic acid too quickly. In this case, if 
production of the boronic acid occurs faster than catalytic turnover, the potentially 
unstable substrate accumulates and can begin to degrade under the reaction 
conditions.21,22  
 Within the realm of the Suzuki-Miyaura reaction and other Pd-catalyzed cross-
couplings, the importance of ligands has begun to be realized as a means for overcoming 
limitations of existent protocols. The tunable nature of phosphine ligands in terms of 
steric and electronic properties has been explored, and a variety of new ligand classes has 
emerged. The Buchwald group prepared a variety of biaryl phosphines that possess 
favorable properties for promoting challenging cross-couplings of organoboron structures 
(Figure 1.5, 1).26–28 This class of ligands has been designed to possess bulky alkyl 
substituents on the aryl rings to ensure monoligation of an electron-rich phosphine onto 
palladium. Diadamantyl phosphine ligands are noteworthy for their large cone angles, 
and they have been used successfully in cross-couplings of aryl chlorides with 
arylboronic acids (Figure 1.5, 3).29 The use of ferrocene-based phosphine ligands (Figure 
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1.5, 2) was found to promote Pd-catalyzed aminations of aryl halides and 
pseudohalides.30 
 
 
Figure 1.5: Recently Developed Ligand Classes for Cross-Coupling Reactions 
 
In addition to advances in ligand development, progress has been made in the 
preparation of Pd sources that are air- and moisture-stable and capable of rapid formation 
of an active Pd(0) species upon exposure to basic reaction conditions.31 Three generations 
of amine-based palladacycles, developed by the Buchwald group, can be prepared with 
various phosphine ligands (Figure 1.6).32–34 In the presence of base, reductive elimination 
occurs to furnish a ligated Pd(0) species that can enter directly into the catalytic cycle. 
These catalysts are advantageous in that, unlike Pd(0) sources, they can be stored outside 
of a glovebox and are not degraded upon exposure to air or moisture. However, unlike 
other Pd(II) sources, they do not require an activation period to allow reduction to Pd(0) 
before the active catalyst is formed. 
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Figure 1.6: Three Variations of Air-Stable Palladacycles Developed for Cross-
Coupling Reactions 
 
 The emergence of organotrifluoroborate salts as cross-coupling partners in 
addition to the recent development of robust catalytic systems has opened doors for 
significant expansion in the area of Suzuki-Miyaura reactions. These advancements now 
make it possible to develop reaction protocols involving only bench-stable components, 
making their use on large-scale synthesis a possibility.  
 
1.3 Introduction to Reductive Cross-Coupling Reactions 
 Despite the monumental advances that have been made in the areas of transition 
metal-catalyzed cross-coupling reactions between organic halides or pseudohalides and 
organometallic reagents, a different approach to carbon-carbon bond formation has 
emerged. Whereas a traditional cross-coupling reaction typically involves metalation of 
an organic halide followed by reaction of the resulting organometallic species with a 
second organic halide, reductive cross-coupling reactions employ two electrophiles that 
can be reacted directly without preformation of an organometallic species (Scheme 1.5).35  
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Scheme 1.5: Traditional vs. Reductive Biaryl Cross-Coupling Pathways 
 
 
Many challenges associated with the formation or handling of organometallic 
reagents can be avoided using a reductive cross-coupling protocol. Unlike many of the 
organometallic reagents purchased or prepared for a typical cross-coupling reaction, 
which are air and moisture sensitive,12 the corresponding organic halides can typically be 
handled and obtained easily from commercial sources.  
Reductive cross-coupling methods have been explored extensively over the last 
decade, and to date Ni-, Co-, Pd-, and Fe-catalyzed protocols have been developed for a 
variety of reaction manifolds.35 Biaryl reductive cross-couplings have been demonstrated 
with catalytic Co36 and Ni.37 However, these protocols necessitate either a significant 
excess of one aryl halide or tuning of electronic properties of the employed substrates. 
Other sp2-sp2 reductive cross-couplings emerged, allowing reductive acylations38 or 
alkenylations39,40 of aryl halides. Early examples of reductive cross-couplings between 
X
metalation
M
X
cat. M
X
cat M, reductant
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aryl halides and sp3 carbon centers made use of activated alkyl systems. Reductive 
allylation and benzylation reactions were developed that utilize Co,41,42 Pd,43 and Ni44 
catalysts, but these protocols also required use of a large excess of the alkyl partner.  
 
1.4 Reductive Cross-Coupling of Aryl Halides with Alkyl Halides 
The implementation of unactivated alkyl halides as reductive cross-coupling 
partners has been explored using Co,45 Pd,46–48 and Fe49–51 catalysts. The coupling of 
alkyl substrates introduces the challenges of β-hydride elimination and alkyl 
dimerization. A number of additives and ligands have been explored under Ni catalysis to 
aid in the successful reductive cross-coupling of alkyl halides with aryl or alkyl 
halides.52–57 Several reductive protocols for the cross-coupling of an aryl halide with an 
alkyl halide employ a catalytic nickel source, a diamine or triamine-based ligand, and a 
superstoichiometric amount of a metal reductant, which is typically Mn powder or Zn 
dust (Scheme 1.6). Developed protocols demonstrate remarkable functional group 
compatibility and have been shown to tolerate amines, alcohols, ketones, and esters. 
 
Scheme 1.6: Reductive Cross-Coupling of Aryl Halides with Alkyl Halides 
 
X
+ Alk-X
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 The major challenge faced by reductive cross-coupling manifolds is achieving 
preferential formation of cross-coupled product over byproducts resulting from 
homocoupled substrates.36,37,58 Biaryl reductive cross-coupling, in particular, faces 
challenges associated with differentiation of the two substrates in terms of reactivity, 
which can result in production of significant amounts of homocoupled products. One 
method for overcoming this obstacle is the use of a large excess of one reagent. This can 
be a feasible solution in cases where one reagent is very inexpensive, but often times this 
is not ideal. In these cases, the two aryl halides must be differentiated either sterically or 
electronically, which limits the substrate scope of the couplings. Reactions between aryl 
halides and alkyl halides are therefore advantageous in this regard, since the two 
substrates exhibit significantly different reactivity, with aryl halides readily undergoing 
oxidative addition to Ni(0) and alkyl halides more readily forming alkyl radicals than the 
aryl substrates.53,58 
 To elucidate the mechanism of the reductive cross-coupling of aryl halides with 
alkyl halides under Ni-catalysis, the Weix group has conducted a variety of 
experiments.53 It was determined through the use of radical clock and racemization 
experiments that an alkyl radical intermediate is likely produced in the reaction. The 
extent of radical rearrangement of 5-hexenyl iodide was directly impacted by the 
concentration of Ni in the reaction, suggesting that a radical chain mechanism is at play 
in which the alkyl radical reacts directly with a Ni center. In a separate report of reductive 
cross-coupling between aryl halides and an alkyl bromides, the addition of TEMPO to the 
 
 
17 
reaction led to inhibition of product formation, further suggesting the presence of a 
radical under Ni-catalysis.59 It was confirmed that when Zn is used as the reductant, the 
alkyl halide is only consumed in the presence of Ni, suggesting that alkylzinc formation 
does not occur under the reaction conditions.53 Based on the results of the mechanistic 
experiments, a mechanism was proposed for the reductive cross-coupling of an aryl 
halide with an alkyl halide under Ni-catalysis, as shown in Figure 1.7.  
 
 
Figure 1.7: Proposed Catalytic Cycle for the Ni-Catalyzed Cross-Coupling of an 
Aryl Halide with an Alkyl Halide 
 
An aryl halide undergoes oxidative addition to a ligated Ni(0) species to generate a 
Ni(II) complex that combines with an alkyl radical to form a Ni(III) species. Reductive 
elimination from the Ni(III) center yields the desired sp2-sp3 cross-coupled product and a 
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resulting Ni(I) complex, which combines with the halide radical from the alkyl halide to 
generate a Ni(II) species, which is reduced back to Ni(0) by a terminal metal reductant. 
Increased understanding of the mechanism for the reductive cross-coupling of aryl 
halides with alkyl halides has led to adoption of this reaction class as a means for reliable 
carbon-carbon bond formation. The role of additives in reductive couplings is not yet 
well understood, but empirical discoveries have led to trends that are allowing progress to 
be made in the coupling of two electrophiles. This field of coupling chemistry has the 
potential to improve on traditional cross-coupling methods for select reactions in terms of 
cost and efficiency. 
 
1.5 Conclusions 
 The past several decades have seen enormous growth in the area of cross-coupling 
chemistry as a means for C-C bond formation.16,28 The Suzuki-Miyaura reaction has been 
revered for its generally mild conditions that allow expansive substrate scope on the 
coupling partners. The Suzuki-Miyaura reaction has been utilized extensively by both 
academic and industrial laboratories because of its robustness and scalability. The 
development of potassium organotrifluoroborate salts and advances in ligand design have 
allowed practioners to make use of reagents that are stable to air and moisture. 
 Reductive protocols have emerged as a means of sp2-sp3 cross-coupling that avoid 
the necessity for an organometallic reagent.  Several methods demonstrate the coupling 
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of aryl halides with alkyl halides under Co-, Ni-, or Fe- catalysis. The use of various 
additives has allowed side product formation to be minimized, and mechanistic studies 
have been conducted that provide insight into the detailed pathway of the coupling. 
Reductive methods are shown to possess excellent substrate scope, and because the 
coupling partners are halides, most are commercially available and bench-stable. 
 Both Suzuki-Miyaura and reductive coupling methods are effective for generation 
of C-C bonds under mild conditions that are often tolerant of sensitive functional groups. 
These two reaction classes provide a basis for improvement of synthetic methods that can 
be broadly applicable toward a variety of substrates.  
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Chapter 2: Palladium Catalyzed Cross-Coupling of 2-Chloroacetates 
and 2-Chloroacetamides with Potassium Organotrifluoroborates 
 
2.1 Introduction 
The synthesis of α-aryl, α-alkenyl, and α-alkynyl esters and amides, derivatives of 
which possess biological activity and are found in the cores of numerous non-steroidal 
anti-inflammatory drugs (NSAIDs) and analgesics, has been extensively investigated 
over the past decade.1–11 There exist a number of limitations within the current methods 
for formation of these moieties, including lack of functional group compatibility and the 
necessity for organometallic species that must be formed under low temperature, inert 
conditions and/or used in large excess in the reaction. For each of these classes, the use of 
organotrifluoroborates as nucleophilic coupling partners was explored as a means of 
overcoming some of these existing limitations. A simple, mild, scalable protocol was 
sought that would provide compatibility across a wide range of functional groups and 
commercially available starting materials.  
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Scheme 2.1: α-Functionalization of 2-Halo Esters and Amides 
 
       
          Optimization was carried out using high-throughput experimentation to determine 
conditions for the cross-coupling of 2-chloroacetates and 2-chloroacetamides with 
potassium aryl-, heteroaryl-, alkenyl, and alkynyltrifluoroborates. The developed methods 
exhibit enhanced functional group compatibility and expand the scope of the electrophilic 
components to include a variety of commercially available alkyl and benzyl ester and 
amide substrates.  
 
2.2 Palladium-Catalyzed α-Arylation of 2-Chloroacetates and 2-
Chloroacetamides 
Compounds containing α-aryl ester and amide moieties as well as their 
corresponding carboxylic acid derivatives have been shown to possess biological activity 
and exist within numerous drug molecules, including analgesics and non-steroidal anti-
inflammatory drugs (Figure 2.1).12–14 Their synthesis through C-C bond forming 
protocols has been investigated in significant detail over the past decade in particular.1–4 
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Although numerous methods have been developed that allow for formation of desired 
structures, these methods pose a number of challenges; development of a simple, 
scalable, protocol that would be broadly applicable to a wide array of substrates was 
envisioned to address some of the limitations of existing approaches. 
 
 
Figure 2.1: Examples of NSAIDS that contain the α-aryl- or α-heteroarylacetic acid 
motif 
 
 Two general strategies exist for C-C bond forming methods leading to the 
preparation of α-aryl esters and amides (Scheme 2.2).  The first involves the Pd-catalyzed 
reaction of an aryl or heteroaryl halide with an enolate that has been generated from an 
ester or amide (Scheme 2.2, route a).1,2 This method has been demonstrated by the 
Buchwald group, who uses a strong base (LiHMDS or NaHMDS) to deprotonate various 
carbonyl-containing moieties that are subsequently reacted with an aryl halide.15,16 
Several limitations exist with this pathway as a result of enolate formation: (1) Many 
functional groups of interest are not compatible with the use of strong base necessary for 
enolate generation, making inclusion of ketone, nitro, and carboxylic acid moieties, in 
particular, problematic.1 (2) Claisen condensation can occur readily between a molecule 
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of the newly generated enolate and the carbonyl-containing starting material, therefore 
necessitating either the use of a large excess of ester or a sterically bulky group on the 
ester to prevent condensation.1,2,15,16 (3) Diarylation occurs readily, and monoarylated 
product is often formed as a mixture with various diarylated side products.2,15,16  
In addition to enolates generated with the use of strong base, the formation of 
Reformatsky reagents from α-bromoesters or amides has been illustrated as an alternative 
approach to metal enolate generation. Once formed, these zinc reagents have been shown 
to undergo cross-coupling with aryl bromides under Pd-catalysis.17,18 This protocol 
requires inert conditions and low temperature to carry out generation of the enolate, and 
the subsequent coupling reactions must be carried out in a glovebox or with Schlenkware. 
Although this method offers an improvement in terms of functional group compatibility, 
there are still significant drawbacks associated with its practical use because of the air- 
and moisture-sensitivity of the reagent, which requires preformation prior to use.  
 
Scheme 2.2: Approaches Toward the Synthesis of α-(Hetero)aryl Esters and Amides 
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 A complementary strategy for effecting the desired C-C bond formation employs 
a reversed polarity for the coupling reaction, in which an α-halo carbonyl compound is 
reacted with an arylmetallic moiety under metal catalysis (Scheme 2.2, route b).  
Arylmetallic species demonstrated in this pathway include both magnesium and boron 
reagents. Aryl Grignard reagents undergo cross-coupling with α-bromoesters under iron 
catalysis; while effective, this method requires in situ formation of the Grignard reagent 
and possesses poor functional group tolerance.19  
Similar approaches have involved the possibility of employing arylboron reagents 
as coupling partners with α-halo carbonyl compounds in an effort to bring better 
functional group compatibility to the reaction through use of milder reaction 
conditions.20–23 In practice, however, many of the same limitations faced by earlier 
protocols are evident in a developed procedure that makes use of aryl 9-BBN compounds 
as nucleophilic coupling partners.24  
The use of more robust boron structures, such as arylboronic acids or esters, for 
the coupling reactions has been explored. These structures provide advantages over a 
variety of other organometallic reagents in coupling reactions because they are often 
compatible with milder reaction conditions and therefore provide better functional group 
compatibility. Protocols for the synthesis of α-aryl carbonyl compounds that make use of 
arylboronic acids offer improvements to the field through the elimination of both strong 
base and the necessity for preformation of air- and temperature-sensitive reagents. 
Methods involving arylboronic acids face challenges associated with 
protodeboronation25,26 or homocoupling27 of the organometallic species in the presence of 
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Pd-catalysis. As a result of these challenges, a large excess (20-50 mol %) of the 
arylboronic acid is often necessary,28–31 or else addition of a phase transfer catalyst is 
required to facilitate transmetalation of the boronic acid.32 Alternatively, a more stable 
arylboron species, such as a boronate ester can be employed.33 However, this causes the 
reaction to suffer from poor atom economy.  
 The current investigation focuses on using potassium aryl and 
heteroaryltrifluoroborate salts as nucleophilic coupling partners in the synthesis of α-aryl 
esters and amides for the purpose of improving previously reported approaches toward 
these structures. Potassium organotrifluoroborates are air- and moisture-stable, crystalline 
solids at room temperature. Compared to boronic acids, trifluoroborate salts are less 
prone to protodeboronation,34,35 and therefore their use in large excess is not typically 
required. Organotrifluoroborates are bench-stable and can be handled in air without 
special precautions,36 but in aqueous reaction conditions a hydrolyzed species capable of 
transmetalation onto Pd is released slowly.37,38  
 The catalytic cycle of the Pd-catalyzed α-arylation of 2-chloroesters begins with 
oxidative addition of the 2-chloroester onto a ligated Pd(0) species. The 
aryltrifluoroborate, in the presence of basic, aqueous conditions, slowly hydrolyzes to a 
tricoordinate boron species that is capable of transmetalation onto the newly generated 
Pd(II) complex. Reductive elimination from the Pd(II) center affords C-C bond formation 
of the α-aryl ester and regenerates a Pd(0) species that can reenter the catalytic cycle. 
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Figure 2.2 Catalytic Cycle of Pd-Catalyzed α-Arylation of 2-Chloroesters 
 
The use of trifluoroborates as nucleophilic coupling partners in the α-arylation of 
2-chloro carbonyl compounds has allowed the implementation of mild conditions that 
accommodate heteroaryl substrates and numerous functional groups not tolerated by 
other methods. It is demonstrated that a wide range of commercially available esters and 
amides can be employed in this reaction. 
Optimization for the α-arylation of 2-haloacetates with potassium 
organotrifluoroborates was begun through examination of the reaction between benzyl 
bromoacetate and potassium phenyltrifluoroborate. In a limited screening process, a 
variety of Pd sources were examined for catalytic activity in this reaction. A preliminary 
result revealed the formation of desired cross-coupled product by GC-MS analysis using 
[Pd(allyl)Cl]2 in the presence of P(o-Tol)3 and K2CO3 (Equation 2.1). Under these 
conditions, the cross-coupling of m-tolyltrifluoroborate and p-methoxytrifluoroborate 
with benzyl bromoacetate also proceeded in good conversion to the desired product.  
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elimination
trifluoroborate hydrolysis
transmetalation
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Equation 2.1:  
 
 
With the initial concept of the cross-coupling confirmed, further work was 
envisioned that would address a number of specific goals for the project: (1) the use of 
air-stable reaction components, (2) the ability to use 2-chloroesters as coupling partners, 
advantageous because of their increased commercial availability compared to the 
corresponding bromides, (3) the extension of developed reaction conditions to 2-
chloroacetamides in addition to esters, and (4) significant expansion of functional group 
scope compared to other methods of accessing α-(hetero)aryl esters and amides. It was 
desired that the developed method be applicable to a wide array of substrates with no or 
little modification required based on the individual substrate.  
Having determined the feasibility of the desired reaction using benzyl 
bromoacetate, the more challenging α-chloroesters were employed for further reaction 
development. Compared to the corresponding bromides, the chloride substrates are 
significantly less expensive and more readily available from commercial sources. 
Unfortunately, extension of the initial conditions to benzyl chloroacetate led to a large 
amount of both homocoupled biaryl product and protodeboronation of the trifluoroborate 
starting material, with minimal formation of desired product. Using high-throughput 
BnO
O
Br KF3B R
[Pd(allyl)Cl]2 (2.5 mol %)
P(o-Tol)3 (5 mol %)
K2CO3 (3 equiv)
THF:H2O (4:1)
60 °C, 20 h
+
1.1 equiv
R
O
BnO
R = H, > 95% conversion
R = m-CH3, > 95% conversion
R = p-COCH3, > 90% conversion
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experimentation to screen various parameters on a 25 µmol reaction scale, a number of 
air-stable Pd sources were explored as catalysts for the reaction between methyl 
chloroacetate and potassium phenyltrifluoroborate (Equation 2.2).  
 
Equation 2.2: 
 
It was determined through screening that XPhos-Pd-G2 [chloro(2-
dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-
biphenyl)]palladium(II)] was an ideal catalyst for the desired transformation. This 
preformed catalyst system (Figure 2.3) is an air-stable Pd(II) source that, in the presence of 
base, rapidly undergoes reductive elimination to form a monoligated Pd(0) species and 
releases carbazole as a byproduct. Catalytic systems of this class are advantageous in that 
they are stable enough to be stored for extended periods of time without special 
consideration for excluding air or moisture, while readily serving as a reactive Pd(0) 
source under basic reaction conditions. Because the conditions required to generate the 
active Pd species are mild, these precatalyst systems have been successfully employed in 
the Suzuki-Miyaura cross-coupling of sensitive aryl and heteroarylboronic acids, which 
are prone to protodeboronation under typical cross-coupling conditions.39–41 The bulky 
monodentate XPhos ligand has recently been proven effective for an enolate arylation 
reaction with aryl benzylsulfonates.42 
MeO
O
Cl +
KF3B
Pd/ligand (1 mol %)
base (1 or 3 equiv)
solvent MeO
O
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Figure 2.3: Structure of XPhos-Pd-G2 precatalyst  
 
          Having determined an effective catalyst for the cross-coupling of methyl 
chloroacetate and potassium phenyltrifluoroborate, a small screen of inorganic bases and 
reaction temperatures was conducted in a solvent mixture of THF/H2O (4:1). The 
reaction proceeded to a significant extent at 80 °C, but conversions were dramatically 
lower for reactions conducted at 60 °C, as a large amount of starting material was 
observed after 18 h. Three of the four bases included in the screen showed comparable 
product to internal standard ratios, with Cs2CO3 providing the highest conversion to 
cross-coupled product (Figure 2.4). 
 
Pd
NH2
Cl
XPhos P
i-Pri-Pr
i-PrXPhos-Pd-G2 XPhos
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Figure 2.4: Screening results from the reaction of methyl chloroacetate with 
potassium phenyltrifluoroborate (1 mol % XPhos-Pd-G2, 0.25 M in 4:1 THF/H2O, 
18 h) in the presence of 3 equiv of each base at the shown temperature. 
 
 Because it was important that a method be developed that could extend to a wide 
array of substrates, including those with steric hindrance, the optimization was continued 
on the reaction of benzyl chloroacetate with potassium 2-methoxyphenyltrifluoroborate 
in the presence of XPhos-Pd-G2 (Equation 2.3).  
 
Equation 2.3: 
 
 
The initially screened bases were investigated for activity in the new reaction 
system on a 0.5 mmol scale, and the conversions to product were monitored by GC-MS. 
BnO
O
Cl +
KF3B
XPhos-Pd-G2 (1 mol %)
base (1 or 3 equiv)
THF/H2O (4:1)
80 °C, 18 h BnO
O
OMeOMe
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As shown in (Table 2.1), Cs2CO3 served to promote the desired transformation to the 
greatest extent, with a conversion of 92% in 18 h. It was noted that use of KF and K3PO4 
led to a significant amount of trifluoroborate homocoupling, while still effecting the 
desired transformation to a significant extent.  
 
Table 2.1: GC-MS Conversions for the Reaction of Benzyl Chloroacetate with 
Potassium 2-Methoxyphenyltrifluoroborate in the Presence of Four Bases 
 
 
 
 
  
The inorganic carbonate bases were used for further optimization, and a more 
challenging system of benzyl chloroacetate with potassium 3-pyridyltrifluoroborate was 
pursued to ensure development of a standard set of conditions that would be optimal for 
both aryl and heteroaryltrifluoroborate substrates.  
 
Equation 2.4: 
 
A variety of organic solvents in combination with H2O were screened in the 
presence of either XPhos or SPhos using HTE (Figure 2.5). On a high-throughput scale 
BnO
O
Cl +
N
KF3B
L-Pd-G2 (1 mol %)
base (3 equiv)
solvent
80 °C, 18 h BnO
O N
Base Conversion (%) 
KF 42 
K3PO4 81 
Cs2CO3 92 
K2CO3 77 
Conditions: 3 equiv of each base shown; 1 mol % 
XPhos-Pd-G2, 0.25 M in 4:1 THF/H2O, 18 h, 80° C. 
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(25 µmol), the ethereal solvents (THF, CPME, and 2-MeTHF) all showed excellent 
activity in a 4:1 ratio with H2O. It was determined upon scaling up several of the best 
reaction conditions (0.5 mmol) that the optimal solvent was THF/H2O (4:1). In agreement 
with the optimal ligand determined for the aryltrifluoroborate systems, it was confirmed 
that XPhos was also the most preferable ligand for the cross-coupling of the heteroaryl 
systems.  
 
 
Figure 2.5: Screening results for the reaction of benzyl chloroacetate with potassium 
3-pyridyltrifluoroborate (1 mol % L-Pd-G2, 3 equiv base, 0.25 M, 80 °C, 18 h). 
 Reaction conditions were optimized for the reaction of 2-chloroesters with aryl 
and heteroaryltrifluoroborates to use 1 mol % of the XPhos-Pd-G2 preformed catalyst in 
the presence of 3 equiv of C2CO3 in THF/H2O (4:1) at 100 °C for 18 h. The reactions 
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were run under an inert atmosphere of Ar, and all components of the reaction were 
weighed open to air without special consideration to exclude moisture. The 
organotrifluoroborates were able to be purchased or prepared in large quantities and 
stored indefinitely on the bench until needed. Only a 5% excess of the aryltrifluoroborate 
relative to the α-chloroester was necessary for the reaction to proceed to completion.  
 With the developed conditions in hand, benzyl chloroacetate was cross-coupled 
with a variety of aryl and heteroaryltrifluoroborate salts in moderate to good yields 
(Table 2.2).  It was noted that hydrolysis of the benzyl ester occurred with most nitrogen-
containing heterocyclic substrates. However, 6-quinolinyltrifluoroborate was successfully 
cross-coupled in good yield (2.4).  The conditions were tolerant of both electron-rich 
(2.6) and ortho-substituted trifluoroborates (2.2 and 2.3). An electron deficient, 
fluorinated substrate (2.7) was cross-coupled in moderate yield.  In the cross-coupling of 
benzyl esters, both K2CO3 and Cs2CO3 allow the reaction to go to completion, and both 
provide good yields for non-sterically hindered substrates (2.8 and 2.9).  
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Table 2.2: Cross-Coupling of Benzyl Chloroacetate with Potassium Aryl- and 
Heteroaryltrifluoroborates  
 
 
Entry Product  Yield (%) 
1 
 
2.1 80 
2 
 
2.2 66 
 
3  
2.3 87 
4 
 
2.4 80 
5 
 
2.5 84 
6 
 
2.6 63 
7 
 
2.7 58 
8 
 
2.8 84a 
BnO
O
Cl BnO
O
(Het)Ar
XPhos-Pd-G2 (1 mol %)
Cs2CO3 (3 equiv)
THF/H2O (4:1)
100 °C, 18 h
+ KF3B
(Het)Ar
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9 
 
2.9 84a  
Reaction conditions: Benzyl ester (0.50 mmol), trifluoroborate 
(0.525 mmol), XPhos-Pd-G2 (0.005 mmol), Cs2CO3 (1.50 mmol) in 
THF (1.6 mL)/H2O (0.4 mL) at 100 °C for 18 h. aK2CO3 used as base 
 
 Although benzyl chloroacetate proved prone to a noticeable amount of hydrolysis 
under the developed conditions, particularly in the presence of heteroaryl substrates, alkyl 
α-chloroesters did not seem to suffer from this fate. Under the standard conditions, tert-
butyl chloroacetate and methyl chloroacetate were cross-coupled with a variety of 
potassium aryltrifluoroborates (Table 2.3). In addition to tolerance for both electron-
deficient and electron-rich aryltrifluoroborates, it was illustrated that the developed 
conditions are amenable to terminal alkene (2.11), nitro (2.12), ester (2.13) and ketone 
(2.14) functional groups present on the organotrifluoroborate. The scalable nature of the 
reaction was also demonstrated, as the cross-coupling of tert-butyl chloroacetate and 
potassium p-tolylphenyltrifluoroborate proceeded on a gram scale (10-fold scale 
increase) with half of the standard Pd loading without suffering a decrease in yield (2.10).  
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Table 2.3: Cross-Coupling of Alkyl Chloroacetates with Potassium 
Aryltrifluoroborates 
 
 
Entry Product  Yield (%) 
1 
 
2.10 95, 96a 
2 
 
2.11 63 
 
3  
2.12 60 
4 
 
2.13 82 
5 
 
2.14 98 
6 
 
2.15 67 
7 
 
2.16 80 
 
Reaction conditions: 2-chloroester (0.50 mmol), trifluoroborate 
(0.525 mmol), XPhos-Pd-G2 (0.005 mmol), Cs2CO3 (1.50 mmol) in 
THF (1.6 mL)/H2O (0.4 mL) at 100 °C for 18 h. aIsolated on a 5.0 
mmol scale, 0.5 mol % XPhos-Pd-G2 
RO
O
Cl RO
O
Ar
XPhos-Pd-G2 (1 mol %)
Cs2CO3 (3 equiv)
THF/H2O (4:1)
100 °C, 18 h
+ KF3B
Ar
tBu-O
O
tBu-O
O
O
tBu-O
O
NO2
tBu-O
O
CO2Me
tBu-O
O
O
MeO
O F
MeO
O
     42 
 The conditions were extended to allow the cross-coupling of potassium 
heteroaryltrifluoroborate substrates (Table 2.4). With alkyl α-chloroesters, the hydrolysis 
observed with benzyl chloroacetate in the presence of nitrogen-containing heteroaryl 
substrates was significantly diminished, and the cross-couplings occurred in good to 
excellent yields. The method provided access to cross-coupled products of quinoline, 
isoquinoline, pyridine, and substituted pyrimidine systems (2.17 – 2.22). In addition to 
nitrogen-containing heteroaryltrifluoroborates, thienyl and furanyl trifluoroborates were 
successfully employed as coupling partners under the standard conditions (2.23 – 2.26). 
In some cases, challenging substrates required an increase to 2 mol % Pd in order to drive 
the reaction to completion in 18 h (2.19).  
 
Table 2.4: Cross-Coupling of Alkyl Chloroacetates with Potassium 
Heteroaryltrifluoroborates 
 
 
Entry Product  Yield (%) 
1 
 
2.17 92 
2 
 
2.18 94 
RO
O
Cl RO
O
(Het)Ar
XPhos-Pd-G2 (1 mol %)
Cs2CO3 (3 equiv)
THF/H2O (4:1)
100 °C, 18 h
+ KF3B
(Het)Ar
tBu-O
O N
tBu-O
O
N
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3 
 
2.19 50, 57a 
4 
 
2.20 93 
5 
 
2.21 80 
6 
 
2.22 40 
7 
 
2.23 88 
8 
 
2.24 76 
9 
 
2.25 75 
10 
 
2.26 79 
 
Reaction conditions: 2-chloroester (0.50 mmol), 
trifluoroborate (0.525 mmol), XPhos-Pd-G2 (0.005 mmol), 
Cs2CO3 (1.50 mmol) in THF (1.6 mL)/H2O (0.4 mL) at 
100 °C for 18 h. a2 mol % XPhos-Pd-G2 (0.010 mmol) 
 
 As a method had initially been desired that would allow a wide array of substrates 
to be cross-coupled under a similar set of reaction conditions, the electrophilic coupling 
partner was next investigated in terms of scope under the developed protocol. 
tBu-O
O N
N
N OMeMeOO
tBu-O
tBu-O
O
N
tBu-O
O N
tBu-O
O O
tBu-O
O
S
O
MeO
O O
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Unfortunately, formation of desired cross-coupled products were not observed when α-
chloroketones or α-haloesters with secondary chlorides or bromides were employed 
(Equation 2.5), and significant formation of protodehalogenated products were observed 
in these reactions.  
 
Equation 2.5: 
 
 
Extension of the developed method to α-chloroacetamides was next pursued, and 
it was observed that under the standard conditions, α-chloro tertiary acetamides could be 
employed as electrophilic coupling partners. The cross-coupling of α-chloro tertiary 
acetamides with a variety of potassium aryl and heteroaryltrifluoroborates was achieved 
in moderate to good yields (Table 2.5). As had been observed in the couplings with α-
chloroesters, both electron-rich and electron-deficient substrates participated successfully 
in the reaction. Ketone (2.30) and carboxylic acid (2.33) functional groups remained 
intact under the developed conditions, and nitrogen-, oxygen-, and sulfur-containing 
heterocyclic trifluoroborate substrates proceeded in the coupling without significant 
protodeboronation. Unfortunately, free or Boc-protected indole substrates did not readily 
undergo cross-coupling under the developed conditions.  
O
Cl
BnO
O
Cl/Br
XPhos-Pd-G2 (1 mol %)
Cs2CO3 (3 equiv)
THF/H2O (4:1)
100 °C, 18 h
+
KF3B
O
H
BnO
O
H
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Table 2.5: Cross-Coupling of 2-Chloro Tertiary Acetamides with Potassium Aryl- 
and Heteroaryltrifluoroborates 
 
 
Entry Product  Yield (%) 
1 
 
2.27 81 
2 
 
2.28 88 
3 
 
2.29 98 
4 
 
2.30 70 
5 
 
2.31 68 
6 
 
2.32 85 
7 
 
2.33 71 
R2N
O
Cl R2N
O
(Het)Ar
XPhos-Pd-G2 (1 mol %)
Cs2CO3 (3 equiv)
THF/H2O (4:1)
100 °C, 18 h
+ KF3B
(Het)Ar
N
O
O
N
O
O
N
O
O
O
O
N
O
O O
N
O
O
F
N
O
O
O
O
N
O
O
HOOC
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8 
 
2.34 85 
9 
 
2.35 62 
10 
 
2.36 86 
11 
 
2.37 72 
Reaction conditions: 2-chloroacetamide (0.50 mmol), trifluoroborate 
(0.525 mmol), XPhos-Pd-G2 (0.005 mmol), Cs2CO3 (1.50 mmol) in 
THF (1.6 mL)/H2O (0.4 mL) at 100 °C for 18 h.  
 
Upon attempts at expanding the substrate scope of the electrophilic coupling 
partner to include α-chloro secondary acetamides, a significant challenge was observed. 
Under the developed conditions, extremely low conversions to the desired product were 
observed, and a significant amount of both starting materials remained after 18 h at 
100 °C. Attempts were made to increase the Pd loading of the reaction, but this only 
served to increase homocoupling of the aryltrifluoroborate to produce undesired biaryl 
side products (Equation 2.6).  
 
 
O
N
O
NSO2Ph
O
N
O
S
N
O
N
O
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Equation 2.6: 
 
 
A recent literature report had revealed the use of Cu(I) additives in conjunction 
with Pd catalysis to achieve the cross-coupling of arylboronic acids with α-
bromoacetamides.28,43 Based on the success of the reported coupling, several Cu(I) 
additives were investigated in the reaction of N-benzyl chloroacetamide with potassium 
p-tolyltrifluoroborate (Figure 2.6). The ligand was also reinvestigated in the presence of 
the Cu additive for the given reaction.  It was determined that the addition of 5 mol % 
Cu2O to the reaction of α-chloro secondary acetamides allowed significant improvement 
in the conversion of trifluoroborates to the desired cross-coupled products. XPhos was 
confirmed to remain the optimal ligand among those screened, and the only modification 
necessary to the original reaction conditions was the addition of the Cu source.  
 
N
H
O
Cl +
KF3B
XPhos-Pd-G2 (1 mol %)
Cs2CO3 (3 equiv)
THF/H2O (4:1)
100 °C, 18 h
major product
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Figure 2.6: Screen results of the addition of Cu(I) sources to the reaction of N-benzyl 
chloroacetamide with potassium 4-methylphenyltrifluoroborate (1 mol % XPhos-
Pd-G2, 3 equiv Cs2CO3, 0.25 M 4:1 THF/H2O, 100 °C, 18 h). 
 
Although the exact role of the Cu(I) additive is unknown, it can be speculated that 
the presence of an N-H bond may interfere with catalysis through ligation of Pd in the 
reaction, and that coordination of the Cu salt to the free nitrogen liberates the Pd catalyst 
to participate effectively in the cross-coupling catalytic cycle. It was noted that the 
reactions of 2-chloroesters and 2-chloro tertiary acetamides were not aided by the 
addition of Cu(I) additives. 
With the modified conditions in hand, α-chloro secondary acetamides were 
successfully cross-coupled with a variety of potassium aryl and heteroaryltrifluoroborate 
salts in good yields (Table 2.6). Nitrogen- and oxygen-containing heteroaryl systems 
proceeded without complication in the presence of the Cu2O additive. The reaction 
system was demonstrated to be scalable, in that the reaction of N-benzyl chloroacetamide 
with potassium p-tolyltrifluoroborate proceeded on gram scale (5.0 mmol) with decreased 
catalyst loading (0.5 mol % Pd) without a significant decrease in yield (2.39).  
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Table 2.6: Cross-Coupling of 2-Chloro Secondary Acetamides with Potassium Aryl- 
and Heteroaryltrifluoroborates 
 
Entry Product  Yield (%) 
1 
 
2.38 70 
2 
 
2.39 75, 69a 
3 
 
2.40 67 
4 
 
2.41 70 
5 
 
2.42 71 
6 
 
2.43 62 
 
Reaction conditions: 2-chloroacetamide (0.50 mmol), trifluoroborate 
(0.525 mmol), XPhos-Pd-G2 (0.005 mmol), Cu2O (0.025 mmol), 
Cs2CO3 (1.50 mmol) in THF (1.6 mL)/H2O (0.4 mL) at 100 °C for 
18 h. a5.0 mmol scale using 0.5 mol % XPhos-Pd-G2 
 
N
H
O
Cl
R2N
O
(Het)Ar
XPhos-Pd-G2 (1 mol %)
Cu2O (5 mol %)
Cs2CO3 (3 equiv)
THF/H2O (4:1)
100 °C, 18 h
R + KF3B
(Het)Ar
N
H
O N
N
H
O
N
H
O
N
H
O O
N
H
O
N
H
O
N
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A versatile reaction manifold was developed that allows the preparation of a wide 
array of α-aryl- and α-heteroaryl-esters and amides. This method boasts mild reaction 
conditions compared to other methods for accessing similar structures and therefore 
offers an expanded functional group tolerance. Other limitations of previous methods 
have been overcome in the disclosed protocol through the use of air-stable, crystalline 
potassium aryl and heteroaryl trifluoroborate salts as nucleophilic coupling partners.  
 
2.3 Palladium-Catalyzed Cross-Coupling of Potassium 
Alkenyltrifluoroborates with 2-Chloroacetates and 2-Chloroacetamides 
          (E)- and (Z)-β,γ-Unsaturated esters and amides represent an important class of 
compounds that are encountered in many natural products that exhibit biological 
activity.5,44 Additionally, they serve as precursors for the preparation of other biologically 
active structures.6,45–48 Because of their importance in the realm of biochemistry, the 
synthesis of β,γ-unsaturated esters and amides has been studied extensively, and a robust 
method for their stereocontrolled preparation is highly desirable.  
 One commonly utilized approach toward accessing these structures is the 
carbonylation of allylic substrates under ruthenium or palladium catalysis to form β,γ-
unsaturated esters7 and amides.8,49,50 Unfortunately these reactions suffer from the 
necessity for using toxic CO gas, often at high pressures.  Another approach is to expose 
α,β-unsaturated carbonyl compounds to successive deprotonation and reprotonation steps. 
However, these protocols often result in a mixture of (E)- and (Z)-isomers.51,52 Alkenyl-9-
BBN has been shown to react with α-carbanions generated from ethyl bromoacetate53 or 
     51 
ethyl (dimethylsulfuranylidene) acetate54 to afford the desired α-alkenyl esters. However, 
low temperatures and inert conditions are required for handling the sensitive 
alkenylboron reagent. Alternative approaches include metathesis between olefin-
containing amides and allyl halides55 as well as SmI2-promoted elimination and 
subsequent reduction of α-halo-β-hydroxy-γ,δ-unsaturated esters.56 Both of these methods 
suffer from the use of complex starting materials that are not readily available from 
commercial sources.  
 More recently, methods have been developed that involve addition of 
organometallic species to commercially available α-halo carbonyl compounds (Scheme 
2.3), including a Et3B-promoted addition of alkenylindium compounds57 to a variety of α-
halo carbonyl compounds and a Ni-catalyzed addition of alkenylzirconium reagents58 to 
α-bromo esters and ketones. Hiyama reactions between alkenyl-TMS substrates and α-
bromoesters have been demonstrated as an effective means of preparing α-alkenyl 
carboxylic acid derivatives.59 Alkenylmetallic species, specifically alkenylsilane and 
alkenylzirconium reagents, necessitate use in significant excess (30 mol % and 100 mol 
%, respectively), thus making their use less than ideal. 
 
 
Scheme 2.3: Preparation of β,γ-Unsaturated Esters and Amides from 
Alkenylmetallic Reagents and 2-Chlorocarbonyl Species 
  
Z
O
R M R Z
O
X+
Z = OR', NR'2, NHR' M = InCl2, ZrCp2Cl, B(OH)2
     52 
Boron reagents have been investigated in the context of alkenylations of α-carbonyl 
structures. Alkenylboranes have been prepared through an in situ hydroboration reaction 
and then cross-coupled with N,N-dimethyl-2-bromoacetamide under Pd-catalysis to 
prepare an (E)-β,γ-unsaturated amide.33 More recently, alkenylboronic acids have been 
successfully cross-coupled with α-bromoacetates in the presence of catalytic Pd to 
produce a variety of β,γ-unsaturated esters in good yield.29,60 Although these protocols 
represent significant improvements over previous methods in terms of starting material 
availability, the substrate scope was quite poor. Only (E)-alkenylboronic acids were 
shown to participate in the cross-coupling reaction, and the compatibility with functional 
groups was not demonstrated. Furthermore, although the alkenylboronic acids are stable 
compared to previously reported organometallic reagents, some alkenylboronic acids tend 
to polymerize readily, especially low molecular weight examples such as vinyl and 
propenylboronic acids.61 Additionally, the boronic acids were generally used in a 20% 
excess relative to the α-bromoacetate.29,60  
 Potassium alkenyltrifluoroborates were envisioned as a suitable alternative to the 
corresponding boronic acids, given their increased stability and ability to be stored 
indefinitely at room temperature under air.35,62–65 The use of alkenyltrifluoroborates as 
cross-coupling partners was anticipated to allow near stoichiometric quantities of the 
organometallic coupling partner to be employed, while expanding the possible scope of 
the reaction in terms of double bond geometry and functional group tolerance. Initial 
reaction screening was carried out on the reaction of benzyl chloroacetate and potassium 
(E)-styryltrifluoroborate (Equation 2.7).  
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Equation 2.7: 
 
        
   A variety of Pd(II) sources were evaluated including Pd(OAc)2 and (η3-C3H5)PdCl2 in 
conjunction with several bulky, electron-rich ligands, based on the success of XPhos in 
the cross coupling of α-chloroesters and α-chloroacetamides with aryl and 
heteroaryltrifluoroborates. Although significant conversion to the desired product was 
achieved with Pd(OAc)2 and XPhos, it was discovered that the use of the XPhos-Pd-G2 
catalyst system used for the arylation reactions reduced the amount of trifluoroborate 
homocoupling observed over the course of the reaction. This precatalyst offered shorter 
reaction times compared to the other Pd sources evaluated, and under its catalysis, most 
of the alkenyl coupling reactions were complete after 8-12 h.  The base used for the 
coupling was evaluated, and it was determined that 3 equiv of K2CO3 was optimal for the 
desired transformation. The temperature of the reaction could be reduced to 80 °C from 
the 100 °C required for the arylation of α-chloroesters and amides, and the catalyst 
loading was reduced to 0.5 mol % Pd for reactions conducted on a 0.5 mmol scale.  
 The reaction between benzyl chloroacetate and potassium (E)-
styryltrifluoroborate, which was used for optimization of reaction conditions, proceeded 
in 96% yield to produce a single product isomer (Equation 2.8). With reaction conditions 
BnO
O
Cl +
BnO
O
Pd/ligand (1 mol %)
base (1 or 3 equiv)
solventKF3B
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in hand, benzyl chloroacetate was cross-coupled with a variety of potassium 
alkenyltrifluoroborates (Table 2.7).  
 
Equation 2.8: 
 
 
The conditions were extended to allow alkenyltrifluoroborates of both (E) and (Z) 
configurations to participate in the desired coupling. In addition to straight-chain 
substituents on the alkenyltrifluoroborate partners, a cyclic alkenyl system was 
accommodated (2.49). The conditions were demonstrated to be tolerant of a nitrile on the 
alkenyl coupling partner (2.50).  The scalable nature of the developed method was 
illustrated, and the reaction of benzyl chloroacetate with potassium trans-1-
propenyltrifluoroborate proceeded on a 5.0 mmol scale (10-fold increase in scale) with 
only 0.25 mol % Pd without a significant decrease in yield (2.45). Isomerization from (Z) 
to (E) alkenyl systems or from β,γ-unsaturated esters to the conjugated α,β-unsaturated 
systems was not observed.  
 
 
BnO
O
Cl +
BnO
O
XPhos-Pd-G2 (0.5 mol %)
K2CO3  3 equiv)
THF/H2O (4:1)
80 °C, 8 h
KF3B
96% yield
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Table 2.7: Cross-Coupling of Benzyl Chloroacetate with Potassium (E)- and (Z)-
Alkenyltrifluoroborates 
 
 
Entry Product  Yield (%) 
1 
 
2.44 96 
2 
 
2.45 94, 86a 
3 
 
2.46 70 
4 
 
2.47 89 
5 
 
2.48 87 
6 
 
2.49 85 
7 
 
2.50 91 
8 
 
2.51 76 
Reaction conditions: chloroacetate (0.50 mmol), 
alkenyltrifluoroborate (0.525 mmol), XPhos-Pd-G2 (0.0025 mmol), 
K2CO3 (1.50 mmol) in THF (1.6 mL)/H2O (0.4 mL) at 80 °C. a5.0 
mmol scale using 0.25 mol % XPhos-Pd-G2 
BnO
O
Cl + KF3B
R
BnO
O
R
XPhos-Pd-G2
(0.5 mol %)
K2CO3 (3 equiv)
THF/H2O (4:1)
80 °C, 8-18 h
BnO
O
Ph
BnO
O
Me
BnO
O
C8H17
BnO
O
C8H17
BnO
O
Ph
BnO
O
BnO
O
CN
BnO
O
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Several new potassium alkenyltrifluoroborates were prepared for use in the 
coupling reaction to demonstrate the extended scope of the developed reaction conditions 
(Table 2.8). Alkenyltrifluoroborates containing an alkyl chloride (2.77), a protected 
amine (2.78), and protected alcohols (2.79, 2.80) were prepared through a Zr-catalyzed 
hydroboration protocol from the corresponding terminal alkynes.66 
 
Table 2.8: Preparation of Potassium (E)-Alkenyltrifluoroborates from Terminal 
Alkynes 
 
Entry Product  Yield (%) 
1  2.77 89 
2 
 
2.78 91 
3  2.79 59 
4  2.80 56 
 
In addition to benzyl chloroacetate, both tert-butyl chloroacetate and iso-propyl 
chloroacetate participated in the developed cross-coupling reaction with a variety of 
potassium (E) and (Z) alkenyltrifluoroborates under the standard conditions (Table 2.9). 
It was demonstrated that an alkyl chloride was left undisturbed by the reaction conditions 
(2.55). Alkenyltrifluoroborates containing protected amino and alcohol functional groups 
R + H B
O
O
Cp2ZrHCl (0.1 equiv)
Et3N (0.1 equiv)
60 °C, 18 h
B
RO
O
acetone/H2O (5:1)
KHF2 (2 equiv)
0 °C --> rt
KF3B
R
KF3B
Cl
KF3B N
Bn
Me
KF3B OBn
KF3B OTHP
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were successfully cross-coupled, but an increase to 1 mol % Pd was required for these 
more challenging substrates (2.56 – 2.58). Although isomerization had not been observed 
with previously coupled (Z)-alkenyl systems (2.46, 2.48), the use of both potassium cis-1-
propenyltrifluoroborate and cis-styryltrifluoroborate resulted in a noticeable amount of 
(Z)/(E) isomerization. The commercially available obtained starting materials of these 
two substrates contained ~ 5% of the corresponding (E)-isomer that could not be 
removed through recrystallization. Upon use of the impure starting trifluoroborate salts in 
the cross-coupling, however, the isolated products contained 10-12% of the undesired 
diastereomer. The quantity of (E)-isomer in the product cannot be accounted for only by 
possible preferential reaction of the (E) starting material, leading to the conclusion that 
(Z)/(E) isomerization must take place, at least to some extent, under the reaction 
conditions.67,68  
 
Table 2.9: Cross-Coupling of 2-Chloroacetates with Potassium (E)- and (Z)-
Alkenyltrifluoroborates 
 
 
Entry Product  Yield (%) 
1 
 
2.52 64 
2 
 
2.53 66 
RO
O
Cl + KF3B
R
RO
O
R
XPhos-Pd-G2
(0.5 mol %)
K2CO3 (3 equiv)
THF/H2O (4:1)
80 °C, 8-18 hR = Bn, t-Bu. i-Pr
t-BuO
O
Ph
t-BuO
O
Ph
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3 
 
2.54 64 
4 
 
2.55 62a 
5 
 
2.56 63a 
6 
 
2.57 74a 
7 
 
2.58 80a 
8 
 
2.59 92b 
9 
 
2.60 72b 
 
Reaction conditions: chloroacetate (0.50 mmol), 
alkenyltrifluoroborate (0.525 mmol), XPhos-Pd-G2 (0.0025 mmol), 
K2CO3 (1.50 mmol) in THF (1.6 mL)/H2O (0.4 mL) at 80 °C .a1.0 
mol % XPhos-Pd-G2. bproduct contains > 5 % trans isomer 
 
The reactivity of 2-chloroacetamides in the cross-coupling reaction with 
potassium alkenyltrifluoroborates was next explored. It was noted that the addition of 
additives was not required to promote the conversion of N-benzyl-2-chloroacetamide to 
the desired cross-coupled product. Under the conditions developed for the cross-coupling 
of 2-chloroesters with potassium alkenyltrifluoroborates, N-benzyl-2-chloroacetamide 
i-PrO
O
Ph
BnO
O
Cl
BnO
O
N
Me
Bn
BnO
O
OBn
BnO
O
OTHP
BnO
O
Me
BnO
O
Ph
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was successfully cross-coupled with several potassium alkenyltrifluoroborates in good to 
excellent yields in the presence of 1 mol % Pd (Table 2.10).  
 
Table 2.10: Cross-Coupling of N-Benzyl-2-chloroacetamide with Potassium (E)- and 
(Z)-Alkenyltrifluoroborates 
 
 
Entry Product  Yield (%) 
1 
 
2.61 95 
2 
 
2.62 88 
3 
 
2.63 93 
4 
 
2.64 90 
5 
 
2.65 72 
6 
 
2.66 89a 
Reaction conditions: N-benzyl-2-chloroacetamide (0.50 mmol), 
alkenyltrifluoroborate (0.525 mmol), XPhos-Pd-G2 (0.005 mmol), 
K2CO3 (1.50 mmol) in THF (1.6 mL)/H2O (0.4 mL) at 80 °C. 
aproduct contains > 5 % trans isomer 
The scope of the 2-chloroacetamide partner was expanded to include a variety of 
tertiary, secondary, and even primary amides. Conjugated and unconjugated potassium 
BnHN
O
Cl + KF3B
R
BnHN
O
R
XPhos-Pd-G2
(1 mol %)
K2CO3 (3 equiv)
THF/H2O (4:1)
80 °C, 12 h
BnHN
O
Ph
BnHN
O
Me
BnHN
O
C8H17
BnHN
O
BnHN
O
Ph
BnHN
O
Me
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(E)-alkenyltrifluoroborates were successfully cross-coupled with 2-chloroacetamides 
under the standard conditions in moderate to good yields (Table 2.11). As was evident 
with N-benzyl-2-chloroacetamide, no Cu additive was necessary for the extension of the 
reaction to secondary or primary amides, but a catalyst loading of 1 mol % Pd was 
required, and many of the reactions took 18 h to go to completion.  
 
Table 2.11: Cross-Coupling of Primary, Secondary, and Tertiary 2-
Chloroacetamides with Potassium (E)- and (Z)-Alkenyltrifluoroborates 
 
 
Entry Product  Yield (%) 
1 
 
2.67 89 
2 
 
2.68 91 
3 
 
2.69 78 
4 
 
2.70 71 
5 
 
2.71 87 
R2N
O
Cl + KF3B
R
R2N
O
R
XPhos-Pd-G2
(1 mol %)
K2CO3 (3 equiv)
THF/H2O (4:1)
80 °C, 12 h
N
O
Me
N
H
O
Me
H2N
O
Me
N
O
Me
O
N
H
O
Me
     61 
6 
 
2.72 94 
7 
 
2.73 58 
8 
 
2.74 68 
9 
 
2.75 79 
 
Reaction conditions: 2-chloroacetamide (0.50 mmol), 
alkenyltrifluoroborate (0.525 mmol), XPhos-Pd-G2 (0.005 mmol), 
K2CO3 (1.50 mmol) in THF (1.6 mL)/H2O (0.4 mL) at 80 °C.  
 
As a consequence of these studies, a simple, scalable, and general protocol has 
been developed for the stereocontrolled synthesis of (E)- and (Z)-β,γ-unsaturated acetates 
and acetamides. The method tolerates inexpensive, commercially available 2-
chloroacetates as well as 2-chloro primary, secondary, and tertiary acetamides as 
electrophilic partners. Unlike many previously disclosed methods for accessing similar 
substrates, all reaction components in the developed method are air-stable and are either 
easily prepared or obtained from common commercial sources.  
N
O
O
Ph
N
H
O
Ph
N
O
Ph
O
N
H
O
F
F
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2.4 Palladium-Catalyzed Alkynylation of 2-Chloroacetates and 2-
Chloroacetamides with Potassium Alkynyltrifluoroborates 
 The known synthetic pathways toward the synthesis of β,γ-alkynyl esters and 
amides are not nearly as diverse as the arrary of methods available for the preparation of 
α-aryl and α-alkenyl esters and amides.  Most of the existing protocols for the preparation 
of these compounds involved Pd-catalyzed alkynylation of α-halo carbonyl compounds 
with alkynylmetallic reagents. A unique set of challenges exist with the synthesis of the 
alkynyl motifs, however.  
 Because the transmetalation of alkynylmetallic reagents to Pd occurs readily, and 
the enolate bound to Pd (from oxidative addition of the 2-chloroester or amide) can serve 
as a good leaving group from the metal center, these reactions are particularly prone to 
diyne formation (Figure 2.7). Reactions focused on the preparation of diynes actually use 
a similar pathway to effect the homocoupling, which in this case, is undesirable.69 
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Figure 2.7: Pd-Catalyzed Diyne Formation from Alkynylmetallic Species and  
α-Haloesters  
 
 In addition to the obstacle created by the ease of alkynylmetallic transmetalation 
to Pd, another limitaiton that abounds in methods making use of alkynylmetallic reagents 
is their inherent instability. Two different protocols have been established by Oshima, et 
al. and Hirashita, et al. for the reaction of α-iodo esters with alkynylgallium9,70 and 
alkynylindium species,71 respectively. The reported protocols allow access to β,γ-alkynyl 
esters in good yields, but suffer from the major drawback that the alkynylmetallic 
reagents cannot be isolated and must be preformed in situ for each coupling.  Similarly, 
alkynylstannanes have been employed as alkynylating agents for α-bromo carbonyl 
compounds under Pd-catalysis using a bidentate XantPhos ligand10 and additionally for 
secondary α-bromoesters and amides in the presence of XPhos.72 The substrate scope of 
the coupling reactions involving alkynylstannanes was poor, and although the 
RO
O
RO
O
X Pd X RO
O Pd X
R M
RO
O
Pd R
R M
Pd RR
RO
O R
RR
oxidative
addition
transmetallation
transmetallation
reductive
elimination
reductive
elimination
cross-coupled product
dyine product
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organometallic species could be isolated, they were typically required to be stored under 
an inert atmosphere until use. The use of tin reagents is another drawback of this 
protocol, given concerns surrounding their toxicity.73  
 
 
Scheme 2.4: Preparation of β,γ-Alkynyl Esters and Amides from Alkynylmetallic 
Reagents and 2-Chlorocarbonyl Species 
 
 The aforementioned methods thus all suffer from the use of alkynylmetallic 
reagents that are unstable to varying degrees and, in addition to commonly requiring the 
use of excess coupling partner, also incorporate expensive metals in their preparation. As 
shown in Table 2.12, the reagents required for formation of the organometallic reagents 
from the corresponding terminal alkynes are extremely expensive, espcially given that the 
metal employed is neither recovered nor incorporated in the final product. By 
comparison, although tin represents a marked improvement in terms of cost, boron would 
allow a significant further reduction in cost if it could be employed for preparation of the 
alkynylating reagent.   
 
 
 
 
Z
O
M Z
O
X+
Z = OR', NR'2, NHR' M = GaCl2, InCl2, SnBu3
R R
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Table 2.12: Cost Comparison of Commonly Used Metal Reagents for Alkynylation 
Reagents 
substance cost
1 
($/mole) 
relative 
cost 
B(OMe)3 9 1 
GaCl3 1775 204 
InCl3 1340 155 
Bu3SnCl 160 18 
 
1Based on SigmaAldrich, 2013 
 
 The work of Fu, et al. has served to enhance the scope of  β,γ-alkynyl esters and 
amides that can be prepared in terms of functional groups on the alkyne partner. The 
developed method makes use of commercially available terminal alkynes, which undergo 
a Cu(I)-catalyzed addition to diazoesters and diazoamides.11 Although this method is 
certainly advantageous in that it does not necessitate preformation of an organometallic 
reagent, the electrophilic partner is somewhat limited by a lack of commercial availability 
of diazoesters and diazoamides, which ultimately require preparation from tosyl azide. 
 A protocol for the preparation of β,γ-alkynyl esters and amides was sought that 
would allow the use of only bench-stable materials that are readily available from 
commercial sources and/or can be prepared easily from inexpensive reagents. The use of  
alkynylboron species for this reaction was envisioned, given the low cost of boron 
compared to other metals used for the preparation of alkynylmetallic reagents. Potassium 
alkynyltrifluoroborates can be simply prepared form terminal acetylides by reaction with 
B(OMe)3 followed by a quench with KHF2; once synthesized, the salts can remain stored 
open to the air indefinitely. Additionally, it was desired that developed conditions would 
allow the use of 2-chloroesters and amides, which have significantly increased 
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commercial availability compared to their bromo, iodo, or diazo counterparts. The cross-
coupling of alkynyltrifluoroborates with 2-chloroesters and amides would allow access to 
β,γ-alkynyl esters and amides at lower cost and improved ease of starting material 
acquisition compared to previously disclosed methods. 
Conditions were initially investigated for the α-alkynylation of 2-chloroesters and 
amides based on the parameters developed for the arylation and alkenylation reactions on 
the same substrates. The reaction of N-benzyl-2-chloroacetamide with potassium 
phenylethynyltrifluoroborate was initially carried out in the presence of K2CO3 and 
catalytic XPhos-Pd-G2 and Cu2O. Although minimal product formation was observed, it 
was accompanied by a significant amount of the homocoupled diyne product (Equation 
2.9).  
 
Equation 2.9: 
 
 
N
H
O
Cl +
XPhos-Pd-G2 (1 mol %)
Cu2O (5 mol %)
K2CO3 (3 equiv)
THF/H2O (4:1)
80 °C, 18 hKF3B
N
H
O
(major)
(minor)
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Reaction screening led to the conclusion that the elimination of the Cu additive 
greatly suppressed the formation of the homocoupled byproduct. In addition to XPhos, 
other bulky, electron-rich ligands such as SPhos, RuPhos, and Xantphos were 
investigated in the reaction (Figure 2.8), but it was determined that XPhos was the 
optimal ligand for the desired transformation.  
 
 
Figure 2.8: Structures of Screened Electron-Rich Ligands  
 
 The initial reaction screening revealed that the choice of base played a major role 
in the extent of homocoupling that was observed as a major side product. A further screen 
of several bases led to the discovery that K3PO4 effected greater conversion to the desired 
cross-coupled product compared to the previously successful carbonate bases. The 
amount of base necessary for the coupling was investigated, and 3 equivalents were 
found to be ideal.  
 
PCy2
OMeMeO
PCy2
Oi-Pri-PrO
PCy2
i-Pri-Pr
i-Pr
SPhos RuPhos XPhos
O
PPh2 PPh2
Xantphos
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Table 2.13: Base Screening for Reaction of N-Benzyl-2-chloroacetamde with 
Potassium Phenylethynyltrifluoroborate 
base product (% conversion) 
homocoupled product 
(% conversion) 
K2CO3 36 2 
Cs2CO3 48 14 
K3PO4 74 6 
(n-Bu4N)H2PO4 4 3 
(NH4)2CO3 6 24 
(n-Bu4N)OH 0 1 
 
 Optimization was continued, in which temperature variation was considered. 
Homocoupling of the alkylyltrifluoroborate was determined to be more prevalent at 
higher temperature (100 °C), but at lower temperature (60 °C), a significant amount of 
starting material remained unreacted after 24 h. The optimal temperature was determined 
to be 80 °C. Several organic solvents were tested for reactivity, and each of the solvents 
was mixed in various ratios with H2O to allow slow hydrolysis of the 
alkynyltrifluoroborate.38 Toluene/H2O in a ratio of 3:1 was determined to be an optimal 
solvent mixture. It was determined that addition of a second equivalent of the bulky 
XPhos ligand relative to Pd served to reduce diyne formation, presumably by creating 
more steric bulk around the metal center to ensure rapid reductive elimination to form the 
desired product before a second transmetalation could occur.   
Optimal conditions developed for the reaction of N-benzyl-2-chloroacetamide 
with potassium phenylethynyltrifluoroborate required the use of 1.1 equivalents of the 
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alkynyltrifluoroborates relative to the 2-chloroacetamide in the presence of 1 mol % 
XPhos-Pd-G2, 1 mol % XPhos, 3 equiv K3PO4 in a 3:1 mixture of toluene/H2O at 80 °C.  
Equation 2.10: 
 
 
Under the developed conditions, N-benzyl-2-chloroacetamide was cross-coupled 
with a variety of potassium alkynyltrifluoroborates (Table 2.14). Substituents on the 
potassium alkynyltrifluoroborate substrates include both straight-chain and cyclic alkyl 
groups, as well as phenyl and benzyl substituents and an alkyl chain containing a 
protected alcohol. Under the developed conditions, the reactions proceeded in good 
yields in 18 h, and only minimal amounts of diyne side products were observed. 
Isomerization to the conjugated α,β-alkynyl systems was not observed in any case. The 
scalable nature of the reaction system was demonstrated, and the cross-coupling of N-
benzyl-2-chloroacetamide with potassium phenylethynyltrifluoroborate proceeded on a 
gram scale (5.0 mmol) with 0.5 mol % Pd without a significant decrease in yield (2.81).  
 
 
 
 
N
H
O
Cl +
XPhos-Pd-G2 (1 mol %)
XPhos (1 mol %)
K3PO4 (3 equiv)
toluene/H2O (3:1)
80 °C, 18 hKF3B
N
H
O
92% yield
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Table 2.14: Cross-Coupling of N-Benzyl-2-chloroacetamide with Potassium 
Alkynyltrifluoroborates 
 
Entry Product  Yield (%) 
1 
 
2.81 92, 88a 
2 
 
2.82 90 
3 
 
2.83 82 
4 
 
2.84 92 
5 
 
2.85 95 
6 
 
2.86 80 
7 
 
2.87 76 
 
Reaction conditions: 2-chloroacetamide (1.0 mmol), potassium 
alkynyltrifluoroborate (1.1 mmol), XPhos-Pd-G2 (1.0 mol %), XPhos 
(1.0 mol %), K3PO4 (3.0 mmol) in toluene/H2O (3:1, 3.2 mL), 80 °C. 
 
N
H
O
Cl +
KF3B
N
H
O
XPhos-Pd-G2
(1.0 mol %)
XPhos (1.0 mol %)
K3PO4 (3 equiv)
toluene/H2O (3:1)
80 °C, 18 h
R
R
BnHN
O
O
BnHN
BnHN
O
BnHN
O
BnHN
O
BnHN
O
BnHN
O OBn
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The scope of the electrophilic partner was next explored for the alkynylation 
reaction of α-chlorocarbonyl substrates. In addition to α-chloro secondary acetamides, α-
chloro tertiary acetamides with morpholino and N,N-diethyl groups participated in the 
reaction under the developed conditions (Table 2.15).  Furthermore, alkyl 2-chloroesters 
were shown to undergo the desired cross coupling in good yield. However, they require 
1.2 equivalents of the alkynyltrifluoroborate to proceed to completion.  
 
 
Table 2.15: Cross-Coupling of Potassium Phenylethynyltrifluoroborate with 2-
Chloroesters and Amides 
 
Entry Product  Yield (%) 
1 
 
2.88 72 
2 
 
2.89 77 
3 
 
2.90 74a 
4 
 
2.91 84a 
Z
O
Cl +
KF3B Z
O
XPhos-Pd-G2
(1.0 mol %)
XPhos (1.0 mol %)
K3PO4 (3 equiv)
toluene/H2O (3:1)
80 °C, 18 hZ = NR2, NHR, OR
O
N
O Ph
N
O Ph
O Ph
t-BuO
O Ph
i-PrO
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5 
 
2.81 92 
 
Reaction conditions: 2-chloroacetamide or 2-chloroacetate (1.0 mmol), 
potassium alkynyltrifluoroborate (1.1 mmol), XPhos-Pd-G2 (1.0 mol 
%), XPhos (1.0 mol %), K3PO4 (3.0 mmol) in toluene/H2O (3:1, 3.2 
mL), 80 °C. a1.2 equiv alkynyltrifluoroborate used 
 
 A variety of additional coupling partners were employed to illustrate the 
versatility of the developed reaction (Table 2.16). Surprisingly, an alkynyltrifluoroborate 
bearing an alkyl chloride proceeded without complication in good yield. Benzyl 
chloroacetate was shown to serve as a viable electrophilic coupling partner, albeit 
requiring 1.2 equivalents of alkynyltrifluoroborate (2.96). Several substrates were 
prepared with N-cyclopropyl-2-chloroacetamide, including one bearing an additional 
cyclopropyl group on the alkynyl partner (2.95).  
 
Table 2.16: Cross-Coupling of 2-Chloroesters and Amides with Potassium 
Alkynyltrifluoroborates  
 
Entry Product  Yield (%) 
1 
 
2.92 75 
BnHN
O Ph
Z
O
Cl + KF3B Z
O
XPhos-Pd-G2
(1.0 mol %)
XPhos (1.0 mol %)
K3PO4 (3 equiv)
toluene/H2O (3:1)
80 °C, 18 h
R R
Z = NHR, OR
N
H
O Ph
     73 
2 
 
2.93 90 
3 
 
2.94 61 
4 
 
2.95 74 
5 
 
2.96 89a 
6 
 
2.97 76a 
 
Reaction conditions: 2-chloroacetamide or 2-chloroacetate (1.0 mmol), 
potassium alkynyltrifluoroborate (1.1 mmol), XPhos-Pd-G2 (1.0 mol 
%), XPhos (1.0 mol %), K3PO4 (3.0 mmol) in toluene/H2O (3:1, 3.2 
mL), 80 °C. a1.2 equiv alkynyltrifluoroborate used 
  
The developed protocol allows the preparation of β,γ-alkynyl esters and amides 
from commercially available, inexpensive chlorides and air-stable, easily prepared 
potassium alkynyltrifluoroborate salts. The substrate scope of β,γ-alkynyl carbonyl 
compounds has been significantly improved as a result of this method, and many of the 
isolated compounds had not been previously prepared. This method is advantageous in 
terms of cost and functional group tolerance over existing protocols for accessing similar 
motifs.  
 
N
H
O Bu
N
H
O Cl
N
H
O
O Bu
BnO
O
O Ph
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2.5 Conclusions 
 New methods toward the synthesis of α-aryl, α-alkenyl, and α-alkynyl esters and 
amides, derivatives of which possess biological activity, were developed. Optimization 
was carried out using high-throughput experimentation to determine conditions for the 
cross-coupling of 2-chloroacetates and 2-chloroacetamides with potassium aryl-, 
heteroaryl-, alkenyl, and alkynyltrifluoroborates. The developed methods exhibit 
enhanced functional group compatibility and expand the scope of the electrophilic 
components to include a variety of commercially available alkyl and benzyl ester and 
amide structures.  
 
 
Figure 2.9: Summary of α-Functionalization of 2-Chloro Esters and Amides 
 
Access to α-functionalized esters and amides using bench-stable, commercially 
available or easily prepared substrates has been made possible with the implementation of 
the disclosed protocols. The use of organotrifluoroborates as nucleophilic coupling 
Z
O
Cl
Z = OR, NR2, NHR
KF3B
RKF3B
R
XPhos-Pd-G2 (1 mol %)
Cs2CO3 (3 equiv)
THF/H2O, 100 °C, 18 h
XPhos-Pd-G2 (0.5 - 1 mol %)
K2CO3 (3 equiv)
THF/H2O, 80 °C, 18 h
XPhos-Pd-G2 (1 mol %)
XPhos (1 mol %)
K3PO4 (3 equiv)
THF/H2O, 80 °C, 12-24 h
Z
O R
Z
O
R
Z
O
(Het)Ar
19 examples
yields: 61-95%
43 examples
yields: 40-96%
32 examples
yields: 58-96%
(Het)Ar-BF3K
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partners allows substantial lowering of cost in some cases, and offers significant 
improvement in terms of the stability of the organometallic reagent employed in similar 
couplings. The potassium aryl-, heteroaryl-, alkenyl-, and alkynyltrifluoroborates can be 
readily handled in air, and do not require use in significant excess of the electrophilic 
coupling partner. The developed methods are scalable, robust, and versatile, allowing 
preparation of numerous novel structures previously inaccessible by parallel methods.  
 
2.6 Experimental  
General considerations.  All cross-coupling reactions were carried out under an Ar 
atmosphere. Deionized H2O, THF, and toluene were thoroughly degassed with Ar prior 
to use.  All solids used in cross-couplings were weighed out open to air. All 2-
chloroacetates and 2-chloroacetamides were purchased from commercial sources and 
used without further purification. 1H and 13C NMR spectra were obtained at 500 and 
125.8 MHz, respectively. For organotrifluoroborates, 11B and 19F NMR spectra were 
recorded at 128.4 and 470.8 MHz, respectively.  Melting points (°C) were determined 
using a Thomas-Hoover capillary melting point apparatus and are uncorrected. HRMS 
data was obtained using a TOF mass spectrometer by ESI or CI, as specified.  
 
General procedure A for cross-coupling of (hetero)aryltrifluoroborates with 2-
chloroacetates and tertiary 2-chloroacetamides.  An oven-dried Biotage 10 mL 
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microwave vial equipped with a magnetic stirbar was charged with the (hetero)aryl 
trifluoroborate (0.525 mmol, 1.05 equiv), Cs2CO3 (1.5 mmol, 3 equiv), and XPhos-Pd-G2 
(3.93 mg, 5.0 µmol, 1 mol %).  A disposable Teflon septum cap was used to seal the vial, 
which was evacuated and purged with Ar three times.  THF (1.6 mL), H2O (0.4 mL), and 
the electrophile (0.5 mmol, 1 equiv) were added via syringe with stirring under Ar.  In 
cases where the electrophile was a solid, it was added along with the solid materials 
before sealing the vial.  The soln was heated at 100 °C overnight.  After cooling to rt, the 
mixture was extracted with EtOAc (3x3 mL), and the combined organic layers were dried 
(Na2SO4). The crude products were purified by flash column chromatography, eluting 
with a gradient of EtOAc in hexanes.  
 
 
Benzyl 2-(3-Methoxyphenyl)acetate (2.1). General procedure A was employed. Column 
chromatography (hexanes/EtOAc = 9:1 to 1:3) provided the title compound as a yellow 
oil in 80% yield (102 mg). 1H NMR (500 MHz, CDCl3): δ 7.33-7.30 (m, 5H), 7.24-7.22 
(m, 1H), 6.92 (d, J =7.5 Hz, 1H), 6.87-6.85 (m, 2H), 5.12 (s, 2H), 3.76 (s, 3H), 3.63 (s, 
2H).  13C NMR (125.8 MHz, CDCl3): δ 171.4, 159.9, 136.0, 135.4, 129.7, 128.7, 128.3, 
128.3, 121.8, 115.0, 113.0, 66.8, 55.3, 41.5. IR (neat): 2919, 1736, 1490, 1261, 1147  
cm-1.  HRMS (ESI) m/z calcd. For C16H17O3 (M+H)+, 257.1178, found 257.1171. 
 
BnO
O
OMe
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Benzyl 2-(2-Methoxyphenyl)acetate (2.2). General procedure A was employed. Column 
chromatography (hexanes/EtOAc = 9:1 to 1:3) provided the title compound as a yellow 
oil in 66% yield (84 mg).  1H NMR (500 MHz, CDCl3): δ 7.38-7.34 (m, 5H), 7.29-7.26 
(m, 1H), 7.22-7.20 (m, 1H), 6.95-6.93 (m, 1H), 6.87-6.86 (m, 1H), 5.16 (s, 2H), 3.75 (s, 
3H), 3.68 (s, 2H).  13C NMR (125.8 MHz, CDCl3): δ 171.9, 157.7, 136.4, 131.1, 128.8, 
128.7, 128.6, 128.2, 128.2, 123.1, 120.6, 110.5, 66.4, 55.5, 36.2.  IR (neat): 2924, 1737, 
1495, 1247, 1148 cm-1.  HRMS (ESI) m/z calcd. For C16H16O3Na (M+Na)+ 279.0997, 
found 279.0997. 
 
 
Benzyl 2-(o-Tolyl)acetate (2.3). General procedure A was employed. Column 
chromatography (hexanes/EtOAc = 9:1 to 1:3) provided the title compound as a light 
yellow oil in 87% yield (104 mg). 1H NMR (500 MHz, CDCl3): δ 7.31-7.29 (m, 5H), 
7.18-7.16 (m, 4H), 5.12 (s, 2H), 3.67 (s, 2H), 2.28 (s, 3H).  13C NMR (125.8 MHz, 
CDCl3): δ 171.4, 137.0, 136.1, 132.8, 130.5, 130.3, 128.7, 128.3, 128.2, 127.6, 126.3, 
66.7, 39.3, 19.7.  IR (neat): 1734, 1498, 1455, 1257, 1146 cm-1.  HRMS (ESI) m/z calcd. 
For C16H16O2Na (M+Na)+ 263.1048, found 263.1048. 
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Benzyl 2-(Quinolin-6-yl)acetate (2.4). General procedure A was employed. Column 
chromatography (hexanes/EtOAc = 9:1 to 1:3) provided the title compound as a brown 
oil in 80% yield (111 mg). 1H NMR (500 MHz, CDCl3): δ 8.91 (br s, 1H), 8.12-8.07 (m, 
2H), 7.72 (s, 1H), 7.69-7.67 (m, 1H), 7.43-7.42 (m, 1H), 7.37-7.34 (m, 5H), 5.16 (s, 2H), 
3.86 (s, 2H).  13C NMR (125.8 MHz, CDCl3): δ 171.2, 150.4, 147.6, 136.0, 135.8, 132.5, 
131.3, 129.9, 128.7, 128.5, 128.4, 128.1, 121.5, 67.0, 41.3.  IR (neat): 2980, 1732, 1500, 
1152 cm-1.  HRMS (ESI) m/z calcd. For C18H16NO2 (M+H)+ 278.1181, found 278.1182. 
 
 
Benzyl 2-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)acetate (2.5).74 General procedure A was 
employed. Column chromatography (hexanes/EtOAc = 9:1 to 1:3) provided the title 
compound as a yellow oil in 84% yield (119 mg).  Spectral data were in accordance with 
those published.  1H NMR (500 MHz, CDCl3): δ 7.34-7.32 (m, 5H), 6.84 (t, J = 4.0 Hz, 
2H), 6.78-6.76 (m, 1H), 5.13 (s, 2H), 4.24 (s, 4H), 3.55 (s, 2H).  13C NMR (125.8 MHz, 
CDCl3): δ 171.7, 143.6, 142.9, 136.0, 128.7, 128.4, 128.3, 127.1, 122.4, 118.3, 117.4, 
66.7, 64.5, 40.7. 
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Benzyl 2-(3,5-Diisopropylphenyl)acetate (2.6). General procedure A was employed. 
Column chromatography (hexanes/EtOAc = 9:1 to 1:3) provided the title compound as a 
yellow oil in 63% yield (98 mg). 1H NMR (500 MHz, CDCl3): δ 7.40-7.39 (m, 1H), 7.36 
-7.31 (m, 5H), 7.01-6.99 (m, 2H), 5.14 (s, 2H), 3.64 (s, 2H), 2.89-2.85 (m, 2H), 1.24 (d, J 
= 6.9 Hz, 12 H).  13C NMR (125.8 MHz, CDCl3): δ 171.8, 149.3, 136.1, 135.1, 133.8, 
128.9, 128.7, 128.3, 128.2, 125.0, 123.7, 68.1, 66.6, 41.7, 34.3, 24.2.  IR (neat): 2959, 
1737, 1601, 1455, 1146 cm-1.  HRMS (ESI) m/z calcd. For C21H27O2 (M+H)+ 311.2011, 
found 311.2011. 
 
 
Benzyl 2-(2,4-Difluorophenyl)acetate (2.7). General procedure A was employed. 
Column chromatography (hexanes/EtOAc = 9:1 to 1:3) provided the title compound as a 
white solid in 58% yield (76 mg). mp 33-34 °C.  1H NMR (500 MHz, CDCl3): δ 7.36-
7.31 (m, 5H), 7.21 (dd, J = 8.2, 6.6 Hz, 1H), 6.84-6.79 (m, 2H), 5.14 (s, 2H), 3.67 (s, 
2H).  13C NMR (125.8 MHz, CDCl3): δ 170.5, 162.7 (dd, J = 158.5, 12.0 Hz), 160.7 (dd, 
J = 159.0, 11.9 Hz), 135.8, 132.1 (dd J = 9.9, 5.5 Hz), 128.7, 128.5, 128.3, 117.3 (dd, J 
= 16.3, 3.7 Hz), 111.3 (dd, J = 21.2, 3.6 Hz), 103.9 (t, J = 25.7 Hz), 67.0, 33.9 (d, J = 
BnO
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2.5 Hz).  IR (neat): 2920, 1739, 1507, 1137, 970 cm-1.  HRMS (ESI) m/z calcd. For 
C15H12F2O2Na (M+Na)+ 285.0703, found 285.0702. 
 
 
Benzyl 2-(Furan-3-yl)acetate (2.8). General procedure A was employed. Column 
chromatography (hexanes/EtOAc = 9:1 to 1:3) provided the title compound as an orange 
oil in 84% yield (91 mg). 1H NMR (500 MHz, CDCl3): δ 7.38 (s, 2H), 7.35-7.33 (m, 5H), 
6.29 (s, 1H), 5.15 (s, 2H), 3.52 (s, 2H).  13C NMR (125.8 MHz, CDCl3): δ 171.3, 143.2, 
140.6, 135.9, 128.8, 128.5, 128.4, 117.3, 111.5, 66.9, 31.0.  IR (neat): 3034, 1736, 1455, 
1163 cm-1.  HRMS (ESI) m/z calcd. For C13H12O3Na (M+Na)+ 239.0684, found 
239.0685. 
 
 
Benzyl 2-(4-Chlorophenyl)acetate (2.9).75 General procedure A was employed, with the 
only modification being the use of K2CO3 (3 equiv, 1.5 mmol) rather than Cs2CO3. 
Column chromatography (hexanes/EtOAc = 9:1 to 1:3) provided the title compound as a 
white, opaque oil in 84% yield (110 mg). Spectral data were in accordance with those 
published. 1H NMR (500 MHz, CDCl3): δ 7.35-7.29 (m, 7H), 7.23 (d, J = 8.4 Hz, 2H), 
5.14 (s, 2H), 3.64 (s, 2H).  13C NMR (125.8 MHz, CDCl3): δ 171.1, 135.9, 133.3, 132.5, 
130.9, 128.9, 128.8, 128.5, 128.4, 67.0, 40.8.  
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tert-Butyl 2-(p-Tolyl)acetate (2.10).16  General procedure A was employed. Column 
chromatography (hexanes/EtOAc = 9:1 to 3:1) provided the title compound as a light 
brown oil in 95% yield (98 mg). Spectral data were in accordance with those published. 
1H NMR (500 MHz, CDCl3): δ 7.17-7.11 (m, 4H), 3.47 (s, 2H), 2.32 (s, 3H), 1.42 (s, 
9H). 13C NMR (125.8 MHz, CDCl3): δ 171.1, 136.3, 131.6, 129.1, 129.0, 80.6, 42.1, 
28.0, 21.0. 
 
 
tert-Butyl 2-[2-{(Pent-4-en-1-yloxy)methyl}phenyl]acetate (2.11). General procedure 
A was employed. Column chromatography (hexanes/EtOAc = 9:1 to 3:1) provided the 
title compound as a colorless oil in 63% yield (92 mg). 1H NMR (500 MHz, CDCl3): δ 
7.38 (d, J = 7.1 Hz, 1H), 7.28-7.22 (m, 3H), 5.82-5.81 (m, 1H), 5.02-4.98 (m, 2H), 4.53 
(s, 2H), 3.65 (s, 2H), 3.51 (q, J = 6.3 Hz, 2H), 2.17 (q, J = 7.3 Hz, 2H), 1.74-1.71 (m, 
2H), 1.43 (s, 9H).  13C NMR (125.8 MHz, CDCl3): δ 171.1, 138.4, 136.9, 133.8, 130.8, 
129.3, 128.1, 127.2, 114.9, 80.9, 71.4, 70.0, 39.6, 30.5, 29.1, 28.2.  IR (neat): 2979, 1731, 
1641, 1150, 1093, 913  cm-1.  HRMS (ESI) m/z calcd. For C18H27O3 (M+H)+ 291.1960, 
found 291.1952. 
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tert-Butyl 2-(3-Nitrophenyl)acetate (2.12).76 General procedure A was employed. 
Column chromatography (hexanes/EtOAc = 9:1 to 3:1) provided the title compound as a 
yellow oil in 60% yield (71 mg). Spectral data were in accordance with those published. 
1H NMR (500 MHz, CDCl3): δ 8.18 (s, 1H), 8.15 (d, J = 8.2 Hz, 1H), 7.61 (d, J = 7.7 Hz, 
1H), 7.54-7.51 (m, 1H), 3.64 (s, 2H), 1.45 (s, 9H).  13C NMR (125.8 MHz, CDCl3): δ 
161.5, 148.2, 136.5, 135.5, 129.2, 124.2, 122.0, 81.6, 41.9, 27.9.  
 
 
Methyl 3-[2-(tert-Butoxy)-2-oxoethyl]benzoate (2.13). General procedure A was 
employed. Column chromatography (hexanes/EtOAc = 9:1 to 3:1) provided the title 
compound as a colorless oil in 82% yield (103 mg).  1H NMR (500 MHz, CDCl3): δ 7.97-
7.95 (m, 2H), 7.48 (d, J = 7.7 Hz, 1H), 7.43 (t, J = 7.6 Hz, 1H), 3.91 (s, 3H), 3.57 (s, 2H), 
1.43 (s, 9H).  13C NMR (125.8 MHz, CDCl3): δ 170.2, 166.8, 135.0, 133.7, 130.3, 130.3, 
128.4, 128.0, 81.0, 51.9, 42.2, 27.9.  IR (neat): 2977.68, 1723.06, 1284.86, 1144.00 cm-1.  
HRMS (ESI) m/z calcd. For C14H18O4Na (M+Na)+ 273.1103, found 273.1098. 
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tert-Butyl 2-(3-Acetylphenyl)acetate (2.14). General procedure A was employed. 
Column chromatography (hexanes/EtOAc = 9:1 to 3:1) provided the title compound as a 
brown oil in 98% yield (115 mg). 1H NMR (500 MHz, CDCl3): δ 7.86-7.84 (m, 2H), 7.49 
(t, J = 5.6 Hz, 1H), 7.44-7.41 (m, 1H), 3.59 (s, 2H), 2.61 (s, 3H), 1.44 (s, 9H). 13C NMR 
(125.8 MHz, CDCl3): δ 198.0, 170.5, 137.4, 135.4, 134.1, 129.3, 128.8, 127.1, 81.2, 42.4, 
28.1, 26.8.  IR (neat): 2979.63, 1729.22, 1685.75, 1367.15, 1275.50, 1144.21 cm-1.  
HRMS (ESI) m/z calcd. For C14H18O3Na (M+Na)+ 257.1154, found 257.1161. 
 
 
Methyl 2-(4-Fluorophenyl)acetate (2.15).77 General procedure A was employed. 
Column chromatography (hexanes/EtOAc = 9:1 to 3:1) provided the title compound as a 
yellow oil in 67% yield (56 mg). Spectral data were in accordance with those published. 
1H NMR (500 MHz, CDCl3): δ 7.26-7.21 (m, 2H), 7.01-6.98 (m, 2H), 3.68 (s, 3H), 3.58 
(s, 2H).  13C NMR (125.8 MHz, CDCl3): δ 172.0, 162.0 (d, J = 244.8 Hz), 130.9 (d, J = 
8.2 Hz), 129.8, 115.5 (d, J = 21.5 Hz), 52.3, 40.4. 
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Methyl 2-(p-Tolyl)acetate (2.16).78 General procedure A was employed. Column 
chromatography (hexanes/EtOAc = 9:1 to 3:1) provided the title compound as a yellow 
oil in 80% yield (66 mg). Spectral data were in accordance with those published. 1H 
NMR (500 MHz, CDCl3): δ 7.14-7.12 (m, 4H), 3.66 (s, 3H), 3.57 (s, 2H), 2.31 (s, 2H). 
13C NMR (125.8 MHz, CDCl3): δ 172.4, 136.9, 131.1, 129.5, 129.3, 52.2, 40.9, 21.2. 
 
 
tert-Butyl 2-(Quinolin-6-yl)acetate (2.17).75 General procedure A was employed. 
Column chromatography (hexanes/EtOAc = 9:1 to 3:1) provided the title compound an 
orange-brown oil in 92% yield (112 mg). Spectral data were in accordance with those 
published. 1H NMR (500 MHz, CDCl3): δ 8.89-8.87 (m, 1H), 8.16 (dd, J = 8.1, 4.6 Hz, 
1H), 8.10-8.08 (m, 1H), 7.69 (s, 1H), 7.68-7.66 (m, 1H), 7.42-7.40 (m, 1H), 3.70 (s, 2H), 
1.43 (s, 9H). 13C NMR (125.8 MHz, CDCl3): δ 170.7, 150.3, 147.6, 135.9, 133.3, 131.3, 
129.6, 128.3, 127.8, 121.4, 81.3, 42.7, 28.2. 
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tert-Butyl 2-(Isoquinolin-5-yl)acetate (2.18). General procedure A was employed. 
Column chromatography (hexanes/EtOAc = 9:1 to 3:1) provided the title compound as an 
orange-brown oil in 94% yield (114 mg). 1H NMR (500 MHz, CDCl3): δ 9.24 (s, 1H), 
8.60 (t, J = 5.0 Hz, 1H), 7.95 (d, J = 8.0 Hz, 1H), 7.77-7.76 (m, 1H), 7.65 (d, J = 6.9 Hz, 
1H), 7.58-7.56 (m, 1H), 3.94 (s, 2H), 1.39 (s, 9H). 13C NMR (125.8 MHz, CDCl3): δ 
170.4, 153.2, 143.3, 135.0, 132.1, 130.8, 129.1, 127.4, 127.1, 117.1, 81.6, 39.8, 28.1.  IR 
(neat): 2977, 1728, 1367, 1253, 1145 cm-1.  HRMS (ESI) m/z calcd. For C15H18NO2 
(M+H)+ 244.1338, found 244.1338. 
 
 
tert-Butyl 2-(Pyridin-3-yl)acetate (2.19).79 General procedure A was employed, with the 
only modification being that 2 mol % of XPhos-Pd-G2 was used. Column 
chromatography (hexanes/EtOAc = 9:1 to 3:1) provided the title compound as a brown 
oil in 57% yield (55 mg). Spectral data were in accordance with those published. 1H 
NMR (500 MHz, CDCl3): δ 8.51-8.50 (m, 2H), 7.64-7.62 (m, 1H), 7.26-7.24 (m, 1H), 
3.53 (s, 2H), 1.44 (s, 9H). 13C NMR (125.8 MHz, CDCl3): δ170.1, 150.5, 148.5, 136.9, 
130.5, 123.5, 81.6, 39.9, 28.1. 
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tert-Butyl 2-(2,4-Dimethoxypyrimidin-5-yl)acetate (2.20). General procedure A was 
employed. Column chromatography (hexanes/EtOAc = 9:1 to 3:1) provided the title 
compound as a yellow solid in 93% yield (118 mg).  mp 40-42 °C.  1H NMR (500 MHz, 
CDCl3): δ 8.02 (s, 1H), 3.96 (s, 6H), 3.36 (s, 2H), 1.41 (s, 9H).  13C NMR (125.8 MHz, 
CDCl3): δ 169.9, 169.5, 164.8, 158.0, 109.3, 81.2, 54.8, 54.0, 33.5, 28.1.  IR (neat): 2985, 
1730, 1569, 1470, 1380, 1227, 1147 cm-1.  HRMS (ESI) m/z calcd. For C12H19N2O4 
(M+H)+ 255.1345, found 255.1347. 
 
 
tert-Butyl 2-(Isoquinolin-4-yl)acetate (2.21). General procedure A was employed, with 
the only modification being that 2 mol %  of XPhos-Pd-G2 was used. Column 
chromatography (hexanes/EtOAc = 9:1 to 3:1) provided the title compound as an orange-
brown oil in 80% yield (97 mg).  1H NMR (500 MHz, CDCl3): δ 9.19-9.18 (m, 1H), 8.43-
8.42 (m, 1H), 8.00-7.97 (m, 2H), 7.75-7.72 (m, 1H), 7.62-7.61 (m, 1H), 3.93 (s, 2H), 1.40 
(s, 9H).  13C NMR (125.8 MHz, CDCl3): δ 170.1, 151.9, 147.3, 135.8, 129.3, 129.3, 
128.0, 127.7, 126.9, 81.6, 40.1, 28.1.  IR (neat): 2977, 1728, 1367, 1141 cm-1.  HRMS 
(ESI) m/z calcd. For C15H18NO2 (M+H)+ 244.1338, found 244.1336. 
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tert-Butyl 2-(Pyridin-4-yl)acetate (2.22).17 General procedure A was employed. Column 
chromatography (hexanes/EtOAc = 9:1 to 3:1) provided the title compound as a brown 
oil in 40% yield (39 mg). Spectral data were in accordance with those published. 1H 
NMR (500 MHz, CDCl3): δ 8.56-8.54 (m, 2H), 7.21-7.20 (m, 2H), 3.53 (s, 2H), 1.44 (s, 
9H).  13C NMR (125.8 MHz, CDCl3): δ169.4, 150.0, 143.6, 124.6, 81.7, 42.1, 28.1. 
 
 
tert-Butyl 2-(Furan-3-yl)acetate (2.23). General procedure A was employed. Column 
chromatography (hexanes/EtOAc = 9:1 to 3:1) provided the title compound as a dark 
brown oil in 88% yield (80 mg).  1H NMR (500 MHz, CDCl3): δ 7.36 (dd, J = 6.1, 1.0 
Hz, 2H), 6.36 (s, 1H), 3.32 (s, 2H), 1.44 (s, 9H).  13C NMR (125.8 MHz, CDCl3): δ 
170.4, 142.7, 140.1, 117.8, 111.3, 80.8, 32.1, 27.9.  IR (neat): 2977, 1729, 1149 cm-1.  
HRMS (CI) m/z calcd. For C10H14O3 (M)+, 182.0943 found 182.0945. 
 
 
 
tBu-O
O N
tBu-O
O O
     88 
 
tert-Butyl 2-(2-Acetylthiophen-3-yl)acetate (2.24). General procedure A was employed. 
Column chromatography (hexanes/EtOAc = 9:1 to 3:1) provided the title compound as a 
brown oil in 76% yield (91 mg).  1H NMR (500 MHz, CDCl3): δ 7.45-7.44 (m, 1H), 7.07-
7.06 (m, 1H), 3.97 (s, 2 H), 2.53 (s, 3H), 1.45 (s, 9H).  13C NMR (125.8 MHz, CDCl3): δ 
191.0, 170.0, 141.1, 136.8, 132.3, 129.7, 81.1, 36.8, 29.6, 28.2.  IR (neat): 2981, 1731, 
1665,  1148 cm-1.  HRMS (ESI) m/z calcd. For C12H16O3SNa (M+Na)+, 263.0718, found 
263.0715. 
 
 
tert-Butyl 2-(Thiophen-2-yl)acetate (2.25). General procedure A was employed. 
Column chromatography (hexanes/EtOAc = 9:1 to 3:1) provided the title compound as a 
yellow oil in 75% yield (74 mg).  1H NMR (500 MHz, CDCl3): δ 7.19-7.17 (m, 1H), 
6.94-6.92 (m, 1H), 6.90-6.89 (m, 1H), 3.72 (s, 2 H), 1.44 (s, 9H).  13C NMR (125.8 MHz, 
CDCl3): δ 169.8.0, 136.0, 126.8, 126.6, 125.0, 81.5, 37.0, 28.1.   
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Methyl 2-(Furan-3-yl)acetate (2.26).80 General procedure A was employed. Column 
chromatography (hexanes/EtOAc = 9:1 to 3:1) provided the title compound as a yellow 
oil in 79% yield (55 mg). Spectral data were in accordance with those published.1H NMR 
(500 MHz, CDCl3): δ 7.37 (s, 2H), 6.34 (s, 1H), 3.70 (s, 3H), 3.45 (s, 2H). 13C NMR 
(125.8 MHz, CDCl3): δ 171.8, 143.2, 140.5, 117.4, 111.5, 52.2, 30.8. 
 
 
1-Morpholino-2-(p-tolyl)ethan-1-one (2.27).81 General procedure A was employed. 
Column chromatography (hexanes/EtOAc = 9:1 to 1:3) provided the title compound as an 
orange solid in 81% yield (89 mg). Spectral data were in accordance with those 
published. mp 77-78 °C (lit. 80-81.5 °C)  1H NMR (500 MHz, CDCl3): δ 7.12-7.11 (m, 
4H), 3.69 (s, 2H), 3.64-3.63 (m, 4H), 3.50 (d, J = 5.1 Hz, 2H), 3.46 (d, J = 5.1 Hz, 2H), 
2.32 (s, 3H).  13C NMR (125.8 MHz, CDCl3): δ 170.0, 136.6, 131.8, 129.6, 128.5, 66.9, 
66.6, 46.6, 42.5, 40.6, 21.2.  
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1-Morpholino-2-(naphthalen-2-yl)ethan-1-one (2.28).  General procedure A was 
employed. Column chromatography (hexanes/EtOAc = 9:1 to 1:3) provided the title 
compound as a white solid in 88% yield (112 mg). mp 118-119 °C.  1H NMR (500 MHz, 
CDCl3): δ 7.85 (d, J = 8.0 Hz, 2H), 7.82 (d, J = 7.7 Hz, 1H), 7.71 (s, 1H), 7.50-7.48 (m, 
2H), 7.42 (d, J = 8.4 Hz, 1H), 3.88 (d, J = 1.4 Hz, 2H), 3.65-3.64 (m, 4H), 3.45 (d, J = 
2.2 Hz, 4H).  13C NMR (125.8 MHz, CDCl3): δ 169.5, 133.5, 132.3, 132.2, 128.5, 127.6, 
127.5, 127.0, 126.7, 126.2, 125.7, 66.7, 66.4, 46.5, 42.1, 41.0.  IR (neat): 2860, 1643, 
1428, 1115 cm-1.  HRMS (ESI) m/z calcd. For C16H17NO2 (M+H)+ 256.1338, found 
256.1337. 
 
 
2-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)-1-morpholinoethan-1-one (2.29). General 
procedure A was employed. Column chromatography (hexanes/EtOAc = 9:1 to 1:3) 
provided the title compound as an orange oil in 98% yield (129 mg). 1H NMR (500 MHz, 
CDCl3): δ 6.78 (d, J = 9.6 Hz, 1H), 6.71 (d, J = 1.8 Hz, 1H), 6.65 (dd, J = 8.2, 1.8 Hz, 
1H), 4.21 (s, 4H), 3.63-3.61 (m, 6H), 3.48 (t, J = 4.7 Hz, 2H), 3.41 (t, J = 4.7 Hz, 2H).  
13C NMR (125.8 MHz, CDCl3): δ 169.7, 143.5, 142.4, 127.8, 121.3, 117.4, 117.2, 66.7, 
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66.4, 64.2, 64.2, 46.4, 42.0, 40.0.  IR (neat): 2979, 1639, 1507, 1285, 1067 cm-1.  HRMS 
(ESI) m/z calcd. For C14H18NO4 (M+H)+, 264.1236, found 264.1235. 
 
 
2-(3-Acetylphenyl)-1-morpholinoethan-1-one (2.30). General procedure A was 
employed. Column chromatography (hexanes/EtOAc = 9:1 to 1:3) provided the title 
compound as a yellow oil in 70% yield (86 mg).  1H NMR (500 MHz, CDCl3): δ 7.84-
7.83 (m, 1H), 7.49-7.48 (m, 1H), 7.40-7.38 (m, 1H), 7.29-7.28 (m, 1H), 4.04 (s, 2H), 
3.74-3.69 (m, 8H), 2.63 (s, 3H).  13C NMR (125.8 MHz, CDCl3): δ 201.7, 169.9, 137.1, 
135.7, 132.5, 132.1, 130.1, 127.2, 66.7, 46.3, 42.4, 40.8, 38.8, 29.1.  IR (neat): 2980, 
1676, 1646, 1435, 1113 cm-1.  HRMS (ESI) m/z calcd. For C14H18NO3 (M+H)+, 
248.1287, found 248.1283. 
 
 
2-(4-Fluorophenyl)-1-morpholinoethan-1-one (2.31).27 General procedure A was 
employed. Column chromatography (hexanes/EtOAc = 9:1 to 1:3) provided the title 
compound as a white solid in 68% yield (76 mg). Spectral data were in accordance with 
those published. mp 79-81 °C.  1H NMR (500 MHz, CDCl3): δ 7.20-7.18 (m, 2H), 7.02 
N
O
O O
N
O
O
F
     92 
(t, J = 8.7 Hz, 2H), 3.67 (s, 2H), 3.63 (s, 4H), 3.51 (t, J = 4.7 Hz, 2H), 3.42 (d, J = 4.9 
Hz, 2H).  13C NMR (125.8 MHz, CDCl3): δ 169.6, 161.9 (d, J =245.2 Hz), 130.4 (d, J 
=3.3 Hz), 130.3 (d, J =7.7 Hz), 115.7 (d, J =21.6), 66.9, 66.6, 46.6, 42.3, 39.0. 
 
 
2-(Furan-3-yl)-1-morpholinoethan-1-one (2.32). General procedure A was employed. 
Column chromatography (hexanes/EtOAc = 9:1 to 1:3) provided the title compound as a 
light brown solid in 85% yield (83 mg). mp 75-77 °C.  1H NMR (500 MHz, CDCl3): δ 
7.39 (t, J = 1.2 Hz, 1H), 7.34 (s, 1H), 6.35 (s, 1H), 3.65-3.63 (m, 4H), 3.59-3.58 (m, 2H), 
3.52 (d, J = 1.9 Hz, 2H), 3.47 (s, 2H).  13C NMR (125.8 MHz, CDCl3): δ 169.1, 143.2, 
139.8, 118.1, 111.0, 66.7, 66.4, 46.4, 42.0, 30.3. IR (neat): 2855, 1645, 1634, 1439., 
1229, 1112 cm-1. HRMS (ESI) m/z calcd. For C10H14NO3 (M+H)+, 196.0974, found 
196.0972. 
 
 
2-(2-Morpholino-2-oxoethyl)furan-3-carboxylic acid (2.33). General procedure A was 
employed. Column chromatography (hexanes/EtOAc = 9:1 to 1:3) provided the title 
compound as a light orange solid in 71% yield (85 mg). mp 108-110 °C.  1H NMR (500 
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MHz, CDCl3): δ 8.10 (s, 1H), 7.44 (t, J = 1.6 Hz, 1H), 6.78 (t, J = 0.9 Hz, 1H), 4.88 (s, 
2H), 3.71 (d, J = 4.4 Hz, 4H), 3.64 (d, J = 3.9 Hz, 2H), 3.44 (d, J = 3.8 Hz, 2H).  13C 
NMR (125.8 MHz, CDCl3): δ 165.0, 162.4, 148.3, 143.8, 118.4, 109.8, 66.7, 66.3, 61.1, 
45.0, 42.1.  IR (neat): 2961, 1733, 1667, 1469, 1311, 1144 cm-1.  HRMS (ESI) m/z calcd. 
For C11H14NO5 (M+H)+, 240.0872, found 240.0875. 
 
 
1-Morpholino-2-[1-(phenylsulfonyl)-1H-indol-3-yl]ethan-1-one (2.34). General 
procedure A was employed. Column chromatography (hexanes/EtOAc = 9:1 to 1:3) 
provided the title compound as an orange oil in 85% yield (157 mg). 1H NMR (500 MHz, 
CDCl3): δ 8.02-8.00 (m, 1H), 7.88-7.87 (m, 2H), 7.55-7.53 (m, 2H), 7.45 (dt, J=J = 12.5, 
6.4 Hz, 3H), 7.35-7.34 (m, 1H), 7.27-7.26 (m, 1H), 3.74 (s, 2H), 3.65-3.64 (m, 4H), 3.43-
3.40 (m, 4H).  13C NMR (125.8 MHz, CDCl3): δ 168.3, 138.0, 135.1, 133.8, 130.2, 129.2, 
126.6, 125.1, 123.8, 123.4, 119.6, 116.2, 113.6, 66.7, 66.3, 46.4, 42.1, 30.7.  IR (neat): 
2979, 1643, 1446, 1365, 1174, 1115 cm-1.  HRMS (ESI) m/z calcd. For C20H21N2O4S 
(M+H)+, 385.1222, found 385.1215. 
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2-(Benzothiophen-2-yl)-1-morpholinoethan-1-one (2.35). General procedure A was 
employed. Column chromatography (hexanes/EtOAc = 9:1 to 1:3) provided the title 
compound as a light orange solid in 62% yield (81 mg). mp 118-120 °C.  1H NMR (500 
MHz, CDCl3): δ 7.79 (d, J = 7.8 Hz, 1H), 7.70 (d, J = 7.9 Hz, 1H), 7.33-7.29 (m, 3H), 
3.98 (s, 2H), 3.68-3.67 (m, 4H), 3.59 (t, J = 4.3 Hz, 2H), 3.54-3.53 (m, 2H). 13C NMR 
(125.8 MHz, CDCl3): δ 167.9, 139.7, 139.6, 137.3, 124.3, 124.0, 123.1, 122.6, 122.1, 
66.6, 66.4, 46.6, 42.2, 35.7.  IR (neat): 2920, 1644, 1436, 1229, 1113 cm-1.  HRMS (ESI) 
m/z calcd. For C14H16NO2S (M+H)+, 262.0902, found 262.0898. 
 
 
1-(Piperidin-1-yl)-2-(p-tolyl)ethan-1-one (2.36).82 General procedure A was employed. 
Column chromatography (hexanes/EtOAc = 9:1 to 1:3) provided the title compound as a 
white solid in 86% yield (93 mg). Spectral data were in accordance with those published.  
mp 59-60 °C.  1H NMR (500 MHz, CDCl3): δ 7.11-7.10 (m, 4H), 3.66 (s, 2H), 3.54 (t, J 
= 5.4 Hz, 2H), 3.33 (t, J = 5.5 Hz, 2H), 2.29 (s, 3H), 1.57-1.55 (m, 2H), 1.50-1.49 (m, 
2H), 1.32 (qt, J = 5.2 Hz, 2H).  13C NMR (125.8 MHz, CDCl3): δ 169.6, 136.3, 132.4, 
129.5, 128.5, 47.4, 43.0, 41.0, 26.3, 25.6, 24.6, 21.2. 
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N,N-Diethyl-2-(p-tolyl)acetamide (2.37).83  General procedure A was employed. 
Column chromatography (hexanes/EtOAc = 9:1 to 1:3) provided the title compound as a 
white solid in 72% yield (74 mg). Spectral data were in accordance with those published. 
mp 103-105 °C.  1H NMR (500 MHz, CDCl3): δ 7.17-7.12 (m, 4H), 3.67 (s, 2H), 3.41 (q, 
J = 6.8 Hz, 2H), 3.31 (q, J = 7.1 Hz, 2H), 2.34 (s, 3H), 1.12 (dt, J = 14.8, 7.3 Hz, 6H). 
13C NMR (125.8 MHz, CDCl3): δ 170.4, 136.3, 132.5, 129.4, 128.6, 42.4, 40.6, 40.2, 
21.2, 14.3, 13.1. 
 
General procedure B for cross-coupling of heteroaryltrifluoroborates with 
secondary 2-chloroacetamides. An oven-dried Biotage 10 mL microwave vial equipped 
with a magnetic stirbar was charged with the (hetero)aryl trifluoroborate (0.525 mmol, 
1.05 equiv), Cs2CO3 (1.5 mmol, 3 equiv), XPhos-Pd-G2 (3.93 mg, 5.0 µmol, 1 mol %), 
and Cu2O (3.6 mg, 25 µmol, 5 mol %).  A disposable Teflon septum cap was used to seal 
the vial, which was evacuated and purged with Ar three times.  THF (1.6 mL), H2O (0.4 
mL), and the electrophile (0.5 mmol, 1 equiv) were added via syringe with stirring under 
Ar.  In cases where the electrophile was a solid, it was added along with the solid 
materials before sealing the vial.  The soln was heated at 100 °C overnight.  After cooling 
to rt, the mixture was extracted with EtOAc (3x3 mL), and the combined organic layers 
N
O
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were dried (Na2SO4). The crude products were purified by flash column chromatography, 
eluting with a gradient of EtOAc in hexanes. 
 
 
N-Benzyl-2-(quinolin-6-yl)acetamide (2.38). General procedure B was employed. 
Column chromatography (hexanes/EtOAc = 9:1 to 1:4) provided the title compound as a 
light orange solid in 55% yield (76 mg). mp 135-137 °C.  1H NMR (500 MHz, CDCl3): δ 
8.89-8.88 (m, 1H), 8.10-8.06 (m, 2H), 7.75 (s, 1H), 7.62 (d, J = 8.6 Hz, 1H), 7.41 (ddd, J 
= 8.2, 4.2, 1.0 Hz 1H), 7.29-7.26 (m, 3H), 7.22 (t, J = 5.7 Hz, 2H), 5.84 (br s, 1H), 4.43 
(d, J = 5.8 Hz, 2H), 3.79 (s, 2H).  13C NMR (125.8 MHz, CDCl3): δ 170.4, 150.6, 138.1, 
136.5, 136.0, 133.4, 131.1, 130.3, 129.3, 128.8, 128.4, 128.2, 127.8, 127.7, 126.2, 121.7, 
43.9, 43.8.  IR (neat): 3229, 2361, 1628, 1554, 1328 cm-1.  HRMS (ESI) m/z calcd. For 
C18H17N2O (M+H)+ 277.1341, found 277.1339. 
 
 
N-Benzyl-2-(p-tolyl)acetamide (2.39).84 General procedure B was employed. Column 
chromatography (hexanes/EtOAc = 9:1 to 1:4) provided the title compound as a white 
solid in 75% yield (90 mg). Spectral data were in accordance with those published. mp 
N
H
O N
N
H
O
     97 
134-135 °C (lit. 136).  1H NMR (500 MHz, CDCl3): δ 7.33 (t, J = 7.2 Hz, 2H), 7.27-7.26 
(m, 1H), 7.21 (d, J = 7.2 Hz, 2H), 7.18 (s, 4H), 5.67 (br s, 1H), 4.41 (d, J = 5.6 Hz, 2H), 
3.60 (s, 2H), 2.33 (s, 3H).  13C NMR (125.8 MHz, CDCl3): δ 171.3, 138.4, 137.2, 131.8, 
129.9, 129.5, 128.8, 127.6, 127.5, 43.7, 43.6, 21.2. 
 
 
N-Cyclopropyl-2-(p-tolyl)acetamide (2.40). General procedure B was employed. 
Column chromatography (hexanes/EtOAc = 9:1 to 1:4) provided the title compound as a 
white solid in 67% yield (63 mg). mp 117-118 °C.  1H NMR (500 MHz, CDCl3): δ 7.16-
7.14 (m, 4H), 5.43 (br s, 1H), 3.50 (s, 2H), 2.67-2.63 (m, 1H), 2.34 (s, 3H), 0.71 (dd, J 
=7.0, 1.3 Hz, 2H), 0.39-0.38 (m, 2H).  13C NMR (125.8 MHz, CDCl3): δ 172.9, 137.0, 
132.0, 129.7, 129.3, 43.3, 22.9, 21.2, 6.6. IR (neat): 3280, 1644, 1545, 1266  cm-1.  
HRMS (ESI) m/z calcd. For C12H16NO (M+H)+ 190.1232, found 190.1238. 
 
 
N-Cyclopropyl-2-(furan-3-yl)acetamide (2.41). General procedure B was employed. 
Column chromatography (hexanes/EtOAc = 9:1 to 1:4) provided the title compound as a 
white solid in 70% yield (58 mg). mp 60-62 °C.  1H NMR (500 MHz, CDCl3): δ 7.43 (d, 
J = 1.3 Hz, 1H), 7.37 (s, 1H), 6.33 (s, 1H), 5.77 (br s, 1H), 3.37 (s, 2H), 2.71-2.68 (m, 
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1H), 0.77 (q, J = 6.9 Hz, 2H), 0.45 (dd, J = 2.2, 1.1 Hz, 2H).  13C NMR (125.8 MHz, 
CDCl3): δ 172.1, 143.7, 140.8, 118.4, 111.3, 32.9, 22.8, 6.6.  IR (neat): 3287, 1650, 1539, 
1022  cm-1.  HRMS (ESI) m/z calcd. For C9H12NO2 (M+H)+ 166.0868, found 166.0870. 
 
 
N-Cyclopropyl-2-(naphthalen-1-yl)acetamide (2.42).85 General procedure B was 
employed. Column chromatography (hexanes/EtOAc = 9:1 to 1:4) provided the title 
compound as a white solid in 71% yield (80 mg). Spectral data were in accordance with 
those published. mp 134-136 °C (lit. 140-141).  1H NMR (500 MHz, CDCl3): δ 7.96 (t, J 
= 6.1 Hz, 1H), 7.91 (q, J = 6.7 Hz, 1H), 7.85 (d, J = 8.2 Hz, 1H), 7.55-7.52 (m, 2H), 
7.46-7.43 (m, 1H), 7.38-7.36 (m, 1H), 5.38 (br s, 1H), 3.99 (s, 2H), 2.60-2.57 (m, 1H), 
0.65 (q, J = 6.3 Hz, 2H), 0.26-0.25 (m, 2H).  13C NMR (125.8 MHz, CDCl3): δ 172.2, 
133.9, 131.9, 131.1, 128.7, 128.4, 128.1, 126.7, 126.1, 125.5, 123.7, 41.7, 22.6, 6.4. 
 
N-Cyclopropyl-2-(isoquinolin-5-yl)acetamide (2.43). General procedure B was 
employed. Column chromatography (hexanes/EtOAc = 9:1 to 1:4) provided the title 
compound as a light orange solid in 62% yield (70 mg). mp 145-147 °C.  1H NMR (500 
MHz, CDCl3): δ 9.26 (s, 1H), 8.57-8.56 (m, 1H), 7.94-7.92 (m, 1H), 7.78 (t, J =4.5 Hz, 
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1H), 7.58-7.57 (m, 2H), 5.49 (br s, 1H), 3.94 (s, 2H), 2.63-2.61 (m, 1H), 0.68 (dd, J = 
7.0, 1.4 Hz, 2H), 0.31 (td, J = 2.5, 1.1 Hz, 2H).  13C NMR (125.8 MHz, CDCl3): δ 171.7, 
153.2, 143.7, 135.0, 132.2, 130.9, 129.1, 127.8, 127.2, 117.0, 40.7, 23.0, 6.6.  IR (neat): 
3281, 1648, 1544 cm-1.  HRMS (ESI) m/z calcd. For C14H15N2O (M+H)+ 227.1184, found 
227.1190. 
 
General procedure for Pd-catalyzed cross-coupling reaction of potassium 
alkenyltrifluoroborates with 2-chloroacetates and 2-chloroacetamides. To a Biotage 
10 mL microwave vial were added the appropriate alkenyltrifluoroborate (0.525 mmol, 
1.05 equiv), K2CO3 (1.5 mmol, 3 equiv) and the Pd-XPhos preformed catalyst (2.5 µmol, 
1.97 mg, 0.5 mol % for 2-chloroacetates or 5 µmol, 3.93 mg, 1 mol % for 2-
chloroacetamides). The vial was sealed with a cap lined with a Teflon septum and was 
evacuated and filled with Ar three times. Degassed THF (1.6 mL) and H2O (0.4 mL) 
were added, followed by the 2-chloroacetate or 2-chloroacetamide (0.5 mmol). In cases 
where the electrophile was a solid, it was added along with the solid materials before 
sealing the vial. The reaction mixture was stirred at 80 °C for the appropriate time (see 
Table 1). The reaction mixture was extracted with EtOAc (3 x 2 mL) and then dried with 
anhydrous MgSO4. The crude product was purified by flash column chromatography 
(elution with hexanes/EtOAc = 9:1 for esters, hexanes/EtOAc = 4:1 to 1:4 for amides) to 
afford the expected product. 
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(E)-Benzyl 4-Phenylbut-3-enoate (2.44). The title compound was obtained as a white 
solid in 96% yield (242 mg). mp = 37-39 °C; 1H NMR (500 MHz, CDCl3): δ 7.34-7.21 
(m, 10H), 6.50 (d, J = 16.0 Hz, 1H), 6.32 (dt, J = 16.0, 7.0 Hz, 1H), 5.16 (s, 2H), 3.30 
(dd, J = 7.0, 1.5 Hz, 2H); 13C NMR (125.8 MHz, CDCl3): δ 171.5, 137.0, 135.9, 133.7, 
128.7, 128.7, 128.4, 128.4, 127.7, 126.4, 121.7, 66.7, 38.5; FT-IR (neat): 1732, 1152, 
966, 746, 693 cm-1; HRMS (ES+) m/z calcd. for C17H16O2Na (M+Na)+ 275.1048, found 
275.1059. 
 
 
(E)-Benzyl Pent-3-enoate (2.45).86 The title compound was obtained as a colorless oil in 
94% yield (179 mg). (For 5.0 mmol reaction, 0.5 mol % XPhos-Pd-G2 was used, 86% 
yield.) The physical data were in accordance with those previously reported. 1H NMR 
(500 MHz, CDCl3): δ 7.42-7.36 (m, 5H), 5.57 (m, 2H), 5.12 (s, 2H), 3.06 (d, J = 5.0 Hz, 
2H), 1.70 (d, J = 5.0 Hz, 3H); 13C NMR (125.8 MHz, CDCl3): δ 172.2, 136.1, 129.7, 
128.7, 128.5, 128.3, 122.7, 66.5, 38.2, 18.0. 
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(Z)-Benzyl Dodec-3-enoate (2.46). The title compound was obtained as a colorless oil in 
70% yield (101 mg).  1H NMR (500 MHz, CDCl3): δ 7.35-7.33 (m, 5H), 5.58-5.55 (m, 
2H), 5.11 (s, 2H), 3.13 (d, J = 5.5 Hz, 2H), 2.03-2.00 (m, 2H), 1.33-1.32 (m, 2H), 1.24 
(br, 10 H), 0.87 (t, J = 6.9 Hz. 3H); 13C NMR (125.8 MHz, CDCl3): δ 172.0, 136.1, 
133.9, 128.7, 128.3, 128.3, 120.7, 66.5, 33.1, 32.0, 31.7, 29.6, 29.4, 29.4, 27.6, 22.8, 
14.2; FT-IR (neat): 1739, 1603, 1498, 1154 cm-1; HRMS (ES+) m/z calcd. for C19H28O2 
(M)+ 288.2089, found 288.2086. 
 
 
(E)-Benzyl Dodec-3-enoate (2.47). The title compound was obtained as a colorless oil in 
89% yield (128 mg). 1H NMR (500 MHz, CDCl3): δ 7.38-7.32 (m, 5H), 5.63-5.53 (m, 
2H), 5.12 (s, 2H), 3.07 (d, J = 5.5 Hz, 2H), 2.02 (q, J = 7.0 Hz, 2H), 1.36-1.25 (m, 12 H), 
0.88 (t, J = 7.0 Hz, 3H); 13C NMR (125.8 MHz, CDCl3): δ 172.2, 136.1, 135.3, 128.7, 
128.3, 128.3, 121.4, 66.4, 38.2, 32.6, 32.0, 29.6, 29.4, 29.3, 22.8, 14.3; FT-IR (neat): 
2925, 1739, 1456, 1151, 967, 697 cm-1; HRMS (ES+) m/z calcd. for C19H28O2Na 
(M+Na)+ 311.1987, found 311.2000. 
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(Z)-Benzyl 6-Phenylhex-3-enoate (2.48). The title compound was obtained as a 
colorless oil in 87% yield (122 mg). 1H NMR (500 MHz, CDCl3): δ 7.37-7.15 (m, 10H), 
5.65-5.57 (m, 2H), 5.10 (s, 2H), 3.05 (d, J = 5.1 Hz, 2H), 2.67 (t, J = 7.6 Hz, 2H), 2.42-
2.31 (m, 2H); 13C NMR (125.8 MHz, CDCl3): δ 171.8, 141.8, 136.1, 132.5, 128.7, 128.6, 
128.5, 128.4, 128.4, 126.1, 121.7, 66.6, 35.6, 33.1, 29.5; FT-IR (neat): 1736, 1154, 697 
cm-1; HRMS (ES+) m/z calcd. for C19H20O2Na (M+Na)+ 303.1361, found 303.1357. 
 
 
Benzyl 2-(Cyclohex-1-en-1-yl)acetate (2.49).87 The title compound was obtained as a 
colorless oil in 85% yield (196 mg). The physical data were in accordance with those 
previously reported. 1H NMR (500 MHz, CDCl3): δ 7.36-7.31 (m, 5H), 5.57 (s, 1H), 5.12 
(s, 2H), 2.99 (s, 2H), 2.03-1.99 (m, 4H), 1.65-1.53 (m, 4H); 13C NMR (125.8 MHz, 
CDCl3): δ 172.0, 136.2, 131.1, 128.6, 128.3, 128.2, 126.0, 66.3, 43.7, 28.6, 25.4, 22.8, 
22.1. 
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(E)-Benzyl 7-Cyanohept-3-enoate (2.50). The title compound was obtained as a 
colorless oil in 91% yield (110 mg). 1H NMR (500 MHz, CDCl3): δ 7.39-7.32 (m, 5H), 
5.64 (dt, J = 15.2, 6.8 Hz, 1H), 5.50 (dt, J = 15.2, 6.8 Hz, 1H), 5.13 (s, 2H), 3.10 (dd, J = 
6.8, 1.1 Hz, 2H), 2.31 (t, J = 7.2 Hz, 2H), 2.20 (qd, J = 7.0, 1.2 Hz, 2H), 1.76-1.71 (m, 
2H); 13C NMR (125.8 MHz, CDCl3): δ 171.6, 135.8, 132.0, 128.6, 128.3, 128.3, 124.0, 
119.6, 66.5, 37.9, 31.1, 24.7, 16.3; FT-IR (neat) 1733, 1149, 970, 699 cm-1; HRMS (ES+) 
m/z calcd. for C15H17NO2Na (M+Na)+ 266.1157, found 266.1161. 
 
 
Benzyl 3-Methylbut-3-enoate (2.51). The title compound was obtained as a colorless oil 
in 76% yield (144 mg). 1H NMR (500 MHz, CDCl3): δ 7.37-7.31 (m, 5H), 5.14 (s, 2H), 
4.92 (s, 1H), 4.86 (s, 1H), 3.09 (s, 2H), 1.80 (s, 3H); 13C NMR (125.8 MHz, CDCl3): δ 
171.4, 138.6, 136.0, 128.7, 128.4, 128.3, 115.0, 66.6, 43.6, 22.6; FT-IR (neat): 1736, 
1239, 1149, 698 cm-1; HRMS (ES+) m/z calcd. for C12H14O2Na (M+Na)+ 213.0891, 
found 213.0898. 
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tert-Butyl (E)-4-Phenylbut-3-enoate (2.52).88 The title compound was obtained as a 
yellow oil in 64% yield (140 mg). The physical data were in accordance with those 
previously reported. 1H NMR (500 MHz, CDCl3): δ 7.40-7.39 (m, 2H), 7.34-7.31 (m, 
2H), 7.28-7.25 (m, 1H), 6.49 (d, J = 15.9 Hz, 1H), 6.32 (dt, J = 15.5, 7.5 Hz, 1H), 3.18 
(d, J = 7.1 Hz, 2H), 1.50 (s, 9H); 13C NMR (125.8 MHz, CDCl3): δ 171.1, 137.2, 133.1, 
128.7, 127.6, 126.4, 122.7, 81.0, 39.8, 28.3. 
 
 
tert-Butyl (E)-5-Phenylpent-3-enoate (2.53). The title compound was obtained as a 
yellow oil in 66% yield (153 mg). 1H NMR (500 MHz, CDCl3): δ 7.27-7.24 (m, 2H), 
7.18-7.16 (m, 3H), 5.67-5.65 (m, 1H), 5.64-5.61 (m, 1H), 3.36 (d, J = 6.5 Hz, 2H), 2.95 
(d, J = 6.6 Hz, 2H), 1.43 (s, 9H); 13C NMR (125.8 MHz, CDCl3): δ 171.6, 140.4, 132.9, 
128.8, 128.7, 128.5, 126.9, 126.2, 124.0, 80.8, 39.4, 39.1, 28.2; FT-IR (neat): 2982, 1729, 
1368, 1149 cm-1; HRMS (ES+) m/z calcd. for C15H20O2Na (M+Na)+ 255.1361, found 
255.1359. 
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Isopropyl (E)-5-Phenylpent-3-enoate (2.54). The title compound was obtained as a 
yellow oil in 64% yield (140 mg).  1H NMR (500 MHz, CDCl3): δ 7.25-7.21 (m, 2H), 
7.17-7.14 (m, 3H), 5.72-5.66 (m, 1H), 5.62-5.58 (m, 1H), 4.97 (dt, J = 12.5, 6.3 Hz, 1H), 
3.34 (d, J = 6.5 Hz, 2H), 2.99 (d, J = 6.6 Hz, 2H), 1.19 (d, J = 6.3 Hz, 6H); 13C NMR 
(125.8 MHz, CDCl3): δ 171.7, 140.4, 133.1, 128.7, 128.6, 126.2, 123.6, 68.1, 39.1, 38.5, 
22.0; FT-IR (neat): 2982, 2357, 1731, 1182, 1107 cm-1; HRMS (ES+) m/z calcd. for 
C14H18O2Na (M+Na)+ 241.1204, found 241.1204. 
 
 
Benzyl (E)-8-Chlorooct-3-enoate (2.55). The title compound was obtained as a colorless 
oil in 62% yield (165 mg).  1H NMR (500 MHz, CDCl3): δ 7.33-7.28 (m, 5H), 5.52-5.51 
(m, 2H), 5.08 (s, 2H), 3.48 (td, J = 6.7, 1.1 Hz, 2H), 3.05-3.04 (m, 2H), 2.04-2.01 (m, 
2H), 1.74-1.71 (m, 2H), 1.49-1.46 (m, 2H); 13C NMR (125.8 MHz, CDCl3): δ 172.0, 
136.1, 134.2, 128.7, 128.4, 128.4, 122.3, 66.5, 45.1, 38.2, 32.1, 31.8, 26.4; FT-IR (neat): 
2941, 1736, 1456, 1157 cm-1; HRMS (ES+) m/z calcd. for C15H19O2ClNa (M+Na)+ 
289.0971, found 289.0972. 
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Benzyl (E)-5-(Benzyl(methyl)amino)pent-3-enoate (2.56). The title compound was 
obtained as a colorless oil in 63% yield (195 mg).  1H NMR (500 MHz, CDCl3): δ 7.34-
7.25 (m, 10H), 5.72 (dt, J = 15.4, 6.3 Hz, 1H), 5.69 (dt, J = 14.9, 7.2, 1H), 5.12 (s, 2H), 
3.47 (s, 2H), 3.14 (d, J = 6.5 Hz, 2H), 3.01 (d, J = 6.3 Hz, 2H), 2.17 (s, 3H); 13C NMR 
(125.8 MHz, CDCl3): δ 171.7, 139.1, 136.0, 132.0, 129.2, 128.7, 128.4, 128.4, 128.4, 
127.1, 125.1, 66.6, 61.8, 59.4, 42.2, 38.0; FT-IR (neat): 2783, 1737, 1454, 1154 cm-1; 
HRMS (ES+) m/z calcd. for C20H24O2N (M+H)+ 310.1807, found 310.1809. 
 
 
Benzyl (E)-5-(Benzyloxy)pent-3-enoate (2.57). The title compound was obtained as a 
colorless oil in 74% yield (219 mg).  1H NMR (500 MHz, CDCl3): δ 7.35-7.32 (m, 10H), 
5.88-5.85 (m, 1H), 5.76-5.72 (m, 1H), 5.12 (s, 2H), 4.49 (s, 2H), 4.01-4.00 (m, 2H), 3.15 
(d, J = 6.8 Hz, 2H); 13C NMR (125.8 MHz, CDCl3): δ 171.5, 138.4, 136.0, 130.8, 128.7, 
128.6, 128.5, 128.4, 128.0, 127.8, 125.5, 72.3, 70.4, 66.7, 37.9; FT-IR (neat): 2982, 1736, 
1454, 1154 cm-1; HRMS (ES+) m/z calcd. for C19H20O3Na (M+Na)+ 319.1310, found 
319.1310. 
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Benzyl (E)-6-((Tetrahydropyran-2-yl)oxy)hex-3-enoate (2.58).  The title compound 
was obtained as a colorless oil in 80% yield (243 mg).  1H NMR (500 MHz, CDCl3): δ 
7.35-7.29 (m, 5H), 5.63-5.59 (m, 2H), 5.09 (s, 2H), 4.55 (t, J = 3.5 Hz, 1H), 3.84 (ddd, J 
= 11.1, 8.1, 2.9 Hz, 1H), 3.75 (dt, J = 9.6, 7.0 Hz, 1H), 3.47-3.44 (m, 1H), 3.39 (dt, J = 
9.7, 6.8 Hz, 1H), 3.07 (d, J = 5.7 Hz, 2H), 2.34-2.30 (m, 2H), 1.80-1.79 (m, 1H), 1.70-
1.69 (m, 1H), 1.68-1.55 (m, 4H); 13C NMR (125.8 MHz, CDCl3): δ 171.9, 136.1, 131.3, 
128.7, 128.4, 128.3, 123.6, 98.9, 67.0, 66.5, 62.5, 38.3, 33.1, 30.8, 25.6, 19.7; FT-IR 
(neat): 2945, 1737, 1154, 1031 cm-1; HRMS (ES+) m/z calcd. for C18H24O4Na (M+Na)+ 
327.1572, found 327.1572. 
 
 
(Z)-Benzyl Pent-3-enoate (2.59).86 The title compound was obtained as a colorless oil in 
92% yield (87 mg). The physical data were in accordance with those previously reported. 
This product is contaminated with approximately 15% of the trans isomer (3b).  1H NMR 
(500 MHz, CDCl3): δ 7.40-7.36 (m, 5H), 5.78-5.45 (m, 2H), 5.13 (s, 2H), 3.15 (d, J = 6.7 
Hz, 2H), 1.64 (dd, J = 6.7, 1.5 Hz, 3H); 13C NMR (125.8 MHz, CDCl3): δ 172.0, 136.1, 
128.7, 128.3, 128.3, 127.8, 121.7, 66.5, 32.8, 13.1. 
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(Z)-Benzyl 4-Phenylbut-3-enoate (2.60). The title compound was obtained as a colorless 
oil in 72% yield (181 mg). This product is contaminated with approximately 15% of the 
trans isomer (3a). 1H NMR (500 MHz, CDCl3): δ 7.35-7.21 (m, 10H), 6.62 (d, J = 11.6, 
1H), 5.18 (s, 1H), 3.37 (d, J = 7.3 Hz, 2H); 13C NMR (125.8 MHz, CDCl3): δ 171.7, 
136.7, 136.0, 132.3, 128.8, 128.8, 128.5, 128.5, 128.4, 127.3, 123.2, 66.8, 34.3; FT-IR 
(neat): 2361, 1735, 1322, 1154 cm-1; HRMS (ES+) m/z calcd. for C17H17O2 (M+H)+ 
253.1229, found 253.1226. 
 
 
(E)-N-Benzyl 4-Phenylbut-3-enamide (2.61). The title compound was obtained as a 
white solid in 92% yield (238 mg). mp: 120-122 °C; 1H NMR (500 MHz, CDCl3): δ 
7.41-7.20 (m, 10H), 6.54 (d, J = 15.9 Hz, 1H), 6.31 (dt, J = 15.8, 7.3 Hz, 1H), 5.91 (br, 
1H), 4.46 (d, J = 5.8 Hz, 2H), 3.22 (dd, J = 7.3, 1.4 Hz, 2H); 13C NMR (125.8 MHz, 
CDCl3): δ 170.7, 138.3, 136.6, 134.8, 128.8, 128.7, 127.9, 127.9, 127.6, 126.4, 122.4, 
43.8, 40.9; FT-IR (neat): 3237, 1632, 1554, 689 cm-1; HRMS (ES+) m/z calcd. for 
C17H18NO (M+H)+ 252.1388, found 252.1384. 
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(E)-N-Benzyl Pent-3-enamide (2.62).89 The title compound was obtained as a colorless 
oil in 88% yield (166 mg). The physical data were in accordance with those previously 
reported. mp: 65-66 °C (Lit.: 66 °C); 1H NMR (500 MHz, CDCl3): δ 7.44-7.11 (m, 5H), 
5.89 (br, 1H), 5.72-5.63 (m, 1H), 5.62-5.53 (m, 1H), 4.45 (d, J = 5.8 Hz, 2H), 2.99 (d, J = 
7.1 Hz, 2H), 1.71 (dd, J = 6.3, 1.3 Hz, 3H); 13C NMR (125.8 MHz, CDCl3): δ 171.3, 
138.4, 131.4, 128.9, 127.9, 127.6, 123.7, 43.7, 40.7, 18.2. 
 
 
(E)-N-Benzyl Dodec-3-enamide (2.63). The title compound was obtained as a white 
solid in 93% yield (267 mg). mp: 57-58 °C; 1H NMR (500 MHz, CDCl3): δ 7.33-7.27 (m, 
5H), 5.88 (br, 1H), 5.71-5.61 (m, 1H), 5.60-5.52 (m, 1H), 4.44 (d, J = 5.5 Hz, 2H), 3.99 
(d, J = 7 Hz, 2H) 2.03 (q, J = 7.0 Hz, 2H) 1.36-1.24 (m, 12H), 0.87 (t, J = 7 Hz, 3H); 13C 
NMR (125.8 MHz, CDCl3): δ 171.4, 138.4, 137.0, 128.8, 127.8, 127.6, 122.5, 43.7, 40.6, 
32.7, 32.0, 29.5, 29.4, 29.3, 29.3, 22.8, 14.2; FT-IR (neat) 3287, 2990, 1638, 1549, 1237, 
962, 694 cm-1; HRMS (ES+) m/z calcd. for C19H30NO (M+H)+ 288.2327, found 
288.2338. 
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N-Benzyl But-3-enamide (2.64).90 The title compound was obtained as a colorless oil in 
90% yield (156 mg). The physical data were in accordance with those previously 
reported. mp: 50-51 °C (Lit.: 48.5-49 °C); 1H NMR (500 MHz, CDCl3): δ 7.35-7.27 (m, 
5H), 5.99-5.90 (m, 1H), 5.89 (br, 1H), 5.24-5.20 (m, 2H), 4.44 (d, J = 5.5 Hz, 2H), 3.05 
(d, J = 7.0 Hz, 2H); 13C NMR (125.8 MHz, CDCl3): δ 170.6, 138.3, 131.4, 128.8, 127.8, 
127.6, 119.9, 43.7, 41.7. 
 
 
(E)-N-Benzyl 5-Phenylpent-3-enamide (2.65). The title compound was obtained as a 
light yellow solid in 72% yield (191 mg). mp = 69-71 °C; 1H NMR (500 MHz, CDCl3), δ 
7.35-7.31 (m, 3H), 7.31-7.27 (m, 3H), 7.25-7.24 (m, 1H), , 7.23-7.17 (m, 1H), 7.15 (d, J 
= 7.2 Hz, 2H), 6.08 (br, 1H), 5.77 (dt, J = 14.8, 7.2 Hz, 1H), 5.65 (dt, J = 15.0, 7.4 Hz, 
1H), 4.42 (t, J = 6.6 Hz, 2H), 3.38 (d, J = 6.7 Hz, 2H), 3.01 (d, J = 7.1 Hz, 2H); 13C NMR 
(125.8 MHz, CDCl3): δ 171.1, 140.1, 138.4, 134.9, 128.9, 128.7, 128.6, 127.9, 127.9, 
127.7, 126.4, 124.2, 43.8, 40.5, 39.1; FT-IR (neat): 3267, 1639, 1561, 1421 cm-1; HRMS 
(ES+) m/z calcd. for C18H20NO (M+H)+ 266.1545, found 266.1544. 
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(Z)-N-Benzyl Pent-3-enamide (2.66). The title compound was obtained as a colorless oil 
in 89% yield (168 mg). This product is contaminated with approximately 20% of the 
trans isomer.  1H NMR (500 MHz, CDCl3): δ 7.39-7.24 (m, 5H), 5.98 (br, 1H), 5.83-5.74 
(m, 1H), 5.67-5.55 (m, 1H), 4.44 (d, J = 5.7 Hz, 2H), 3.08 (d, J = 7.5 Hz, 2H), 1.65 (dd, J 
= 6.9, 0.9 Hz, 3H); 13C NMR (125.8 MHz, CDCl3): δ 170.9, 138.3, 129.3, 128.7, 127.7, 
127.5, 122.7, 43.6, 34.8, 13.0; FT-IR (neat): 3286, 1637, 1547, 694 cm-1; HRMS (ES+) 
m/z calcd. for C12H16NO (M+H)+ 190.1232, found 190.1235. 
 
 
(E)-1-(Piperidin-1-yl)pent-3-en-1-one (2.67).7 The title compound was obtained as a 
pale yellow oil in 89% yield (74 mg). The physical data were in accordance with those 
previously reported. 1H NMR (500 MHz, CDCl3): δ 5.58-5.30 (m, 2H), 3.53 (t, J = 5.5 
Hz, 2H), 3.37 (t, J = 5.5 Hz, 2H), 3.06 (d, J = 4.2 Hz, 2H), 1.69 (d, J = 4.2 Hz, 3H), 1.68-
160 (m, 2H), 1.55-1.51 (m, 4H); 13C NMR (125.8 MHz, CDCl3): δ 169.9, 128.4, 124.3, 
47.0, 42.8, 37.9, 26.6, 25.7, 24.7, 18.1. 
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(E)-N-Isopropyl Pent-3-enamide (2.68). The title compound was obtained as a colorless 
oil in 91% yield (64 mg). 1H NMR (500 MHz, CDCl3): δ 5.64-5.49 (m, 2H), 5.38 (br, 
1H), 4.10-4.01 (m, 1H), 2.88 (dd, J = 7.0, 1.0 Hz, 2H) 1.72 (d, J = 6.5 Hz, 3H), 1.13 (d, J 
= 6.0 Hz, 6H); 13C NMR (125.8 MHz, CDCl3): δ 170.6, 130.8, 124.0, 41.4, 40.8, 22.9, 
18.1; FT-IR (neat) 3283, 1641, 1547, 966 cm-1; HRMS (ES+) m/z calcd. for C8H16NO 
(M+H)+ 142.1232, found 142.1234. 
 
 
(E)-Pent-3-enamide (2.69).91 The title compound was obtained as a white solid in 78% 
yield (38 mg). The physical data were in accordance with those previously reported. mp: 
69-70 °C (Lit.: 70-71°C); 1H NMR (500 MHz, CDCl3): δ 5.69-5.52 (m, 4H), 2.94 (d, J = 
7.0 Hz, 2H), 1.72 (d, J = 6.5 Hz, 3H); 13C NMR (125.8 MHz, CDCl3): δ 174.4, 131.1, 
123.7, 40.1, 18.1. 
 
 
(E)-1-Morpholinopent-3-en-1-one (2.70).92 The title compound was obtained as a 
yellow oil in 71% yield (120 mg). The physical data were in accordance with those 
previously reported. 1H NMR (500 MHz, CDCl3): δ 5.58-5.57 (m, 2H), 3.68-3.66 (m, 
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4H), 3.64 (d, J = 4.9 Hz, 2H), 3.47 (t, J = 4.6 Hz, 2H), 3.09 (s, 2H), 1.72 (s, 3H); 13C 
NMR (125.8 MHz, CDCl3) δ 170.3, 128.9, 123.7, 66.9, 66.7, 46.3, 42.0, 37.5, 18.1. 
 
 
(E)-N-Cyclopropyl Pent-3-enamide (2.71). The title compound was obtained as a 
yellow oil in 87% yield (121 mg). 1H NMR (500 MHz, CDCl3): δ 5.72 (br, 1H), 5.64-
5.58 (m, 1H), 5.52-5.47 (m, 1H), 2.89 (d, J = 6.98 Hz, 2H), 2.70-2.67 (m, 1H), 1.71 (t, J 
= 6.05 Hz, 3H), 0.77-0.75 (m, 2H), 0.49-0.48 (m, 2H); 13C NMR (125.8 MHz, CDCl3) δ 
173.1, 130.7, 123.9, 40.5, 22.7, 18.1, 6.6; FT-IR (neat) 3280, 1645, 1542, 967 cm-1; 
HRMS (ES+) m/z calcd. for C8H14NO (M+H)+ 140.1075, found 140.1075. 
 
 
(E)-1-Morpholino-5-phenylpent-3-en-1-one (2.72). The title compound was obtained as 
a yellow oil in 94% yield (230 mg). 1H NMR (500 MHz, CDCl3), δ 7.24-7.22 (m, 2H), 
7.13-7.12 (m, 3H), 5.64 (qt, J = 15.1, 6.1 Hz, 2H), 3.59 (t, J = 4.6 Hz, 2H), 3.54 (dt, J = 
10.8, 5.9 Hz, 4H), 3.38 (t, J = 4.8 Hz, 2H), 3.34 (d, J = 6.4 Hz, 2H), 3.07 (d, J = 6.0 Hz, 
2H); 13C NMR (125.8 MHz, CDCl3): δ 170.0, 140.2, 132.9, 128.7, 128.6, 126.3, 124.2, 
67.0, 66.7, 46.3, 42.1, 39.1, 37.6; FT-IR (neat): 2860, 1649, 1436, 1114 cm-1; HRMS 
(ES+) m/z calcd. for C15H20NO2 (M+H)+ 246.1494, found 246.1496. 
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(E)-N-Cyclopropyl 5-Phenylpent-3-enamide (2.73). The title compound was obtained 
as a yellow oil in 58% yield (125 mg). 1H NMR (500 MHz, CDCl3): δ 7.31-7.27 (m, 2H), 
7.22-7.15 (m, 3H), 5.82 (br, 1H), 5.77-5.72 (m, 1H), 5.62-5.56 (m, 1H), 3.37 (d, J = 6.8 
Hz, 2H), 2.92 (d, J = 7.1 Hz, 2H), 2.67 (q, J = 7.0, 3.5 Hz, 1H), 0.75-0.73 (m, 2H), 0.45-
0.44 (m, 2H); 13C NMR (125.8 MHz, CDCl3) δ 172.7, 140.1, 134.8, 128.7, 128.6, 126.4, 
124.3, 40.4, 39.1, 22.8, 6.7; FT-IR (neat): 3282, 2360, 2341, 1645, 1540 cm-1; HRMS 
(ES+) m/z calcd. for C14H18NO (M+H)+ 216.1388, found 216.1388. 
 
 
(E)-1-Morpholino-4-phenylbut-3-en-1-one (2.74).93 The title compound was obtained 
as a white solid in 69% yield (159 mg). The physical data were in accordance with those 
previously reported. mp = 90-91 °C; 1H NMR (500 MHz, CDCl3): δ 7.36-7.35 (m, 2H), 
7.31-7.28 (m, 2H), 7.23-7.22 (m, 1H), 6.46 (d, J = 16.0 Hz, 1H), 6.32 (dt, J = 15.9, 6.7 
Hz, 1H), 3.66-3.64 (m, 6H), 3.49-3.48 (m, 2H), 3.28 (d, J = 6.7 Hz, 2H); 13C NMR 
(125.8 MHz, CDCl3) δ 169.7, 137.0, 133.1, 128.7, 127.7, 126.4, 122.9, 67.0, 66.8, 46.4, 
42.2, 37.9.  
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N-Cyclopropyl 2-(4,4-Difluorocyclohex-1-en-1-yl)acetamide (2.75). The title 
compound was obtained as a white solid in 79% yield (170 mg). mp = 102-103 °C. 1H 
NMR (500 MHz, CDCl3): δ 6.00 (s, 1H), 5.44 (s, 1H), 2.89 (s, 2H), 2.67 (s, 1H), 2.57-
2.51 (m, 2H), 2.25 (s, 2H), 2.02 (td, J = 12.4, 5.7 Hz, 2H), 0.75 (s, 2H), 0.46 (s, 2H); 13C 
NMR (125.8 MHz, CDCl3): δ 171.7, 132.5, 124.6, 122.7, 121.0 (q, J = 5.0 Hz), 44.8, 
34.7 (t, J = 26.7 Hz), 30.3 (t, J = 24.5 Hz), 26.8 (t, J = 5.4 Hz), 22.8, 8.5, 6.7;  FT-IR 
(neat): 3304, 1641, 1542, 1271, 1110, 1067 cm-1; HRMS (ES+) m/z calcd. for 
C11H15F2NONa (M+Na)+ 238.1019, found 238.1027. 
 
 
Preparation of Potassium (Z)-Dec-1-en-1-yltrifluoroborate (2.76).94 The compound 
was prepared as described in the literature, and spectral data were in agreement with 
those previously reported. mp >260 °C (Lit mp > 250 °C); 1H NMR (500 MHz, acetone-
d6): 5.61(br, 1H), 5.29-5.23 (m, 1H), 2.18 (d, J = 5.8 Hz, 2H), 1.28 (br, 12H), 0.87 (t, J = 
6.7 Hz, 3H); 13C NMR (125.8 MHz, acetone-d6): δ 137.4, 31.9, 31.3, 30.7, 29.8, 29.7, 
29.6, 22.6, 13.6. 
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General procedure for preparation of potassium (E)-alkenyltrifluoroborates. The 
corresponding pinacol esters of the desired alkenyltrifluoroborate substrates were 
prepared according to a published procedure by Wang, Y. D., et al.66 from commercially 
available terminal alkynes (3.0 mmol). The alkenyl boronate ester was dried under 
vacuum, after which it was dissolved in a 5:1 mixture of acetone/H2O and cooled to 0 °C. 
Solid KHF2 (6.0 mmol) was added to the solution while stirring, and cold H2O (1.5 mL) 
was added dropwise to the reaction flask.  After 30 min, the solution was allowed to 
slowly warm to rt.  The reaction was allowed to stir at rt until conversion to the 
trifluoroborate was complete, as monitored by 11B NMR (30 min – 2 h).  The mixture 
was concentrated in vacuo and dried under vacuum. The solid was dissolved in hot 
acetone and filtered, and the filtrate was concentrated.  A minimal amount of acetone was 
used to dissolve the dried solid, and the alkenyltrifluoroborate was crashed out using 
Et2O and hexanes.  The solid was collected by vacuum filtration and dried overnight 
under vacuum.  
 
 
Potassium (E)-(6-Chlorohex-1-en-1-yl)trifluoroborate (2.77).63 The title compound 
was obtained as a white solid in 58% yield from the corresponding alkyne (389 mg). The 
physical data were in accordance with those previously reported. mp >260 °C (Lit mp > 
260 °C); 1H NMR (500 MHz, acetone-d6): δ 5.71-5.67 (m, 1H), 5.38-5.35 (m, 1H), 3.56 
(t, J = 6.3 Hz, 2H), 1.97-1.96 (m, 2H), 1.74-1.72 (m, 2H), 1.46-1.44 (m, 2H); 13C NMR 
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(125.8 MHz, acetone-d6): δ 135.0, 45.2, 34.9, 32.4, 26.7; 19F NMR: (470.8 MHz, 
acetone-d6) δ  -141.0. 11B NMR: (128.4 MHz, acetone-d6) δ3.70.  
 
 
Potassium (E)-N-Benzyl-N-methyl-3-(trifluoroborato)prop-2-en-1-amine (2.78). The 
title compound was obtained as a white solid in 42% yield from the corresponding alkyne 
(112 mg). mp:125-126 °C; 1H NMR (500 MHz, acetone-d6): δ 7.37 (d, J = 7.4 Hz, 2H), 
7.30 (t, J = 7.5 Hz, 2H), 7.25 (t, J = 7.3 Hz, 1H), 5.83-5.79 (m, 1H), 5.67-5.63 (m, 1H), 
3.60 (s, 2H), 3.05 (d, J = 6.2 Hz, 2H), 2.19 (s, 3H); 13C NMR (125.8 MHz, acetone-d6): δ 
138.4, 130.8, 129.3, 128.3, 127.2, 63.0, 61.0, 41.0; 19F NMR: (470.8 MHz, acetone-d6) δ  
-141.2. 11B NMR: (128.4 MHz, acetone-d6) δ3.21. FT-IR (neat): 2783, 1646, 1454, 1089, 
950 cm-1; HRMS (ES+) m/z calcd. for C11H14BNF3 (M-K)- 228.1171, found 228.1169.  
 
 
Potassium (E) -(3-(Benzyloxy)prop-1-en-1-yl)trifluoroborate (2.79).  The title 
compound was obtained as a white solid in 59% yield from the corresponding alkyne 
(150 mg). mp: 108-110 °C; 1H NMR (500 MHz, acetone-d6): δ 7.29 (q, J = 7.3 Hz, 4H), 
7.23-7.20 (m, 1H), 5.84-5.79 (m, 1H), 5.65-5.61 (m, 1H), 4.42 (s, 2H), 3.91-3.90 (m, 
2H); 13C NMR (125.8 MHz, acetone-d6): δ 139.7, 131.6, 128.2, 127.5, 127.1,  74.1, 71.0. 
19F NMR: (470.8 MHz, acetone-d6) δ  -141.2. 11B NMR: (128.4 MHz, acetone-d6) δ3.38. 
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FT-IR (neat): 2359, 1650, 1101, 1075 cm-1; HRMS (ES+) m/z calcd. for C10H11BOF3 (M-
K)- 215.0855, found 215.0858.  
 
 
Potassium (E)-(3-((Tetrahydropyran-2-yl)oxy)prop-1-en-1-yl)trifluoroborate (2.80). 
The title compound was obtained as a white solid in 56% yield from the corresponding 
alkyne (147 mg). mp: 207-209 °C; 1H NMR (500 MHz, acetone-d6): 5.73-5.68 (m, 1H), 
5.46-5.42 (m, 1H), 4.53 (s, 1H), 3.78 (ddd, J = 11.2, 8.1, 3.0 Hz, 1H), 3.67-3.62 (m, 1H), 
3.41 (dd, J = 10.7, 5.9 Hz, 1H), 3.35-3.32 (m, 1H), 2.20 (q, J = 6.7 Hz, 2H), 1.77-1.74 
(m, 1H), 1.63-1.61 (m, 1H), 1.59-1.45 (m, 4H); 13C NMR (125.8 MHz, acetone-d6): δ 
131.9, 98.6, 67.5, 61.8, 36.3, 30.8, 25.6, 19.7. 19F NMR: (470.8 MHz, acetone-d6) δ  -
141.6. 11B NMR: (128.4 MHz, acetone-d6) δ3.36. FT-IR (neat): 2941, 1646, 1116, 1030, 
934 cm-1; HRMS (ES+) m/z calcd. for C9H15BO2F3 (M-K)- 223.1117, found 223.1112.  
 
General procedure for Pd-catalyzed cross-coupling reaction of potassium 
alkynyltrifluoroborates with 2-chloroacetates and 2-chloroacetamides. To a Biotage 
10 mL microwave vial equipped with a magnetic stirbar were added the appropriate 
alkynyltrifluoroborate (1.1 mmol, 1.10 equiv), K3PO4 (3.0 mmol, 3 equiv), XPhos (10 
µmol, 4.7 mg, 1 mol %) and the XPhos-Pd-G2 (10 µmol, 7.86 mg, 1 mol %). The vial 
was sealed with a cap lined with a Teflon septum and was evacuated and filled with Ar 
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three times. Degassed toluene (2.4 mL) and H2O (0.8 mL) were added, followed by the 2-
chloroacetate or 2-chloroacetamide (1.0 mmol) under Ar. In cases where the electrophile 
was a solid, it was added along with the solid materials before sealing the vial. The 
reaction mixture was stirred at 80 °C for 18 h. The cooled reaction mixture was extracted 
with EtOAc (3 x 3 mL) and dried (Na2SO4). The crude product was purified by flash 
column chromatography (elution with hexanes/EtOAc = 9:1 for esters, hexanes/EtOAc = 
4:1 to 1:4 for amides) to afford the expected product. 
 
 
N-Benzyl-4-phenylbut-3-ynamide (2.81).70 The title compound was obtained as a 
yellow solid (92% yield, 118 mg). Spectral data are in accordance with those previously 
reported. mp 74-75 °C; 1H NMR (500 MHz, CDCl3): δ 7.40-7.26 (m, 10H), 6.82 (br, 1H), 
4.52 (d, J = 5.9 Hz, 2H), 3.50 (s, 2H); 13C NMR (125.8 MHz, CDCl3): δ 166.6, 137.8, 
131.6, 128.7, 128.6 (2C), 128.3, 127.5, 122.2, 85.8, 82.1, 43.7, 28.3. 
 
 
N-Benzyloct-3-ynamide (2.82). The title compound was obtained as an orange solid 
(90% yield, 206 mg). mp 50-51 °C;  1H NMR (500 MHz, CDCl3): δ 7.36-7.26 (m, 5H), 
N
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6.83 (br, 1H), 4.47 (d, J = 5.8 Hz, 2H), 3.22 (t, J = 2.3 Hz, 2H), 2.19-2.16 (m, 2H), 1.46-
1.43 (m, 2H), 1.35 (dt, J = 14.9, 7.3, 2H), 0.86 (t, J = 7.3 Hz, 3H); 13C NMR (125.8 
MHz, CDCl3): δ 167.5, 138.1, 128.9, 127.8, 127.7, 86.7, 73.2, 43.9, 30.8, 27.9, 22.1, 
18.5, 13.6; FT-IR (neat): 2931, 1643, 1547, 1247 cm-1; HRMS (ES+) m/z calcd. for 
C15H19NONa (M+Na)+ 252.1364, found 252.1366. 
 
 
N-Benzyl-4-cyclohexylbut-3-ynamide (2.83). The compound was isolated as a yellow 
solid (82% yield, 209 mg). mp 74-76 °C; 1H NMR (500 MHz, CDCl3): δ 7.32 (t,  J = 7.4 
Hz, 2H), 7.25 (m, 3H), 6.83 (br, 1H), 4.44 (d, J = 5.7 Hz, 2H), 3.21 (s, 2H), 2.35 (br, 1H), 
1.71-1.69 (m, 2H), 1.60-1.59 (m, 2H), 1.46-1.45 (m, 1H), 1.34 (t, J = 9.5 Hz, 2H), 1.25 
(d, J = 7.1 Hz, 3H); 13C NMR (125.8 MHz, CDCl3): δ 167.6, 138.0, 128.9, 127.7, 127.7, 
90.9, 73.3, 43.9, 32.7, 29.1, 28.0, 25.9, 24.9; FT-IR (neat): 2924, 1644, 1540, 1244 cm-1; 
HRMS (ES+) m/z calcd. for C17H21NONa (M+Na)+ 278.1521, found 278.1530. 
 
 
N-Benzyl-4-cyclopropylbut-3-ynamide (2.84). The compound was isolated as a yellow 
solid (92% yield, 196 mg). mp 86-87 °C; 1H NMR (500 MHz, CDCl3): δ 7.35-7.32 (m, 
N
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2H), 7.28-7.26 (m, 3H), 6.85 (br, 1H), 4.44 (d, J = 5.9 Hz, 2H), 3.16 (s, 2H), 1.23-1.18 
(m, 1H), 0.75-0.71 (m, 2H), 0.62-0.61 (m, 2H); 13C NMR (125.8 MHz, CDCl3): δ 167.5, 
138.2, 128.8, 127.7, 127.6, 89.5, 68.4, 43.8, 27.9, 8.4, -0.4; FT-IR (neat): 2924, 1644, 
1540, 1244 cm-1; HRMS (ES+) m/z calcd. for C14H15NONa (M+Na)+ 236.1051, found 
236.1049. 
 
 
N-Benzyl-5-phenylpent-3-ynamide (2.85). The compound was isolated as a yellow 
solid (95% yield, 250 mg); mp 64-67 °C; 1H NMR (500 MHz, CDCl3): δ 7.36-7.32 (m, 
2H), 7.30-7.23 (m, 8H), 6.87 (br, 1H), 4.46 (d, J = 5.8 Hz, 2H), 3.61 (s, 2H), 3.30 (s, 2H); 
13C NMR (125.8 MHz, CDCl3): δ 167.3, 138.1, 136.6, 128.9, 128.8, 127.9, 127.8, 127.7, 
126.8, 84.2, 75.5, 43.9, 28.0, 25.3; FT-IR (neat): 3279, 1651, 1552, 1240 cm-1; HRMS 
(ES+) m/z calcd. for C18H18NO (M+H)+ 264.1388, found 264.1387. 
 
 
4-([1,1'-Biphenyl]-4-yl)-N-Benzylbut-3-ynamide (2.86). The compound was isolated as 
a light yellow solid (80% yield, 260 mg); mp 153-155 °C; 1H NMR (500 MHz, CDCl3): δ 
N
H
O
N
H
O
     122 
7.56-7.45 (m, 4H), 7.43-7.41 (m, 4H), 7.36-7.23 (m, 6H), 6.83 (br, 1H), 4.51 (d, J = 5.9 
Hz, 2H), 3.50 (s, 2H); 13C NMR (125.8 MHz, CDCl3): δ 166.8, 141.6, 140.3, 138.0, 
132.3, 129.0, 128.9, 127.9 (2C), 127.8, 127.2, 127.2, 121.3, 85.9, 83.0, 44.0, 28.6; FT-IR 
(neat): 3299, 1642, 1540 cm-1; HRMS (ES+) m/z calcd. for C23H20NO (M+H)+ 326.1545, 
found 326.1552. 
 
 
N-Benzyl-8-(benzyloxy)oct-3-ynamide (2.87). The compound was isolated as a light 
yellow solid (76% yield, 255 mg); mp 46-48 °C; 1H NMR (500 MHz, CDCl3): δ 7.33-
7.29 (m, 6H), 7.26-7.22 (m, 4H), 6.84 (br, 1H), 4.44-4.42 (m, 4H), 3.41 (t, J = 6.1 Hz, 
2H), 3.19 (t, J = 2.3 Hz, 2H), 2.19 (tt, J = 6.9, 2.4 Hz, 2H), 1.65-1.61 (m, 2H), 1.58-1.54 
(m, 2H); 13C NMR (125.8 MHz, CDCl3): δ  167.6, 138.7, 138.1, 128.9, 128.5, 127.8, 
127.7 (2C), 127.7, 86.3, 73.5, 73.1, 69.8, 43.8, 29.0, 28.0, 25.6, 18.7; FT-IR (neat): 3286, 
1645, 1551, 1116 cm-1; HRMS (ES+) m/z calcd. for for C22H26NO2 (M+H)+ 336.1964, 
found 336.1963. 
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1-Morpholino-4-phenylbut-3-yn-1-one (2.88). The compound was obtained as a red-
orange oil in (72% yield,165 mg). 1H NMR (500 MHz, CDCl3): δ 7.38-7.37 (m, 2H), 
7.28-7.27 (m, 3H), 3.71 (t, J = 4.6 Hz, 2H), 3.67 (t, J = 4.7 Hz, 2H), 3.62 (d, J = 3.9 Hz, 
4H), 3.48 (s, 2H); 13C NMR (125.8 MHz, CDCl3): δ 165.9, 131.7, 128.5, 128.4, 123.0, 
84.4, 81.8, 66.9, 66.7, 47.1, 42.6, 27.2; FT-IR (neat): 1652, 1441, 1273, 1114 cm-1; 
HRMS (ES+) m/z calcd. for C14H16NO2 (M+H)+ 230.1181, found 230.1175. 
 
 
N,N-Diethyl-4-phenylbut-3-ynamide (2.89). The compound was isolated as a red-
orange oil (77% yield, 166 mg); 1H NMR (500 MHz, CDCl3): δ 7.40-7.38 (m, 2H), 7.28-
7.24 (m, 3H), 3.47 (s, 2H), 3.46-3.36 (m, 4H), 1.23 (t, J = 7.1 Hz, 3H), 1.13 (t, J = 7.1 
Hz, 3H); 13C NMR (125.8 MHz, CDCl3): δ 166.4, 131.8, 128.3, 128.2, 123.4, 83.8, 82.7, 
42.7, 40.5, 27.3, 14.3, 12.9; FT-IR (neat): 2970, 2929, 1646, 1432 cm-1; HRMS (ES+) 
m/z calcd. for C14H17NONa (M+Na)+ 238.1208, found 238.1208. 
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tert-Butyl 4-Phenylbut-3-ynoate (2.90).95 The compound was isolated as an orange oil 
(74% yield, 160 mg); Spectral data are in accordance with those previously reported. 1H 
NMR (500 MHz, CDCl3): δ 7.45-7.43 (m, 2H), 7.30-7.26 (m, 3H), 3.42 (s, 2H), 1.50 (s, 
9H); 13C NMR (125.8 MHz, CDCl3): δ 167.5, 131.9, 128.3, 128.2, 123.4, 83.5, 82.0 (2C), 
28.1, 28.1. 
 
 
Isopropyl 4-Phenylbut-3-ynoate (2.91). The compound was isolated as an orange oil 
(84% yield, 170 mg); 1H NMR (500 MHz, CDCl3): δ 7.43-7.42 (m, 2H), 7.28-7.27 (m, 
3H), 5.08-5.05 (m, 1H), 3.45 (s, 2H), 1.27 (d, J = 6.3 Hz, 6H); 13C NMR (125.8 MHz, 
CDCl3): δ 167.9, 131.9, 128.3, 128.2, 123.3, 83.5, 81.6, 69.3, 27.2, 21.8; FT-IR (neat): 
2981, 1732, 1106 cm-1; HRMS (CI+) m/z calcd. for C13H14O2 (M)+ 202.0994, found 
202.0995. 
 
N-Cyclopropyl-7-phenylhept-3-ynamide (2.92). The compound was obtained as a light 
yellow solid (75% yield, 242 mg). mp 62-64 °C; 1H NMR (500 MHz, CDCl3): δ 7.28 (q, 
J = 6.7 Hz, 2H), 7.21-7.16 (dd, J = 14.0, 7.2 Hz, 3H), 6.58 (br, 1H), 3.14 (s, 2H), 2.72-
2.69 (m, 3H), 2.21 (tt, J = 7.0, 2.4 Hz, 2H), 1.85-1.82 (m, 2H), 0.78 (q, J = 6.2 Hz, 2H), 
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0.53-0.52 (m, 2H); 13C NMR (125.8 MHz, CDCl3): δ 168.9, 141.4, 128.6, 128.6, 126.2, 
85.9, 73.9, 35.0, 30.3, 27.9, 22.9, 18.3, 6.7; FT-IR (neat): 1646, 1553, 1264 cm-1; HRMS 
(ES+) m/z calcd. for C16H20NO (M+H)+ 242.1545, found 242.1552. 
 
 
N-Cyclopropyloct-3-ynamide (2.93). The compound was isolated as a yellow oil (90% 
yield, 161 mg). mp 40-43 °C; 1H NMR (500 MHz, CDCl3): δ 6.58 (br, 1H), 3.13-3.12 (m, 
2H), 2.73-2.72 (m, 1H), 2.21 (tt, J = 7.0, 2.5 Hz, 2H), 1.51-1.48 (m, 2H), 1.43-1.40 (m, 
2H), 0.94-0.91 (m, 3H), 0.81-0.80 (m, 2H), 0.79-0.78 (m, 2H); 13C NMR (125.8 MHz, 
CDCl3): δ 169.1, 86.0, 73.1, 30.7, 27.7, 22.8, 22.0, 18.4, 13.5, 6.5; FT-IR (neat): 3396, 
1652, 1538, 1264 cm-1; HRMS (ES+) m/z calcd. for C11H17NONa (M+Na)+ 202.1208, 
found 202.1212. 
 
 
7-Chloro-N-cyclopropylhept-3-ynamide (2.94). The compound was isolated as a light 
yellow solid (61% yield, 121 mg). mp 47-49 °C; 1H NMR (500 MHz, CDCl3: δ 6.6 (br, 
1H), 3.66 (dd, J = 8.0, 4.5 Hz, 2H), 3.14 (t, J = 2.4 Hz, 2H), 2.72 (m, 1H), 2.43 (tt, J = 
6.8, 2.4 Hz, 2H), 2.00-1.94 (m, 2H), 0.82-0.78 (m, 2H), 0.57-0.56 (m, 2H); 13C NMR 
(125.8 MHz, CDCl3): δ 168.7, 84.1, 74.5, 43.7, 31.1, 27.7, 22.9, 16.3, 6.6; FT-IR (neat): 
N
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3289, 1652, 1539, 1263 cm-1; HRMS (ES+) m/z calcd. for C10H14NONaCl (M+Na)+ 
222.0662, found 222.0664. 
 
 
N,4-Dicyclopropylbut-3-ynamide (2.95). The compound was obtained as a light yellow 
solid (74% yield, 121 mg). mp 52-54 °C; 1H NMR (500 MHz, CDCl3: δ 6.55 (br, 1H), 
3.04 (s, 2H), 2.67-2.64 (td, J = 7.0, 3.5 Hz, 1H), 1.22-1.18 (m, 1H), 0.76-0.71 (t, J = 6.6 
Hz, 4H), 0.62-0.60 (q, J = 5.0 Hz, 2H), 0.59-0.51 (m, 2H); 13C NMR (125.8 MHz, 
CDCl3): δ 169.0, 89.2, 68.4, 27.8, 22.8, 8.2, 6.6, -0.5; FT-IR (neat): 3295, 1651, 1542, 
1267 cm-1; HRMS (ES+) m/z calcd. for C10H14NO (M+H)+ 164.1075, found 164.1078. 
 
 
Benzyl Oct-3-ynoate (2.96). The compound was isolated as a yellow oil (89% yield, 205 
mg); 1H NMR (500 MHz, CDCl3): δ 7.32-7.30 (m, 5H), 5.13 (s, 2H), 3.25 (s, 2H), 2.15 
(tt, J = 7.0, 2.4 Hz, 2H), 1.47-1.44 (m, 2H), 1.39-1.36 (m, 2H), 0.89-0.85 (m, 3H); 13C 
NMR (125.8 MHz, CDCl3): δ 169.0, 135.7, 128.7, 128.5, 128.4, 84.2, 71.3, 67.2, 30.9, 
26.3, 22.0, 18.6, 13.1; FT-IR (neat): 2953, 1743, 1262, 1163 cm-1; HRMS (ES+) m/z 
calcd. for C15H19O2 (M+H)+ 231.1385, found 231.1382. 
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Isopropyl 7-Phenylhept-3-ynoate (2.97). Compound was isolated as a colorless oil 
(76% yield, 185 mg); 1H NMR (500 MHz, CDCl3): δ 7.26-7.25 (m, 2H), 7.19-7.17 (m, 
3H), 5.05-5.02 (m, 1H), 3.22 (s, 2H), 2.73-2.70 (t, 2H), 2.20 (s, 2H), 1.83-1.80 (m, 2H), 
1.25 (d, J = 6.2 Hz, 6H); 13C NMR (125.8 MHz, CDCl3): δ 168.6, 141.8, 128.7, 128.6, 
128.5, 126.0, 72.5, 69.1, 34.8, 30.4, 26.6, 22.0, 21.9, 18.3; FT-IR (neat): 2938, 1732, 
1180, 1105 cm-1; HRMS (ES+) m/z calcd. for C16H20O2Na (M+Na)+ 267.1361, found 
267.1359. 
 
 
Preparation of Potassium (3-Phenylprop-1-yn-1-yl)trifluoroborate (2.98). In a flame-
dried flask, a solution of 3-phenyl-1-propyne (10 mmol, 1.16 g) in dry THF (20 mL) was 
cooled to –78 °C under Ar.  n-BuLi (10 mmol, 4 mL, 2.5 M in hexanes) was added 
dropwise with stirring, and the mixture was stirred for 1 h at –78 °C, at which point it 
was allowed to  warm slowly to –20 °C.  After cooling the mixture back down to –78 °C, 
B(Oi-Pr)3 (15 mmol, 3.5 mL) was added, and the mixture was stirred for 1 h before it was 
allowed to warm to 0 °C.  Aqueous KHF2 (4.5 M, 60 mmol, 13.3 mL) was added 
dropwise, and after 1 h the solution was allowed to warm to rt.  The solution was 
concentrated and dried under high vacuum for 12 h.  The solid was dissolved in hot 
acetone (3 x 15 mL), and the insoluble material was removed by filtration.  The 
O
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combined filtrates were concentrated to a minimal volume at which the solid remained 
dissolved, and cold Et2O (~ 30 mL) was added dropwise until white crystals appeared.  
The solid was collected by filtration. The compound was isolated as a white solid (998 
mg, 4.5 mmol, 45% yield). mp > 250 °C; 1H NMR (500 MHz, DMSO): δ 7.34-7.28 (m, 
4H), 7.21-7.18 (m, 1H), 3.44 (s, 2H); 13C NMR (125.8 MHz, DMSO): δ 139.0, 128.7, 
128.5, 126.6, 25.7;   11B NMR (128.4 MHz , DMSO): δ -1.82; 19F NMR (470.8 MHz , 
DMSO): δ -131.2; FT-IR (neat): 1106, 1001, 953 cm-1; HRMS (ES+) m/z calcd. for 
C9H7BF3 (M)- 183.0593 found 183.0599. 
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Chapter 3: Reductive Cross-Coupling of Nonaromatic, Heterocyclic 
Structures 
 
3.1 Introduction 
A great deal of interest has recently emerged in the forging of sp2-sp3 bonds to 
non-aromatic heterocyclic cores, e.g., piperidines, pyrrolidines, azetidines, 
tetrahydropyrans, tetrahydrofurans, and oxetanes. Over the past decade, dramatic strides 
in sp3-sp2 couplings have been made, the outcome of which is the increasing tendency 
toward flat, planar molecules as drug targets.1,2 In an effort to create stuctures that may 
have greater selectivity toward a specific target, drugs containing saturated heterocyclic 
ring systems are currently under exploration. Compared to corresponding aromatic 
heterocycles, these substructures allow greater occupation of three-dimensional space, 
providing higher potential binding selectivity within a target without significantly 
affecting the physical attributes of the drug. Although methods for sp3-sp2 cross-coupling 
reactions are abundant, most methods result in little to no product formation when 
applied to nonaromatic, heterocyclic systems under coupling conditions that are 
otherwise successful for secondary alkyl substrates.2  
 To access aryl- and heteroaryl-substituted nonaromatic heterocyclic structures, 
several methods have been developed that circumvent the direct sp2-sp3 cross-coupling. A 
popular approach within medicinal chemistry inolves the sp2-sp2 Suzuki cross-coupling 
of an alkenyl piperidine structure with an aryl halide followed by hydrogenation of the 
alkene to yield the saturated heterocyclic system (Scheme 3.1).3–5 This reaction suffers 
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from limited use in late-stage synthesis because of a lack of compatibility with a variety 
of functional groups.  
 
Scheme 3.1: Suzuki Cross-Coupling/Hydrogenation Sequence for Accessing 
Arylated Piperidine Systems 
 
 
 A method for the prepartion of aryl-substituted tetrahydropyran systems involves 
the gold-catalyzed cyclization of a diol bearing the desired aryl moiety (Scheme 3.2).6–8 
Additionally, several C-H arylation protocols have been developed to allow the 
functionalization of saturated heterocyclic systems with arenes.9–12 One severe drawback 
common among these approaches is the requirement for optimization on each individual 
substructure, resulting in the inability to introduce a variety of nonaromatic heterocyclic 
moieties by a single method.  Such a limitation is not conducive to coupling in a high-
throughput fashion for the purpose of medicinal chemistry research.  
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Scheme 3.2: Gold-Catalyzed Cyclization for Formation of Tetrahydropyran Rings 
 
A variety of protocols have been explored for the cross-coupling of nonaromatic 
heterocyclic halides with arylmetallic species generated from Mg, Si, Zn, and B reagents 
(Scheme 3.3).13–16 These methods are effective for accessing the target structures, but 
because they require metalation of the aryl halide, their use on larger structures bearing 
sensitive functional groups is quite limited. As a result, the use of these methods for late-
stage introduction of a saturated heterocyclic ring system onto an arene is not common. 
 
Scheme 3.3: Cross-Coupling of Arylmetallic Reagents with Nonaromatic 
Heterocyclic Halides 
 
 
Organometallic reagents have been generated from nonaromatic heterocyclic 
halides and subsequently cross-coupled with aryl halides (Scheme 3.4). These approaches 
are advantageous in that they allow direct installation of the saturated heterocyclic 
structure onto an aryl halide without necessitating metalation of the core structure, and 
therefore offer improvements in terms of functional group tolerance. Limited examples of 
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this approach have been illustrated, making use of organozinc and stannane reagents of 
the nonaromatic heterocyclic components. Alkylzinc substrates are unfortunately not 
stable to air and moisture, and must be formed immediately prior to or during the 
reaction.17–22 Air-stable alkylstannanes were prepared, but these reagents make use of a 
protecting group on tin that is actually larger than the alkyl group being incorporated into 
the final structure.23  
 
Scheme 3.4: Metalation of Nonaromatic Heterocyclic Halides and Subsequent 
Cross-Coupling with Aryl Halides 
 
 
Although the Negishi and Stille coupling protocols have served to advance the 
progress that has been made toward the sp2-sp3 coupling of nonaromatic heterocycles, a 
method was desired that allows the direct installation of saturated heterocyclic ring 
systems onto aryl and heteroaryl halides using air-stable reagents under a standard set of 
conditions that are robust, mild, scalable, and applicable to an entire class of saturated 
heterocyclic structures. 
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3.2 Reductive Cross-Coupling of Nonaromatic, Heterocyclic Bromides with 
Aryl and Heteroaryl Bromides 
 Initial efforts were made to improve the versatility and scope of the sp2-sp3 
coupling of nonaromatic heterocycles with aryl halides through the use of organoboron 
reagents. A protocol had been recently developed for the synthesis of potassium 
trifluoroborate salts of nonaromatic heterocyclic moieties employing a Cu-catalyzed 
borylation (Scheme 3.5).24 The resulting products, which are air- and moisture-stable 
crystalline solids, were shown undergo Minisci reactions with heterocycles, but their 
participation in traditional cross-coupling reactions was never demonstrated.  
 
Scheme 3.5: Synthesis of Nonaromatic Heterocyclic Trifluoroborate Salts from 
Alkyl Halides 
 
 
 Following the established protocol for their preparation, several potassium 
trifluoroborate salts of nonaromatic heterocycles were synthesized. Unlike previously 
reported organometallic reagents of these subunits, the trifluoroborate salts could be 
prepared in advance and stored open to the air until use. It was intended that conditions 
could be developed for the metal-catalyzed sp2-sp3 cross-coupling of nonaromatic 
Z
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heterocyclic trifluoroborates with aryl and heteroaryl halides (Scheme 3.6). Extensive 
screening was conducted with the prepared trifluoroborates in the presence of an aryl 
iodide, bromide, chloride, and triflate. Over the course of the screening, 12 different Ni, 
Cu, and Pd sources were evaluated in the presence of 12 bases, more than 40 ligands, and 
more than 20 different additives. The ligands tested included a variety of mono-, bi-, and 
tridentate phosphines, diamines, diols, alkenes, and other ligand classes. Greater than 
1400 sets of reaction conditions were evaluated, but none led to more than 5% conversion 
to the desired cross-coupled product.  
 
Scheme 3.6: Cross-Coupling of Nonaromatic Heterocyclic Trifluoroborates with 
Aryl Halides 
 
 
 
 Given the difficulties faced in determining a viable set of conditions for the 
Suzuki cross-coupling of the nonaromatic heterocyclic trifluoroborate salts with aryl 
halides, a new approach was considered in which a reductive coupling method would be 
employed. Under the initially envisioned pathway, the alkyl bromide of the nonaromatic 
heterocycle would undergo a Cu-catalyzed borylation to furnish the desired 
Alk =
Y Y Y
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alkyltrifluoroborate salt, which would then undergo a metal-catalyzed cross-coupling 
with an aryl halide. The proposed reductive cross-coupling pathway would allow the 
same transformation to take place in a single step and would avoid metalation of the alkyl 
halide altogether (Scheme 3.7).  
 
Scheme 3.7: Traditional vs. Reductive Cross-Coupling Pathways toward Arylated 
Nonaromatic Heterocycles 
 
 
 
The concept of metal-catalyzed reductive cross-coupling reactions between two 
electrophiles has been explored extensively over the last decade (See Chapter 1).25–39 
Specifically, in the area of Ni-catalyzed couplings between aryl halides and alkyl halides, 
the works of Weix, et al. and Gong, et al. have been influential.25–27,29,31 In these 
reactions, catalytic Ni is used in combination with a diamine ligand and a reducing metal 
(typically Zn or Mn) in the presence of a polar solvent to effect the coupling between two 
halides to form an sp2-sp3 C-C bond. Methods of this sort have been illustrated to have 
remarkable functional group compatibility, allowing amines, free alcohols, esters, 
ketones, and boronate esters to remain unscathed by the reaction conditions.  
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 The use of a reductive cross-coupling pathway was envisioned for the 
introduction of nonaromatic heterocyclic structures onto aryl halides. The anticipated 
method would be applicable to a wide array of saturated heteroaromatic ring systems and 
would tolerate the presence of a multitude of functional groups on the aryl halide 
coupling partner. Initial optimization was begun on the reaction of 1-Boc-4-
bromopiperidine with 4-chloro-, 4-bromo-, and 4-iodoanisole (Scheme 3.8). High 
throughput experimentation (HTE) techniques were employed to screen a large number 
of reaction parameters, including the Ni source, ligand, additive, and solvent necessary to 
promote the desired transformation. Approximately 200 sets of reaction conditions were 
assessed, and it was determined that the reaction proceeded to the greatest extent with 4-
bromoanisole. Initially Ni(COD)2 was employed as a source of Ni(0), but optimization 
quickly led to the use of an air-stable Ni(II) source, NiCl2!glyme, which could be reduced 
to Ni(0) under the reaction conditions. A variety of amine ligands, particularly those with 
bipyridine and phenanthroline scaffolds, were explored for the desired reaction, and 1,10-
phenanthroline was determined to be an effective ligand when used in a 2:1 ratio with the 
Ni catalyst. 
 
Scheme 3.8: Reductive Cross-Coupling of N-Boc-4-Bromopiperidine with an Aryl 
Halide 
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As had been empirically noted by Weix, et al.,25–28 the use of both a pyridine 
derivative and NaI as additives were crucial to the success of the reductive cross-coupling 
between aryl and alkyl halides.  Screening included testing of various pyridine 
derivatives as additives, and for each reaction a ratio of the product to the two major side 
products observed in the reductive coupling is reported (Table 3.1). It was observed that 
use of 4-ethylpyridine served to reduce the protodehalogenation of the alkyl halide (Alk-
H) as well as effectively suppress homocoupling of the aryl halide (Ar-Ar).  
 
Table 3.1: Optimization of Pyridine Additives for the Reductive Cross-Coupling of 
4-Bromoanisole with 1-Boc-4-Bromopiperidine 
 
 
entry amine product : Alk-H : Ar-Ar 
1 pyridine       1 : 1.14 : 0.09 
2 3,5-lutidine       1 : 1.70 : 0.04 
3 4-dimethylaminopyridine       1 : 2.76 : 0.04 
4 4-ethylpyridine       1 : 0.84 : 0 
5 4-benzylpyridine       1 : 2.20 : 0.04 
  
With side product formation minimized by the 4-ethylpyridine additive, further 
optimization was conducted in which the solvent, salt additive, temperature, and metal 
+
BocN
Br
BocN
Br
OMe
OMe
NiCl2•glyme (2.5 mol %)
phenanthroline (5 mol %)
amine (50 mol %)
NaI (25 mol %)
Mn (2 equiv)
DMF (0.1 M)
60 °C, 18 h
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reductant were investigated. Screening of a number of polar solvents revealed that MeOH 
was an acceptable solvent for the desired transformation, and a reaction temperature of 
60 °C was ideal. Interestingly, the use of anhydrous and/or degassed MeOH was found to 
be unnecessary, and special consideration for exclusion of air or moisture from the 
solvent did not improve the coupling. The reaction conversions did suffer to a significant 
extent when conducted under air, and an inert atmosphere of Ar was required to effect the 
desired transformation.   
It was observed that Mn powder served as a better reductant than Zn dust for the 
reductive cross-coupling in terms of minimization of protodehalogenation of the alkyl 
halide. Furthermore, the Mn powder was advantageous compared to Zn in that it did not 
require activation prior to use, which had led to inconsistencies associated with the use of 
Zn dust.  
 Upon testing of various inorganic salts as additives in the transformation, 
improved conversions were observed with the use of one equivalent of NaBF4. Given the 
presumed role(s) of NaI as an additive in the reductive coupling,26,40,41 which include in 
situ formation of an alkyl iodide from the corresponding alkyl bromide, facilitation of 
reductive elimination from Ni(III), and bridging ligation of Ni complexes, this observation 
was somewhat surprising. The noncoordinating BF4- anion should not be able to fulfill 
any of these presumed roles, and its function in the reaction remains unknown.  It was 
noted that the use of KI, NaI, and CsI all led to satisfactory conversions to the desired 
product, albeit leading to slightly greater side-product formation (Alk-H and Ar-Ar).  
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 The developed conditions were utilized for the reaction of 1-Boc-4-
bromopiperidine with several aryl bromides (Table 3.2). The conditions were tolerant of 
ortho-substitution on the aryl ring in addition to amide and ketone functional groups. The 
conditions were shown to be scalable through the reaction of 1-Boc-4-bromopiperidine 
with 4-bromoanisole on a gram scale (6.0 mmol) with only 5 mol % Ni-loading without a 
decrease in yield.  
 
Table 3.2: Cross-Coupling of 1-Boc-4-Bromopiperidine with Aryl Bromides 
 
Entry Product  Yield (%) 
1 
 
3.1 65, 68a 
2 
 
3.2 64 
 
3  
3.3 58 
NiCl2•glyme (10 mol %)
phenanthroline (20 mol %)
4-ethylpyridine (50 mol %)
NaBF4 (50 mol %)
Mn (2 equiv)
MeOH (0.2 M)
60 °C, 18 h
+
BocN
Br
BocN
Ar
Ar-Br
1 equiv 1 equiv
OMe
BocN
BocN
OMe
BocN
OMe
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4 
 
3.4 70 
5 
 
3.5 53 
6 
 
3.6 62 
 
Standard conditions: 1.0 mmol alkyl bromide, 1.0 mmol aryl bromide, 
0.1 mmol NiCl2!glyme, 0.2 mmol 1,10-phenanthroline, 0.5 mmol 
NaBF4, 2.0 mmol Mn powder, 0.5 mmol 4-ethylpyridine, 5 mL MeOH 
a6.0 mmol scale, modification to general conditions: 5 mol % 
NiCl2!glyme, 10 mol % phenanthroline 
  
The developed conditions were next explored in reductive couplings involving 
heteroaryl bromides. There were significant limitations observed in this realm of 
substrates, but several heteroaryl bromides were successfully cross-coupled with 1-Boc-
4-bromopiperidine, including 5-bromobenzofuran and several bromopyridine derivatives 
(Table 3.3). 
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O
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Table 3.3: Cross-Coupling of 1-Boc-4-Bromopiperidine with Select Heteroaryl 
Bromides 
 
Entry Product  Yield (%) 
1 
 
3.7 58 
2 
 
3.8 43 
 
3 
 
3.9 24 
4 
 
3.10 22 
5 
 
3.11 40 
6 
 
3.12 35 
 
Standard conditions: 1.0 mmol alkyl bromide, 1.0 mmol heteroaryl 
bromide, 0.1 mmol NiCl2!glyme, 0.2 mmol 1,10-phenanthroline, 0.5 
mmol NaBF4, 2.0 mmol Mn powder, 0.5 mmol 4-ethylpyridine, 5 mL 
MeOH 
NiCl2•glyme (10 mol %)
phenanthroline (20 mol %)
4-ethylpyridine (50 mol %)
NaBF4 (50 mol %)
Mn (2 equiv)
MeOH (0.2 M)
60 °C, 18 h
+
BocN
Br
BocN
(Het)Ar
(Het)Ar-Br
1 equiv 1 equiv
BocN
O
N
BocN
N
BocN
N
BocN
N
BocN
N
BocN
MeO
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 Extension of the conditions to a different alkyl bromide was next undertaken, and 
4-bromotetrahydropyran was successfully cross-coupled with a variety of aryl bromides. 
It was noted that in the case of oxygen-containing nonaromatic heterocyclic bromides, 
the reaction actually proceeded to greater conversions with lower catalyst loading. The 
use of 2.5 mol % Ni (instead of the 10 mol % Ni required for bromopiperidine couplings) 
allowed reduction of side product formation and higher reaction yields. With this 
modification, 4-bromotetrahydropyran was cross-coupled with aryl bromides bearing 
ketone, trifluoromethyl, and sulfonamide functional groups in satisfactory yields (Table 
3.4). 
 
Table 3.4: Cross-Coupling of 4-Bromotetrahydropyran with Aryl Bromides 
 
Entry Product  Yield (%) 
1 
 
3.13 62 
2 
 
3.14 59 
NiCl2•glyme (2.5 mol %)
phenanthroline (5 mol %)
4-ethylpyridine (50 mol %)
NaBF4 (50 mol %)
Mn (2 equiv)
MeOH (0.2 M)
60 °C, 18 h
+
O
Br
O
Ar
Ar-Br
1 equiv 1 equiv
OMe
O
O
OMe
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3  
3.15 58 
4 
 
3.16 50 
5 
 
3.17 43 
6 
 
3.18 53 
7 
 
3.19 41 
 
Standard conditions: 1.0 mmol alkyl bromide, 1.0 mmol aryl bromide, 
0.025 mmol NiCl2!glyme, 0.05 mmol 1,10-phenanthroline, 0.5 mmol 
NaBF4, 2.0 mmol Mn powder, 0.5 mmol 4-ethylpyridine, 5 mL MeOH  
 
 One goal of the project had been development of a method that would be 
extendable to all of the saturated heterocycles of interest. The reaction conditions were 
illustrated in the cross-coupling of 4-bromoanisole with six-, five, and four-membered 
alkyl rings containing nitrogen and oxygen (Table 3.5). As had been observed with the 
O
OMe
O
O
O
CF3
O
S
O
OO
NH2
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coupling of 4-bromotetrahydropyran, the oxygen-containing substrates could be cross-
coupled at reduced catalyst loadings compared to the nitrogen-containing systems.  
 
 
Table 3.5: Cross-Coupling of 4-Bromoanisole with Various Nonaromatic, 
Heterocyclic Bromides 
 
Entry Product  Yield (%) 
1 
 
3.1 65 
2 
 
3.20 50 
 
3 
 
3.21 40 
4 
 
3.22 48 
NiCl2•glyme
phenanthroline
4-ethylpyridine
NaBF4 
Mn
MeOH (0.2 M)
60 °C, 18 h
+
Alk
Alk-Br
Br
OMe OMe
1 equiv 1 equiv
OMe
BocN
OMe
Boc
N
OMe
Boc
N
OMe
BocN
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5 
 
3.13 62 
6 
 
3.23 43 
7 
 
3.24 41a 
8 
 
3.25 43 
 
Standard conditions: 1.0 mmol alkyl bromide, 1.0 mmol aryl bromide, 
0.1 or 0.025 mmol NiCl2!glyme, 0.2 or 0.05 mmol 1,10-
phenanthroline, 0.5 mmol NaBF4, 2.0 mmol Mn powder, 0.5 mmol 4-
ethylpyridine, 5 mL MeOH amodification to general conditions: 20 mol 
% NiCl2!glyme, 10 mol % phenanthroline; product isolated was 8:1 
mixture of isomers (3-substituted product/2-substituted product) 
 
Interestingly, the coupling of 3-bromotetrahydrofuran resulted in the formation of 
two product isomers, with arylation occurring in both the 2- and 3- positions on the 
saturated ring in an 8:1 ratio. Increasing the Ni loading from 2.5 mol % to 20 mol % led 
to a complete reversal in selectivity, and the 3-substituted product was isolated as the 
major isomer.  The notion that increased catalyst led to decreased isomerization may be 
suggestive of an isomerization event involving a radical, but there is no known 
OMe
O
OMe
O
O
OMe
OMe
O
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precedence for the occurrence of this pathway. It is therefore presumed that the 
isomerization must occur through a β-hydride elimination/hydrometalation sequence 
involving Ni, but in that case the dependence of the extent of isomerization on the 
amount of Ni cannot be rationalized. 
In an effort to elucidate substrate dependence for the occurrence of the observed 
isomerization, an electron-poor aryl bromide was cross-coupled with 3-
bromotetrahydrofuran under the same reaction conditions (Equation 3.1). In this case, 
isomerization to the 2-arylated product only occurred to the extent of 3.5%, and increased 
Ni catalyst did not served to reduce the amount of isomerized product further. It was 
noted that isomerization was not observed with the use of any other nonaromatic 
heterocyclic bromide.  
 
Equation 3.1: 
 
 
 A wide scope of heteroaromatic bromides was unable to be cross-coupled with the 
saturated heterocyclic bromides under the developed conditions. Optimization was 
NiCl2•glyme (2.5 mol %)
phenanthroline (5 mol %)
4-ethylpyridine (50 mol %)
NaBF4 (50 mol %)
Mn (2 equiv)
MeOH (0.2 M)
60 °C, 18 h
+
O
Br
Br
O
O
O
yield = 54%
 isomerization to 2-substituted product = 3.5%
3.26
     155 
undertaken therefore on the reaction of 1-Boc-4-bromopiperidine with 3-bromoquinoline 
for the development of a modified set of reaction conditions that would be applicable to a 
range of heteroaromatic substrates. Using screening techniques to explore a variety of 
Ni(II) salts in addition to diamine ligands, solvents, and additives, it was determined that 
NiI2 in the presence of DMA allowed formation of the desired cross-coupled product, 
which was not observed under the originally developed conditions. The use of 4,4’-di-
tert-butylbipyridine in place of 1,10-phenanthroline served to improve conversions when 
used in a 1:1 ratio with the Ni catalyst. Based on a previously reported reductive coupling 
protocol developed by Gong, et al.,31 a MgCl2 additive was found to promote product 
formation significantly when used in the place of NaBF4. Modification to the original 
conditions included switching the catalyst from NiCl2!glyme to NiI2, the ligand from 
1,10-phenanthroline to 4,4’-di-tert-butylbipyridine, the salt additive from NaBF4 to 
MgCl2, and the solvent from MeOH to DMA. 4-Ethylpyridine remained the most 
effective amine additive, though a full equivalent was required under the modified 
conditions (compared to 0.5 equiv), and Mn powder remained the optimal reductant 
(Scheme 3.9). 
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Scheme 3.9: Reaction of 1-Boc-4-Bromopiperidine with 3-Bromoquinoline with 
Original and Modified Conditions 
 
 
 
 The modified conditions were demonstrated in the reactions of several 
nonaromatic heterocyclic bromides with heteroaromatic bromides (Table 3.6). A variety 
of heteroaromatic bromides that were previously unreactive could successfully be cross-
coupled under this set of reaction conditions, including free and protected indoles, as well 
as quinolone and isoquinoline systems. Aryl bromides bearing pyrazole and oxadiazole 
rings also participated in the reductive cross-coupling under the modified conditions. 
 
 
 
NiCl2•glyme (10 mol %)
phenanthroline (20 mol %)
4-ethylpyridine (50 mol %)
NaBF4 (50 mol %)
Mn (2 equiv)
MeOH (0.2 M)
60 °C, 18 h
+
BocN
Br N
Br
N
BocN
+
BocN
Br N
Br
N
BocN
NiI2 (10 mol %)
di-t-Bu-bipyridine (10 mol %)
4-ethylpyridine (1 equiv)
MgCl2 (1 equiv)
Mn (2 equiv)
DMA (0.2 M)
60 °C, 18 h 60% yield
not observed
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Table 3.6: Cross-Coupling of Heteroaromatic Bromides with Nonaromatic 
Heterocyclic Bromides 
 
Entry Product  Yield (%) 
1 
 
3.27 60 
2 
 
3.28 27 
 
3 
 
3.29 38 
4 
 
3.30 29 
5 
 
3.31 65 
NiI2 (10 mol %)
di-t-Bu-bipyridine (10 mol %)
4-ethylpyridine (1 equiv)
MgCl2 (1 equiv)
Mn (2 equiv)
DMA (0.2 M)
60 °C, 18 h
+ Alk (Het)ArAlk-Br (Het)Ar-Br
1 equiv 1.1 equiv
N
BocN
BocN
N
H
N
BocN
BocN
N
N
BocN
N
H
N
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6 
 
3.32 32 
7 
 
3.33 41 
8 
 
3.34 45 
9 
 
3.35 49 
10 
 
3.36 30 
 
Standard conditions: 1.0 mmol alkyl bromide, 1.1 mmol heteroaryl 
bromide, 0.1 mmol NiI2, 0.1 mmol 4,4’-di-tert-butyl-2,2’-bipyridine, 
1.0 mmol MgCl2, 2.0 mmol Mn powder, 1.0 mmol 4-ethylpyridine, 5 
mL N,N-dimethylacetamide  
 
 To demonstrate the versatility of the newly developed conditions toward each of 
the nonaromatic heterocycles of interest, the cross-coupling of the six-, five-, and four-
membered ring systems containing nitrogen and oxygen with N-Boc-5-bromoindole was 
BocN
O N
N
N
O
O
N N
H
O
O
N
BocN
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conducted (Table 3.7). All of the reactions yielded the desired cross-coupled product, 
with no isomerization observed, even with the use of 3-bromotetrahydrofuran.  
 
Table 3.7: Cross-Coupling of N-Boc-5-Bromoindole with Various Nonaromatic 
Heterocyclic Bromides 
 
 
Entry Product  Yield (%) 
1 
 
3.37 73 
2 
 
3.38 37 
 
3 
 
3.39 44 
4 
 
3.40 70 
NiI2 (10 mol %)
di-t-Bu-bipyridine (10 mol %)
4-ethylpyridine (1 equiv)
MgCl2 (1 equiv)
Mn (2 equiv)
DMA (0.2 M)
60 °C, 18 h
+
Alk
Alk-Br
N
Boc
Br
N
Boc
1 equiv 1.1 equiv
O
N
Boc
O
N
Boc
N
Boc
O
N
Boc
O
     160 
5 
 
3.41 51 
6 
 
3.42 48 
7 
 
3.43 38 
8 
 
3.44 36 
 
Standard conditions: 1.0 mmol alkyl bromide, 1.1 mmol heteroaryl 
bromide, 0.1 mmol NiI2, 0.1 mmol 4,4’-di-tert-butyl-2,2’-bipyridine, 
1.0 mmol MgCl2, 2.0 mmol Mn powder, 1.0 mmol 4-ethylpyridine, 5 
mL N,N-dimethylacetamide  
 
 The reductive cross-coupling of saturated heterocyclic bromides with 
heteroaromatic bromides did not occur under the initially developed set of reaction 
conditions (with the general exception of pyridyl bromides), and likewise, aryl bromides 
did not react under the latter set of conditions. The only observed substrate that 
underwent the cross-coupling to a significant extent under both sets of conditions was 5-
bromobenzofuran. Two sets of conditions were therefore developed for the reductive 
BocN
N
Boc
Boc
N
N
Boc
N
Boc
Boc
N
N
Boc
BocN
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cross-coupling of nonaromatic heterocyclic bromides with aryl and heteroaryl bromides, 
respectively. The two methods represent orthogonal substrate scopes, but between the 
two developed protocols, a wide array of aryl and heteroaryl bromides can be cross-
coupled in the presence of a variety of functional groups.  
 
3.3 Reductive Cross-Coupling of 3-Bromo-2,1-borazaronaphthalenes with 
Alkyl Iodides 
 A class of molecules known collectively as azaborines is composed of pseudo-
aromatic structures that possess a B-N connection in place of a C=C bond within a cyclic 
core.  In particular, 2,1-borazaronaphthalenes are of interest because of their possible 
beneficial properties within the realms of pharmaceutical and materials science.42–48 
These pseudo-aromatic structures exhibit reactivity patterns much like their 
corresponding all-carbon analogues, but distinct properties result from their lack of 
planarity and B-N dipole, which give them potential for unique binding affinity and 
photophysical properties. 
 Because of the interest surrounding this class of boron-containing structures, 
progress has been made in development of methods for construction of azaborine cores 
and functionalization of the basic structures.49–54 The bromination of 2,1-
borazaronaphthalenes has been demonstrated, and subsequent arylation in the 3-position 
can be carried out on various core structures (Scheme 3.10).53 
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Scheme 3.10:Bromination and Subsequent Cross-Coupling of 2,1-
Borazaronaphthalenes 
 
 
 Progress had been made toward synthesis of a small a library of interesting 2,1-
borazaronaphthalene variants, but a method had not yet been successfully employed for 
the introduction of alkyl substituents onto the 3-position of these core structures. Based 
on the success of C-C bond formation using a reductive cross-coupling process for the 
introduction of nonaromatic heterocyclic moieties onto (hetero)aryl halides, a similar 
manifold was investigated for alkyl functionalization of azaborines.  
 Investigation of reaction conditions for the reductive cross-coupling of 3-bromo-
2,1-borazaronaphthalenes with nonaromatic heterocyclic halides was begun on the 
reaction of 3-bromo-2-phenyl-2,1-borazaronaphthalene and 1-Boc-4-bromopiperidine. 
The substrates were initially reacted under the conditions that had been recently 
developed for the reductive coupling of saturated heterocycles with aryl and heteroaryl 
bromides (Equation 3.2).55 Under the unoptimized conditions, the alkylation proceeded in 
44% yield. Although the desired product was formed to a respectable extent, a significant 
amount of protodehalogenation of the azaborine was observed under these conditions.  
 
B
N R2
R1
Br2
CH2Cl2
0 °C to rt
B
N R2
R1
Br
Ar-BF3K
t-Bu3P-Pd-G2
Cs2CO3
1:1 CPME/H2O
60 °C, 18 h
B
N R2
R1
Ar
R1 = H, alkyl
R2 = alkyl, (hetero)aryl
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Equation 3.2: 
 
 
 Optimization was carried out on this model reaction, and it was quickly 
discovered that modification of the ligand from 1,10-phenanthroline to 4,4’-dimethyl-
2,2’-bipyridine led to increased product formation. A variety of nickel sources and 
additives were explored for the desired transformation, but 4-ethylpyridine and NaBF4 
were confirmed to be suitable additives for the reaction. Although the alkyl bromide 
served as an effective coupling partner, it was determined that the temperature could be 
lowered to 40 °C with the use of the corresponding alkyl iodide. The lowering of reaction 
temperature significantly reduced the otherwise prominent protodehalogenation 
byproduct. With the alkyl iodide, a variety of modifications to the reaction conditions 
were explored, a few of which are shown in Table 3.8. 
 
 
 
B
N Ph
Br
+
N
Boc
Br
B
N Ph
NBoc
NiCl2•glyme (10 mol %)
1,10-phenanthroline (20 mol %)
4-ethylpyridine (50 mol %)
NaBF4 (50 mol %)
Mn (2.0 equiv)
MeOH, 0.2 M
60 °C, 18 h
44% yield
H
H
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Table 3.8: Optimization of Reductive Cross-Coupling of 3-Bromo-2-phenyl-2,1-
borazaronaphthalene and 1-Boc-4-Bromopiperidine 
 
 
entry modification P/ISa 
1 none 2.78 
2 temp = rt 2.58 
3 1:1 cyclohexane/MeOH 2.07 
4 2:1 cyclohexane/DMA 3.10 
5 2:1 DMA/cyclohexane 2.51 
6 anhydrous, degassed solvent 2.65 
7 1.0 equiv Alk-I 2.61 
8 5 mol % Ni, 5 mol % L 2.75 
 
   a ratio of product to internal standard of 4,4’-di-tert- 
butylbiphenyl, as monitored by HPLC 
  
Further reduction of reaction temperature was detrimental to product formation, 
as was the use of only one equivalent of the alkyl iodide coupling partner. The catalyst 
loading could be reduced to 5 mol % without a significant loss in activity, and it was 
determined that the use of anhydrous, degassed solvent was not necessary. A screen of 
various solvents had revealed that a mixture of cyclohexane with a more polar organic 
solvent was beneficial for the reaction, and upon optimization, a 2:1 mixture of 
cyclohexane/DMA was determined to be ideal.  
B
N Ph
Br
+
N
Boc
I
B
N Ph
NBoc
NiCl2•glyme (10 mol %)
4,4'-dimethyl-2,2'-bipyridine (10 mol %)
4-ethylpyridine (1.0 equiv)
NaBF4 (50 mol %)
Mn (2.0 equiv)
1:1 cyclohexane/DMA, 0.2 M
40 °C, 18 h
1.2 equiv
H
H
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 With the optimized reaction conditions in hand, 1-Boc-4-iodopiperidine was used 
in the alkylations of several 3-bromo-2,1-borazaronaphthalenes bearing aryl and 
heteroaryl substituents on the boron atom (Table 3.9). Sterically bulky heteroaryl 
substituents of dibenzofuran and dibenzothiophene were tolerated as well as aryl groups 
bearing fluoro-, methoxy-, and carbomethoxy- groups. The reactions proceeded in good 
yields at 40 °C in 18 h. 
 
 
Table 3.9: Cross-Coupling of 1-Boc-4-Iodopiperidine with Various 3-Bromo-2,1-
borazaronaphthalenes 
 
 
Entry Product  Yield (%) 
1 
 
3.45 78 
2 
 
3.46 96 
B
N (Het)Ar
Br
+ NBoc
I B
N (Het)Ar
NBoc
NiCl2•glyme (5 mol %)
4,4'-dimethyl-2,2'-bipyridine (5 mol %)
4-ethylpyridine (1.0 equiv)
NaBF4 (50 mol %)
Mn (2.0 equiv)
2:1 cyclohexane/DMA, 0.2 M
40 °C, 18 h
1.2 equiv
H
H
1 equiv
B
H
N
N
Boc
B
H
N
N
Boc
F
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3 
 
3.47 77 
4 
 
3.48 80 
5 
 
3.49 74 
6 
 
3.50 74 
7 
 
3.51 89 
 
Standard conditions: 0.5 mmol 3-bromo-2,1-borazaronaphthalene, 0.6 
mmol alkyl iodide, 0.025 mmol NiCl2!glyme, 0.025 mmol 4,4’-di-tert-
butyl-2,2’-bipyridine, 0.25 mmol NaBF4, 1.0 mmol Mn powder, 0.5 
mmol 4-ethylpyridine, 2.5 mL solvent (2:1 cyclohexane: N,N-
dimethylacetamide) 
 
B
H
N
N
Boc
OMe
B
H
N
N
Boc
F F
B
H
N
N
Boc
CO2Me
B
H
N
N
Boc
S
B
H
N
N
Boc
O
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 A variety of 3-bromo-2,1-borazaronaphthalenes bearing alkyl substituents on the 
boron atom were shown to participate in the reductive alkylation with 1-Boc-4-
iodopiperidine (Table 3.10). In addition to B-alkyl systems with a free N-H, several 
nitrogen-substituted structures also participated effectively in the reductive coupling in 
good to excellent yield under the established conditions.  
 
Table 3.10: Cross-Coupling of 1-Boc-4-Iodopiperidine with Various 3-Bromo-2,1-
borazaronaphthalenes 
 
 
Entry Product  Yield (%) 
1 
 
3.52 62 
2 
 
3.53 37 
 
3 
 
3.54 88 
B
N Alk
Br
+ NBoc
I B
N Alk
NBoc
NiCl2•glyme (5 mol %)
4,4'-dimethyl-2,2'-bipyridine (5 mol %)
4-ethylpyridine (1.0 equiv)
NaBF4 (50 mol %)
Mn (2.0 equiv)
2:1 cyclohexane/DMA, 0.2 M
40 °C, 18 h
1.2 equiv
H
H
1 equiv
B
H
N Me
N
Boc
B
H
N
N
Boc
B
H
N
N
Boc
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4 
 
3.55 84 
5 
 
3.56 51 
6 
 
3.57 90 
 
Standard conditions: 0.5 mmol 3-bromo-2,1-borazaronaphthalene, 0.6 
mmol alkyl iodide, 0.025 mmol NiCl2!glyme, 0.025 mmol 4,4’-di-tert-
butyl-2,2’-bipyridine, 0.25 mmol NaBF4, 1.0 mmol Mn powder, 0.5 
mmol 4-ethylpyridine, 2.5 mL solvent (2:1 cyclohexane: N,N-
dimethylacetamide) 
 
 The scope of the reaction was next expanded to demonstrate the effectiveness of 
the developed method on a variety of alkyl iodides (Table 3.11). It was illustrated that the 
coupling could be extended to the iodides of azetidine, tetrahydropyran, tetrahydrofuran, 
and oxetane substrates, and the reactions proceeded in moderate to good yields. The 
reaction of 3-bromo-2-phenyl-2,1-borazaronaphthalene with 1-Boc-3-iodoazetidine was 
carried out on a gram scale (3.0 mmol) at reduced catalyst loading, and a decrease in 
yield was not observed, demonstrating the scalable nature of the developed method. In 
addition to saturated heterocyclic iodides, the method was determined to be compatible 
B
N Me
N
Boc
Ph
B
N Me
N
Boc
B
N
N
Boc
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with both secondary and primary alkyl iodides containing no heteroatoms as well as an 
alkyl iodide with an acetate substituent.  
 
Table 3.11: Cross-Coupling of 3-Bromo-2-phenyl-2,1-borazaronaphthalene with 
Various Alkyl Iodides  
 
 
Entry Product  Yield (%) 
1 
 
3.58 61, 65a 
 
2 
 
3.59 90 
3 
 
3.60 48 
4 
 
3.61 59 
B
N Ph
Br
+ B
N Ph
Alk
NiCl2•glyme (10 mol %)
4,4'-dimethyl-2,2'-bipyridine (10 mol %)
4-ethylpyridine (1.0 equiv)
NaBF4 (50 mol %)
Mn (2.0 equiv)
2:1 cyclohexane/DMA, 0.2 M
40 °C, 18 h
H H
Alk-I
1.2 equiv1 equiv
B
H
N
N
Boc
B
H
N
O
B
H
N
O
B
H
N
O
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5 
 
3.62 62 
6 
 
3.63 70 
7 
 
3.64 91 
 
Standard conditions: 0.5 mmol 3-bromo-2,1-borazaronaphthalene, 0.6 
mmol alkyl iodide, 0.025 mmol NiCl2!glyme, 0.025 mmol 4,4’-di-tert-
butyl-2,2’-bipyridine, 0.25 mmol NaBF4, 1.0 mmol Mn powder, 0.5 
mmol 4-ethylpyridine, 2.5 mL solvent (2:1 cyclohexane: N,N-
dimethylacetamide). a3.0 mmol scale; 2.5 mol % NiCl2!glyme, 2.5 mol 
% 4,4’-di-tert-butyl-2,2’-bipyridine 
 
 An effective method for the alkylation of 3-bromo-2,1-borazaronaphthalenes was 
developed. The protocol employs mild conditions and is tolerant of several substituted 
2,1-borazaronaphthalenes as well as a variety of alkyl iodides, including the important 
class of nonaromatic heterocycles. The method provides advancement toward the 
preparation of azaborine libraries.  
 
B
H
N
B
H
N
B
H
N
OAc
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3.4 Engaging Nonaromatic, Heterocyclic Tosylates in Reductive Cross-
Coupling with Aryl and Heteroaryl Bromides 
 Methods have been established for the introduction of nonaromatic heterocyclic 
structures onto aryl halides through Ni-catalyzed reductive cross-coupling methods 
(Scheme 3.11).31,55 Although these methods have allowed more efficient access to 
arylated saturated heterocyclic ring systems and eliminate the need for a metalation step 
of either substrate, there exists ample room for improvement of the existing protocols.  
 
Scheme 3.11: Methods for Reductive Cross-Coupling of Nonaromatic Heterocyclic 
Halides 
 
  
+
(Het)Ar
TsNTsN
Br
NiI2 (10 mol %)
di-tert-Bu-bipyridine (10 mol %)
pyridine (1 equiv)
MgCl2 (1 equiv)
Zn (2 equiv)
DMA, rt
(Het)Ar-Br
16 examples
yields 33-98%
+ (Het)ArAlk
NiCl2•glyme (10 mol %)
1,10-phenanthroline (20 mol %)
4-ethylpyridine (0.5 equiv)
NaBF4 (0.5 equiv)
Mn (2 equiv)
MeOH, 60 °C 26 examplesyields 22-70%
Ar-BrAlk-Br
Alk-Br: Y
Br
Y
Br
Y
Br
Y
Br
Y = NBoc, O
Gong, et al.
Molander, et al.
(A)
(B)
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One significant feature of the developed protocols that may prohibit their use is 
the cost of the alkyl halides of the saturated heterocycles of interest. Although the 
reductive cross-couplings eliminate the cost of a stoichiometric metalating reagent, a 
protocol was envisioned that would allow the use of substrates that are less expensive and 
more readily available from commercial sources. It was noted that compared to the 
corresponding halides, the alcohols of the saturated heterocycles were significantly less 
expensive, and could generally be ordered in larger quantities from common commercial 
sources, making the price difference even more pronounced. The use of pseudohalides of 
the desired nonaromatic heterocyclic substrates in a reductive cross-coupling method was 
pursued since these compounds could be easily and quickly prepared from the 
commercially obtained alcohols (Scheme 3.12).  
 
Scheme 3.12: Reductive Cross-Coupling of Nonaromatic Heterocyclic Tosylates 
 
 
O
OTs
+
N
Boc
Br
NiI2 (10 mol %)
di-t-Bu-bipyridine (10 mol %)
4-ethylpyridine (1 equiv)
MgCl2 (1 equiv)
Mn powder (2 equiv)
DMA (0.2 M), 60 °C, 18 h
N
Boc
O
O
OH
($7/g)
vs.
O
Br
($434/g)
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Reductive homocoupling of alkyl tosylates and mesylates had been reported in an 
early work by the Weix group under Ni-catalyzed conditions,56 and in a more recent 
disclosure, the Gong group reported a reductive methylation of alkyl halides with methyl 
tosylate.57 Although these examples did not illustrate the use of nonaromatic heterocyclic 
alkyl tosylates, a Cu-catalyzed method for the cross coupling of alkyl tosylates with aryl 
and alkyl halides has employed a select few examples of these substrates (Equation 
3.3).58 
 
Equation 3.3:  
 
 
 Development of a protocol for the reductive cross-coupling of alkyl tosylates of 
saturated heterocyclic structures that would be mild enough to tolerate the presence of a 
variety of functional groups was desired. A major goal of this endeavor was reduction in 
overall cost for the purpose of increasing usability of the reductive coupling manifold for 
introduction of nonaromatic heterocyclic structures onto aryl halides. 
 Based on previously developed conditions for the reductive cross-coupling of 
nonaromatic heterocyclic halides with heteroaryl bromides, the reaction of tert-butyl 4-
Ts
N
OTs
+
Br CuI (10 mol %)DPPM (20 mol %)
LiOMe (1 equiv)
Mg (2 equiv)
THF, 0 ºC, 24 h
Ts
N
3 equiv
57% yield
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(tosyloxy)piperidine-1-carboxylate with N-Boc-5-bromoindole was initially investigated 
in the presence of catalytic NiI2 and di-tert-butylbipyridine, with 4-ethylpyridine and 
MgCl2 additives (Equation 3.4). Although the desired cross-coupled product was formed, 
a significant amount of both protodehalogenated and homocoupled arene were observed.  
 
Equation 3.4: 
 
 
 Optimization of the reaction components revealed that the use of NiBr2!glyme in 
place of NiI2 and the elimination of MgCl2 both served to greatly enhance the conversion 
to desired product and decrease the extent of byproduct formation. The addition of a KI 
additive was beneficial to the cross-coupling, similar to the phenomenon that had also 
been observed by Weix, in which the reductive dimerization of alkyl tosylates was 
greatly enhanced with the addition of NaI.56 An increase in reaction temperature from 
60 °C to 80 °C allowed consumption of starting materials after 18 h. With the developed 
set of conditions, a variety of nonaromatic heterocyclic tosylates were shown to undergo 
reductive coupling with N-Boc-5-bromoindole to yield the desired products (Table 3.12). 
+
N
Boc
Br
N
Boc
BocN
BocN
OTs
NiI2 (10 mol %)
di-tert-Bu-bipyridine (10 mol %)
4-ethylpyridine (1 equiv)
MgCl2 (1 equiv)
Mn (2 equiv)
DMA (0.2 M)
60 °C, 18 h
N
Boc
H
+
+ N
Boc
Boc
N
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Unfortunately, both azetidine and oxetane tosylates were unreactive under the developed 
conditions. Alkyl mesylates also participated in the reductive coupling under the standard 
set of reaction conditions, albeit in lower yield than the corresponding tosylates (Table 
3.12, entries 1 and 3).  
 
Table 3.12: Cross-Coupling of N-Boc-5-Bromoindole with Nonaromatic 
Heterocyclic Tosylates 
 
 
Entry Product  Yield (%) 
1 
 
3.65 73, 51a 
2 
 
3.66 69 
 
3 
 
3.67 36, 28a 
4 
 
3.68 66 
Alk-OTs    +
N
Boc
Br
NiBr2•glyme (5 mol %)
di-tert-butylbipyridine (5 mol %)
4-ethylpyridine (1 equiv)
KI (1 equiv)
Mn (2 equiv)
DMA (0.2 M), 80 °C, 18 h
N
Boc
Alk
1 equiv
1 equiv
N
Boc
BocN
N
Boc
O
N
Boc
O
BnN
N
Boc
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5 
 
3.69 52 
6 
 
3.70 24 
 
Standard conditions: 0.5 mmol alkyl tosylate, 0.5 mmol aryl bromide, 
0.025 mmol NiBr2!glyme, 0.025 mmol 4,4’-di-tert-butyl-2,2’-
bipyridine, 0.5 mmol KI, 1.0 mmol Mn powder, 0.5 mmol 4-
ethylpyridine, 2.5 mL N,N-dimethylacetamide. aFrom the 
corresponding alkyl mesylate 
 
The scope of the aryl halide coupling partner was explored, and a variety of 
heterocyclic bromides including quinoline, pyridine, benzothiophene, and benzofuran 
substrates were demonstrated to react under the standard conditions to furnish the desired 
products in moderate to good yields (Table 3.13). In addition to heteroaryl bromides, aryl 
bromides reacted under the developed set of conditions as well, and the functional group 
tolerance of the method was demonstrated by the inclusion of ketone and amide 
substituents on the aryl bromide coupling partners. The reaction of tert-butyl 4-
(tosyloxy)piperidine-1-carboxylate with 3-bromoquinoline was carried out on a gram 
scale (3.0 mmol) without a decrease in yield, illustrating the scalable nature of the 
developed reaction conditions.  
 
 
N
Boc
BocN
N
Boc
Boc
N
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Table 3.13: Cross-Coupling of Nonaromatic Heterocyclic Tosylates with Aryl and 
Heteroaryl Bromides 
 
 
Entry Product  Yield (%) 
1 
 
3.71 74,81a 
2 
 
3.72 60 
 
3  
3.73 42 
4 
 
3.74 49 
5 
 
3.75 62 
6 
 
3.76 38 
Alk-OTs  +   (Het)Ar-Br
NiBr2•glyme (5 mol %)
di-tert-butylbipyridine (5 mol %)
4-ethylpyridine (1 equiv)
KI (1 equiv)
Mn (2 equiv)
DMA (0.2 M), 80 °C, 18 h
HetArAlk
1 equiv 1 equiv
BocN
N
BocN
N
BocN
S
O
O
O
O
N
N
BocN
N
H
O
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7 
 
3.77 65 
8 
 
3.78 60 
9 
 
3.79 72 
 
Standard conditions: 0.5 mmol alkyl tosylate, 0.5 mmol aryl bromide, 
0.025 mmol NiBr2!glyme, 0.025 mmol 4,4’-di-tert-butyl-2,2’-
bipyridine, 0.5 mmol KI, 1.0 mmol Mn powder, 0.5 mmol 4-
ethylpyridine, 2.5 mL N,N-dimethylacetamide. a3.0 mmol scale  
 
 Although the possibility of in situ alkyl iodide formation from the alkyl tosylate in 
the presence of KI may be feasible, the formation of N-Boc-4-iodopiperidine was never 
observed in crude reaction mixtures during the optimization process. Additionally, the 
direct use of N-Boc-4-iodopiperidine in the reaction with or without the KI additive did 
not result in product formation. The elimination of KI from the reaction (with the use of 
NaBF4 as an additive) caused a dramatic decrease in the conversion to product, but it was 
noted that product formation did occur in this case. These observations suggest that while 
the possibility of some in situ alkyl iodide formation cannot be completely ruled out, it is 
clear that the KI additive plays a more complex role under the reaction conditions.26,40,41  
 The developed method allows the reductive cross-coupling of nonaromatic 
heterocyclic tosylates with aryl and heteroaryl bromides under a single set of reaction 
BocN
F
BocN OMe
O
O
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conditions. These pseudohalides are advantageous as coupling partners because they are 
air-stable crystalline solids that are easily prepared from inexpensive, commercially 
available alkyl alcohols. 
 
3.5 Conclusions 
 Methods for the introduction nonaromatic heterocyclic systems onto aryl and 
heteroaryl halides as well as azaborine cores without the necessity for metalation of either 
component have been developed. Reductive cross-coupling protocols have been 
optimized to use bench-stable reagents under conditions that are tolerant of numerous 
functional groups, making them compatible with late-stage incorporation of saturated 
heterocyclic ring systems into larger molecules of interest.  
 The developed methods allow the reductive coupling of nonaromatic heterocyclic 
halides or their corresponding alkyl tosylates with aryl and heteroaryl bromides. 
Although the alkyl halides are bench-stable, their cost and difficulty being obtained from 
common commercial sources may be prohibitive in some cases. To address this 
limitation, a modified reductive coupling protocol was developed that allows the use of 
saturated heterocyclic tosylates.  
 A valuable, direct route to alkylated, functionalized azaborine systems has been 
developed as well. The reductive method allows the cross-coupling of primary and 
secondary alkyl iodides with 3-bromo-2,1-borazaronaphthalene cores. This method will 
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aid in the synthesis of a library of azaborine structures, which are anticipated to have 
valuable physical properties for the fields of medicinal chemistry and materials science.  
 
3.6 Experimental 
General considerations. All cross-coupling reactions were carried out under an Ar 
atmosphere.  MeOH and DMA were used as received and was neither dried nor degassed 
prior to use. Mn powder (~325 mesh) was purchased and used directly. 4-Ethylpyridine 
was distilled under vacuum. Solids were weighed out in air and were stored on a 
laboratory bench without special considerations. 1H and 13C NMR spectra were recorded 
at 500 and 125.8 MHz, respectively. 11B NMR spectra were recorded at 128.4 MHz. 
Melting points (°C) were determined using a Thomas-Hoover capillary melting point 
apparatus and are uncorrected. HRMS data was obtained using a TOF mass spectrometer 
using ESI or CI, as specified.  
 
Procedure for the reductive cross-coupling of non-aromatic heterocyclic bromides 
with aryl bromides.  An oven-dried Biotage 10 mL microwave vial equipped with a 
magnetic stirbar was charged with alkyl bromide (1.0 mmol), NiCl2•glyme (0.1 mmol, 
22.0 mg), 1,10-phenanthroline (0.2 mmol, 36.0 mg), NaBF4 (0.5 mmol, 54.9 mg), and 
Mn powder (2.0 mmol, 109.9 mg).  The vial was sealed with a disposable Teflon septum 
cap and was evacuated and purged with Ar three times. MeOH (5 mL) and 4-
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ethylpyridine (0.5 mmol, 54 mg) were added via syringe, followed by the aryl bromide 
(1.0 mmol). In cases where the aryl bromide was a solid, it was added to the vial along 
with the other solids. The reaction was stirred under Ar with conventional heating at 60 
°C for 18 h, after which the solution was cooled and diluted with 5 mL of EtOAc. The 
resulting mixture was filtered through Celite, which was rinsed with EtOAc (~ 10 mL). 
The solution was concentrated, and the product was isolated by column chromatography, 
eluting with a gradient of EtOAc in hexanes (0 to 20% EtOAc).  Note: For 
tetrahydropyranyl, tetrahydrofuranyl, and oxetanyl substrates, the amount of 
NiCl2•glyme was reduced to 0.025 mmol (5.5 mg) and the amount of 1,10-
phenanthroline was reduced to 0.05 mmol (9.0 mg). 
 
Procedure for the reductive cross-coupling of non-aromatic heterocyclic bromides 
with heteroaryl bromides. An oven-dried Biotage 10 mL microwave vial equipped with 
a magnetic stirbar was charged with the alkyl bromide (1.0 mmol), NiI2 (0.1 mmol, 31.3 
mg), 4,4’-di-tert-butyl-2,2’-bipyridine (0.1 mmol, 26.8 mg), MgCl2 (1 mmol, 95.2 mg), 
and Mn powder (2.0 mmol, 109.9 mg).  The vial was sealed with a disposable Teflon 
septum cap and was evacuated and purged with Ar three times. Dimethylacetamide (5 
mL) and 4-ethylpyridine (1.0 mmol, 108 mg) were added via syringe, followed by the 
heteroaryl bromide (1.1 mmol). In cases where the aryl bromide was a solid, it was added 
to the vial along with the other solids. The reaction was stirred under Ar with 
conventional heating at 60 °C for 18 h, after which the solution was cooled and diluted 
with 25 mL of distilled H2O. The resulting mixture was extracted (3 x 10 mL) with 
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EtOAc, and the combined organic portions were washed (2 x 10 mL) with H2O. The 
organic layer was dried (NaSO4), after which it was filtered and concentrated.  The 
product was isolated by column chromatography eluting with a gradient of EtOAc in 
hexanes (10 to 60 % EtOAc).  
 
 
tert-Butyl 4-(4-Methoxyphenyl)piperidine-1-carboxylate (3.1).19 The title compound 
was obtained as a colorless oil in 65% yield (189 mg) according to method A. Spectral 
data were in accordance with those published. 1H NMR (500 MHz, CDCl3): δ 7.13-7.11 
(m, 2H), 6.86-6.84 (m, 2H), 4.23 (br, 2H), 3.79 (s, 3H), 2.80-2.77 (m, 2H), 2.59 (tt, J = 
12.2, 3.5 Hz, 1H), 1.81-1.78 (m, 2H), 1.60-1.57 (m, 2H), 1.48 (s, 9H); 13C NMR (125.8 
MHz, CDCl3): δ 158.2, 155.0, 138.1, 127.8, 114.0, 79.5, 55.4, 44.8 (br), 42.0, 33.6, 28.6. 
 
 
 
tert-Butyl 4-(3-Methoxyphenyl)piperidine-1-carboxylate (3.2). The title compound 
was obtained as a colorless oil in 64% yield (186 mg) according to method A. 1H NMR 
(500 MHz, CDCl3): δ 7.25-7.21 (m, 1H), 6.81-6.75 (m, 3H), 4.24 (br, 2H), 3.80 (s, 3H), 
OMe
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2.81-2.74 (m, 2H), 2.64-2.59 (m, 1H), 1.83-1.81 (m, 2H), 1.63-1.61 (m, 2H), 1.48 (s, 
9H); 13C NMR (125.8 MHz, CDCl3): δ 159.9, 155.0, 147.7, 129.6, 119.3, 112.9, 111.5, 
79.6, 55.3, 44.2 (br), 42.9, 33.3, 28.6; FT-IR (neat): 2974, 1690, 1423, 1166 cm-1; HRMS 
(ES+) m/z calcd. for C17H25NO3Na (M+Na)+ 314.1732, found 314.1737. 
 
 
tert-Butyl 4-(2-Methoxyphenyl)piperidine-1-carboxylate (3.3).5 The title compound 
was obtained as a white solid in 58% yield (169 mg) according to method A. mp: 63-65 
°C; Spectral data were in accordance with those published. 1H NMR (500 MHz, CDCl3): 
δ 7.24-7.12 (m, 2H), 6.92-6.89 (m, 1H), 6.85-6.83 (m, 1H), 4.21 (br, 2H), 3.81 (s, 3H), 
3.09-3.04 (m, 1H), 2.81-2.80 (m, 2H), 1.77-1.75 (m, 2H), 1.58-1.54 (m, 2H), 1.46 (s, 
9H); 13C NMR (125.8 MHz, CDCl3): δ 156.9, 155.1, 134.0, 127.2, 126.6, 120.1, 110.5, 
79.4, 55.4, 45.2 (br), 35.5, 32.0, 28.7. 
 
 
tert-Butyl 4-(4-Fluorophenyl)piperidine-1-carboxylate (3.4).5 The title compound was 
obtained as a colorless oil in 70% yield (195 mg) according to method A. Spectral data 
BocN
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were in accordance with those published. 1H NMR (500 MHz, CDCl3): δ 7.15-7.12 (m, 
2H), 6.99-6.96 (m, 2H), 4.23 (br, 2H), 2.82-2.74 (m, 2H), 2.64-2.59 (m, 1H), 1.80-1.77 
(m, 2H), 1.59-1.55 (m, 2H), 1.47 (s, 9H); 13C NMR (125.8 MHz, CDCl3): δ 161.5 (d, J = 
244.1 Hz), 154.9, 141.6 (d, J = 3.7 Hz), 128.2 (d, J = 7.8 Hz), 115.3 (d, J = 21.0 Hz), 
79.6, 44.1 (br), 42.1, 33.5, 28.6. 
 
 
tert-Butyl 4-(4-Acetamidophenyl)piperidine-1-carboxylate (3.5). The title compound 
was obtained as a white solid in 53% yield (169 mg) according to method A. mp: 165-
168 °C. 1H NMR (500 MHz, CDCl3): δ 7.57 (br, 1H), 7.40 (d, J = 8.1 Hz, 2H), 7.11-7.10 
(m, 2H), 4.20 (br, 2H), 2.80-2.72 (m, 2H), 2.60-2.55 (m, 1H), 2.12 (s, 3H), 1.77-1.74 (m, 
2H), 1.58-1.53 (m, 2H), 1.45 (s, 9H);  13C NMR (125.8 MHz, CDCl3): δ 168.9, 155.1, 
141.8, 136.5, 127.3, 120.4, 79.7, 44.4 (br), 42.2, 33.4, 28.6, 24.5; FT-IR (neat): 3312, 
1700, 1661, 1427, 1170 cm-1; HRMS (ES+) m/z calcd. for C18H26N2O3Na (M+Na)+ 
341.1841, found 341.1851. 
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tert-Butyl 4-(4-Acetylphenyl)piperidine-1-carboxylate (3.6). The title compound was 
obtained as a yellow solid in 62% yield (188 mg) according to method A. mp: 81-82 °C. 
1H NMR (500 MHz, CDCl3): δ 7.88 (d, J = 8.1 Hz, 2H), 7.27 (d, J = 8.1 Hz, 2H), 4.24 
(br, 2H), 2.79-2.72 (m, 2H), 2.69-2.67 (m, 1H), 2.56 (s, 3H), 1.80 (d, J = 12.8 Hz, 2H), 
1.63-1.60 (m, 2H), 1.46 (s, 9H); 13C NMR (125.8 MHz, CDCl3): δ 197.8, 154.9, 151.4, 
135.7, 128.8, 127.2, 79.7, 44.3 (br), 42.9, 33.0, 28.6, 26.7; FT-IR (neat): 2980, 1678, 
1425, 1173 cm-1; HRMS (ES+) m/z calcd. for C18H25NO3Na (M+Na)+ 326.1732, found 
326.1729. 
 
 
tert-Butyl 4-(Benzofuran-5-yl)piperidine-1-carboxylate (3.7). The title compound was 
obtained as a white solid in 58% yield (175 mg) according to method A. mp: 104-106 °C. 
1H NMR (500 MHz, CDCl3): δ 7.60-7.59 (m, 1H), 7.44-7.42 (m, 2H), 7.14-7.13 (m, 1H), 
6.72 (s, 1H), 4.26 (br, 2H), 2.82-2.76 (m, 2H), 2.75-2.71 (m, 1H), 1.86-1.84 (m, 2H), 
1.68-1.65 (m, 2H), 1.50 (s, 9H); 13C NMR (125.8 MHz, CDCl3): δ 155.0, 153.9, 145.4, 
140.6, 127.7, 123.6, 118.9, 111.4, 106.6, 79.6, 44.5 (br), 42.9, 33.9, 28.7;  FT-IR (neat): 
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2974, 1678, 1428, 1164 cm-1; HRMS (ES+) m/z calcd. for C18H23NO3Na (M+Na)+ 
324.1576, found 324.1588. 
 
 
tert-Butyl 4-(Pyridin-3-yl)piperidine-1-carboxylate (3.8).2 The title compound was 
obtained as an orange oil in 43% yield (113 mg) according to method A. Spectral data 
were in accordance with those published. 1H NMR (500 MHz, CDCl3): δ 8.48-8.47 (m, 
2H), 7.50-7.48 (m, 1H), 7.25-7.22 (m, 1H), 4.25 (br, 2H), 2.82-2.78 (m, 2H), 2.68-2.66 
(m, 1H), 1.83-1.80 (m, 2H), 1.65-1.60 (m, 2H), 1.47 (s, 9H); 13C NMR (125.8 MHz, 
CDCl3): δ 154.9, 148.9, 148.0, 140.9, 134.2, 123.6, 79.7, 44.2 (br), 40.3, 33.0, 28.6. 
 
 
tert-Butyl 4-(2-Methylpyridin-3-yl)piperidine-1-carboxylate (3.9). The title compound 
was obtained as an orange oil in 24% yield (66 mg) according to method A. 1H NMR 
(500 MHz, CDCl3): δ 8.34-8.33 (m, 1H), 7.45-7.43 (m, 1H), 7.11-7.09 (m, 1H), 4.27 (br, 
2H), 2.85-2.80 (m, 3H), 2.58 (s, 3H), 1.77-1.74 (m, 2H), 1.60-1.55 (m, 2H), 1.47 (s, 9H); 
13C NMR (125.8 MHz, CDCl3): δ 155.9, 154.9, 146.7, 138.8, 133.4, 121.7, 79.7, 44.4 
N
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(br), 38.2, 32.2, 28.6, 22.2; FT-IR (neat): 2975, 1690, 1422, 1161 cm-1; HRMS (ES+) m/z 
calcd. for C16H25N2O2 (M+H)+ 277.1916, found 277.1920. 
 
 
tert-Butyl 4-(5-Methylpyridin-2-yl)piperidine-1-carboxylate (3.10). The title 
compound was obtained as a red-orange oil in 22% yield (61 mg) according to method A. 
1H NMR (500 MHz, CDCl3): δ 8.35 (s, 1H), 7.43-7.41 (m, 1H), 7.03-7.02 (m, 1H), 4.24 
(br, 2H), 2.82-2.79 (m, 3H), 2.29 (s, 3H), 1.89-1.87 (m, 2H), 1.69-1.66 (m, 2H), 1.46 (s, 
9H); 13C NMR (125.8 MHz, CDCl3): δ 161.6, 154.9, 149.6, 137.3, 130.9, 120.4, 79.4, 
44.2, 44.1 (br), 31.9, 28.6, 18.1; FT-IR (neat): 2973, 1690, 1422, 1167 cm-1; HRMS 
(ES+) m/z calcd. for C16H25N2O2 (M+H)+ 277.1916, found 277.1915. 
 
 
tert-Butyl 4-(2-Methylpyridin-4-yl)piperidine-1-carboxylate (3.11). The title 
compound was obtained as a yellow oil in 40% yield (111 mg) according to method A. 
1H NMR (500 MHz, CDCl3): δ 8.40-8.39 (m, 1H), 6.97 (s, 1H), 6.91-6.90 (m, 1H), 4.24 
(br, 2H), 2.80-2.76 (m, 2H), 2.61-2.58 (m, 1H), 2.55 (s, 3H), 1.81-1.78 (m, 2H), 1.62-
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1.57 (m, 2H), 1.47 (s, 9H); 13C NMR (125.8 MHz, CDCl3): δ 158.6, 154.8, 154.8, 149.4, 
121.8, 119.4, 79.7, 44.3 (br), 42.1, 32.4, 28.6, 24.5; FT-IR (neat): 1690, 1422, 1165 cm-1; 
HRMS (ES+) m/z calcd. for C16H25N2O2 (M+H)+ 277.1916, found 277.1917. 
 
 
tert-Butyl 4-(5-Methoxypyridin-3-yl)piperidine-1-carboxylate (3.12). The title 
compound was obtained as a yellow solid in 35% yield (102 mg) according to method A. 
mp: 79-80 °C.  1H NMR (500 MHz, CDCl3): δ 8.19 (m, 2H), 6.99 (s, 1H), 4.25 (br, 2H), 
3.84 (s, 3H), 2.85-2.74 (m, 2H), 2.69-2.65 (m, 1H), 1.83-1.80 (m, 2H), 1.62-1.60 (m, 
2H), 1.47 (s, 9H); 13C NMR (125.8 MHz, CD3OD): δ 156.6, 155.2, 142.9, 139.9, 134.6, 
119.8, 79.8, 55.0, 44.0 (br), 39.9, 32.6, 27.5; FT-IR (neat): 1681, 1421, 1166 cm-1; 
HRMS (ES+) m/z calcd. for C16H25N2O3 (M+H)+ 293.1865, found 293.1866. 
 
 
4-(4-Methoxyphenyl)tetrahydro-2H-pyran (3.13).2 The title compound was obtained 
as a colorless oil in 62% yield (119 mg) according to method A. Spectral data were in 
accordance with those published. 1H NMR (500 MHz, CDCl3): δ 7.14 (d, J = 8.7 Hz, 
N
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2H), 6.86 (d, J = 8.2 Hz, 2H), 4.06 (dd, J = 10.6, 3.3 Hz, 2H), 3.79 (s, 3H), 3.51(td, J = 
11.3, 2.8 Hz, 2H), 2.73-2.66 (m, 1H), 1.82-1.72 (m, 4H); 13C NMR (125.8 MHz, CDCl3): 
δ 158.2, 138.3, 127.7, 114.0, 68.6, 55.4, 40.9, 34.6. 
 
 
4-(3-Methoxyphenyl)tetrahydro-2H-pyran (3.14). The title compound was obtained as 
a colorless oil in 59% yield (113 mg) according to method A. 1H NMR (500 MHz, 
CDCl3): δ 7.26-7.23 (m, 1H), 6.84-6.76 (m, 3H), 4.09-4.07 (m, 2H), 3.81 (s, 3H), 3.55-
3.50 (m, 2H), 2.75-2.71 (m, 1H), 1.84-1.76 (m, 4H); 13C NMR (125.8 MHz, CDCl3): δ 
159.9, 147.7, 129.6, 119.3, 113.0, 111.4, 68.5, 55.3, 41.8, 34.0; FT-IR (neat): 2980, 1601, 
1270, 1130 cm-1; HRMS (ES+) m/z calcd. for C12H17O2 (M+H)+ 193.1229, found 
193.1221. 
 
 
4-(2-Methoxyphenyl)tetrahydro-2H-pyran (3.15). The title compound was obtained as 
a white solid in 58% yield (111 mg) according to method A. mp: 79-80 °C. 1H NMR (500 
MHz, CDCl3): δ 7.18-7.17 (m, 2H), 6.94-6.93 (m, 1H), 6.86-6.85 (m, 1H), 4.05 (d, J = 
11.3 Hz, 2H), 3.81 (s, 3H), 3.56 (t, J = 11.6 Hz, 2H), 3.22-3.17 (m, 1H), 1.80-1.71 (m, 
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4H); 13C NMR (125.8 MHz, CDCl3): δ 157.0, 134.1, 127.2, 126.7, 120.8, 110.5, 68.8, 
55.4, 34.6, 32.8; FT-IR (neat): 2940, 1494, 1234 cm-1; HRMS (ES+) m/z calcd. for 
C12H17O2 (M+H)+ 193.1229, found 193.1233. 
 
 
1-(4-(Tetrahydro-2H-pyran-4-yl)phenyl)ethan-1-one (3.16). The title compound was 
obtained as a white solid in 50% yield (102 mg) according to method A. mp: 75-76 °C. 
1H NMR (500 MHz, CDCl3): δ 7.91 (d, J = 8.2 Hz, 2H), 7.31 (d, J = 8.1 Hz, 2H), 4.10-
4.07 (m, 2H), 3.56-3.51 (m, 2H), 2.85-2.84 (m, 1H), 2.58 (s, 3H), 1.84-1.75 (m, 4H); 13C 
NMR (125.8 MHz, CDCl3): δ 197.9, 151.5, 135.6, 128.9, 127.1, 68.3, 41.8, 33.7, 26.7; 
FT-IR (neat): 2940, 1681, 1268, 1118 cm-1; HRMS (CI+) m/z calcd. for C13H16O2 (M)+ 
204.1150, found 204.1144. 
 
 
4-(o-Tolyl)tetrahydro-2H-pyran (3.17). The title compound was obtained as a colorless 
oil in 43% yield (76 mg) according to method A. 1H NMR (500 MHz, CDCl3): δ 7.24-
7.17 (m, 4H), 4.14-4.11 (m, 2H), 3.61-3.58 (m, 2H), 3.07-2.99 (m, 1H), 2.40 (s, 3H), 
O
O
O
     191 
1.93-1.82 (m, 2H), 1.75-1.68 (m, 2H); 13C NMR (125.8 MHz, CDCl3): δ 143.6, 135.0, 
130.0, 126.3, 125.9, 125.4, 68.6, 37.3, 33.1, 19.2; FT-IR (neat): 2951, 1386, 1133, 1122 
cm-1; HRMS (CI+) m/z calcd. for C12H16O (M)+ 176.1201, found 176.1209. 
 
 
4-(4-(Trifluoromethyl)phenyl)tetrahydro-2H-pyran (3.18).2 The title compound was 
obtained as a white solid in 53% yield (122 mg) according to method A. mp: 30-31 °C. 
Spectral data were in accordance with those published. 1H NMR (500 MHz, CDCl3): δ 
7.57 (d, J = 8.1 Hz, 2H), 7.34 (d, J = 8.2 Hz, 2H), 4.11-4.08 (m, 2H), 3.57-3.51 (m, 2H), 
2.83-2.81 (m, 1H), 1.84-1.76 (m, 4H); 13C NMR (125.8 MHz, CDCl3): δ 149.9, 128.8 (q, 
J = 32 Hz), 127.3, 125.6 (q, J = 4 Hz), 125.5 (q, J = 272 Hz), 68.3, 41.6, 33.8. 
 
 
4-(Tetrahydro-2H-pyran-4-yl)benzenesulfonamide (3.19). The title compound was 
obtained as a white solid in 41% yield (99 mg) according to method A. mp: 186-188 °C. 
1H NMR (500 MHz, acetone-d6): δ 7.82 (d, J = 8.1 Hz, 2H), 7.44 (d, J = 8.2  Hz, 2H), 
6.51 (s, 2H), 3.97 (d, J = 11.1 Hz, 2H), 3.50-3.45 (m, 2H), 2.91-2.88 (m, 1H), 1.74-1.72 
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(m, 4H); 13C NMR (125.8 MHz, acetone-d6): δ 150.7, 142.3, 127.4, 126.4, 67.7, 41.4, 
33.7; FT-IR (neat): 3306, 1339, 1156 cm-1; HRMS (ES+) m/z calcd. for C11H14NO3S (M-
H)- 240.0694, found 240.0702. 
 
 
tert-Butyl 3-(4-Methoxyphenyl)piperidine-1-carboxylate (3.20).2 The title compound 
was obtained as a colorless oil in 50% yield (146 mg) according to method A. Spectral 
data were in accordance with those published. 1H NMR (500 MHz, CDCl3): δ 7.14 (d, J = 
8.7 Hz, 2H), 6.85 (d, J = 8.7  Hz, 2H), 4.15 (br, 2H), 3.77 (s, 3H), 2.71-2.63 (m, 3H), 
1.99-1.97 (m, 1H), 1.81-1.72 (m, 1H), 1.59-1.57 (m, 2H), 1.46 (s, 9H); 13C NMR (125.8 
MHz, CDCl3): δ 158.4, 155.0, 135.8, 128.1, 114.0, 79.5, 55.3, 51.4 (br), 43.9 (br), 41.9, 
32.1, 28.6, 25.7.  
 
 
tert-Butyl 3-(4-Methoxyphenyl)pyrrolidine-1-carboxylate (3.21).2 The title compound 
was obtained as a colorless oil in 40% yield (111 mg) according to method A. Spectral 
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data were in accordance with those published. 1H NMR (500 MHz, CDCl3): δ 7.15 (d, J = 
8.6 Hz, 2H), 6.86 (d, J = 8.6 Hz, 2H), 3.82-3.73 (m, 4H), 3.65-3.52 (m, 1H), 3.40-3.19 
(m, 3H), 2.22-2.21 (m, 1H), 1.98-1.92 (m, 1H), 1.47 (s, 9H) ; 13C NMR (125.8 MHz, 
CDCl3): δ 158.5, 154.7, 133.6, 128.1, 114.1, 79.3, 55.4, 52.9 and 52.1, 46.1 and 45.8, 
43.7 and 42.8, 33.7 and 32.8, 28.7. 
 
 
tert-Butyl 3-(4-Methoxyphenyl)azetidine-1-carboxylate (3.22).2 The title compound 
was obtained as a colorless oil in 48% yield (126 mg) according to method A. Spectral 
data were in accordance with those published. 1H NMR (500 MHz, CDCl3): δ 7.23 (d, J = 
6.9 Hz, 2H), 6.88 (d, J = 7.2  Hz, 2H), 4.31-4.28 (m, 2H), 3.93-3.92 (m, 2H), 3.80 (s, 
3H), 3.69-3.68 (m, 1H), 1.46 (s, 9H); 13C NMR (125.8 MHz, CDCl3): δ 158.7, 156.6, 
134.5, 127.9, 114.2, 79.6, 57.0 (br), 55.4, 33.0, 28.6. 
 
 
3-(4-Methoxyphenyl)tetrahydro-2H-pyran (3.23). The title compound was obtained as 
a light yellow solid in 43% yield (83 mg) according to method A. mp: 38-39 °C. 1H NMR 
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(500 MHz, CDCl3): δ 7.14 (d, J = 8.3 Hz, 2H), 7.86 (d, J = 8.4 Hz, 2H), 4.00-3.94 (m, 
2H), 3.79 (s, 3H), 3.46-3.42 (m, 1H), 3.36-3.31 (m, 1H), 2.81-2.80 (m, 1H), 2.03-2.01 
(m, 1H), 1.79-1.69 (m, 3H); 13C NMR (125.8 MHz, CDCl3): δ 158.4, 134.9, 128.4, 114.0, 
74.2, 68.3, 55.4, 42.3, 30.7, 26.4; FT-IR (neat): 2932, 1513, 1247, 1084 cm-1; HRMS 
(ES+) m/z calcd. for C12H16O2 (M)+ 192.1150, found 192.1147. 
 
 
3-(4-Methoxyphenyl)tetrahydrofuran (3.24).2 The title compound was obtained as a 
colorless oil in 41% yield (39 mg) according to method A. Compound was isolated as a 
mixture of isomers (approx. 17% 2-(4-Methoxyphenyl)tetrahydrofuran9)). Spectral data 
were in accordance with those published for the major isomer.  1H NMR (500 MHz, 
CDCl3): 7.18-7.16 (m, 2H), 6.88-6.85 (m, 2H), 4.13-4.10 (m, 1H), 4.08-4.03 (m, 1H), 
3.93-3.89 (m, 1H), 3.80 (s, 3H), 3.70-3.66 (m, 1H), 3.37-3.34 (m, 1H), 2.35-2.32 (m, 
1H), 2.01-1.95 (m, 1H); 13C NMR (125.8 MHz, CDCl3): δ 158.4, 134.7, 128.3, 114.1, 
74.9, 68.6, 55.4, 44.4, 34.9. 
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3-(4-Methoxyphenyl)oxetane (3.25).2 The title compound was obtained as a colorless oil 
in 43% yield (71 mg) according to method A. Spectral data were in accordance with 
those published. 1H NMR (500 MHz, CDCl3): δ 7.32 (d, J = 8.4 Hz, 2H), 6.91 (d, J = 8.2 
Hz, 2H), 5.05 (t, J = 7.2 Hz, 2H), 4.74 (t, J = 6.4 Hz, 2H), 4.20-4.17 (m, 1H), 3.81 (s, 
3H); 13C NMR (125.8 MHz, CDCl3): δ 158.8, 133.8, 128.0, 114.3, 79.4, 55.4, 39.8. 
 
 
1-(4-(Tetrahydrofuran-3-yl)phenyl)ethan-1-one (3.26). The title compound was 
obtained as a colorless oil in 54% yield (102 mg) according to method A.  Compound 
was isolated as a mixture of isomers (approx. 3.5% 1-(4-(tetrahydrofuran-2-
yl)phenyl)ethan-1-one). 1H NMR (500 MHz, CDCl3): δ 8.05 (d, J = 7.9 Hz, 2H), 7.34 (d, 
J = 8.0 Hz, 2H), 4.15-4.06 (m, 2H), 3.94-3.90 (m, 1H), 3.77-3.74 (m, 1H), 3.49-3.44 (m, 
1H), 2.58 (s, 3H), 2.43-2.38 (m, 1H), 2.04-1.99 (m, 1H); 13C NMR (125.8 MHz, CDCl3): 
δ 197.7, 148.9, 135.8, 128.9, 127.6, 74.5, 68.6, 45.1, 34.7, 26.7; FT-IR (neat): 2925, 
1681, 1606, 1269 cm-1; HRMS (ES+) m/z calcd. for C12H15O2 (M+H)+ 191.1072, found 
191.1066. 
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tert-Butyl 4-(Quinolin-3-yl)piperidine-1-carboxylate (3.27). The title compound was 
obtained as a yellow oil in 60% yield (187 mg) according to method B. 1H NMR (500 
MHz, CDCl3): δ 8.81-8.80 (m, 1H), 8.08-8.06 (m, 1H), 7.91-7.90 (m, 1H), 7.77-7.76 (m, 
1H), 7.68-7.64 (m, 1H), 7.53-7.50 (m, 1H), 4.30 (br, 2H), 2.89-2.84 (m, 3H), 1.94-1.92 
(m, 2H), 1.74-1.72 (m, 2H), 1.48 (s, 9H); 13C NMR (125.8 MHz, CDCl3): δ 154.9, 151.0, 
147.2, 138.3, 132.6, 129.2, 129.0, 128.2, 127.6, 126.8, 79.7, 44.5 (br), 40.3, 33.0, 28.6; 
FT-IR (neat): 1687, 1424, 1233, 1167 cm-1; HRMS (ES+) m/z calcd. for C19H25N2O2 
(M+H)+ 313.1916, found 313.1914. 
 
 
tert-Butyl 4-(1H-Indol-5-yl)piperidine-1-carboxylate (3.28). The title compound was 
obtained as a yellow oil in 27% yield (81 mg) according to method B. 1H NMR (500 
MHz, CDCl3): δ 8.23 (br, 1H), 7.46 (s, 1H), 7.33 (d, J = 8.4 Hz, 1H), 7.19-7.18 (m, 1H), 
7.05 (dd, J = 8.4 Hz, 1.6 Hz, 1H), 6.51-6.50 (m, 1H), 4.26 (br, 2H), 2.84-2.82 (m, 2H), 
2.76-2.70 (m, 1H), 1.88-1.86 (m, 2H), 1.73-1.68 (m, 2H), 1.50 (s, 9H); 13C NMR (125.8 
MHz, CDCl3): δ 155.2, 137.4, 134.9, 128.2, 124.8, 121.5, 118.2, 111.2, 102.4, 79.6, 44.8 
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(br), 43.0, 34.1, 28.7; FT-IR (neat): 1669, 1428, 1166 cm-1; HRMS (ES+) m/z calcd. for 
C18H24N2O2Na (M+Na)+ 323.1735, found 323.1738. 
 
 
tert-Butyl 4-(Isoquinolin-4-yl)piperidine-1-carboxylate (3.29).2 The title compound 
was obtained as a yellow oil in 38% yield (204 mg) according to method B. Spectral data 
were in accordance with those published. 1H NMR (500 MHz, CDCl3): δ 9.13 (s, 1H), 
8.41-8.40 (m, 1H), 8.04 (d, J = 8.6 Hz, 1H), 7.98 (d, J = 8.1 Hz, 1H), 7.75-7.71 (m, 1H), 
7.61-7.58 (m, 1H), 4.33 (br, 2H), 3.40-3.35 (m, 1H), 2.94-2.92 (m, 2H), 2.00-1.97 (m, 
2H), 1.85-1.80 (m, 2H), 1.49 (s, 9H); 13C NMR (125.8 MHz, CDCl3): δ 155.0, 151.6, 
140.2, 134.2, 134.0, 130.5, 128.8, 128.5, 126.9, 122.1, 79.8, 44.8 (br), 36.5, 32.6, 28.6. 
 
 
tert-Butyl 4-(Quinoxalin-6-yl)piperidine-1-carboxylate (3.30). The title compound was 
obtained as a yellow solid in 29% yield (91 mg) according to method B. mp: 108-110 °C. 
1H NMR (500 MHz, CDCl3): δ 8.82-8.81 (m, 2H), 8.07-8.05 (m, 1H), 7.91 (s, 1H), 7.68-
7.66 (m, 1H), 4.31 (br, 2H), 2.93-2.88 (m, 3H), 1.97-1.94 (m, 2H), 1.79-1.73 (m, 2H), 
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1.50 (s, 9H); 13C NMR (125.8 MHz, CDCl3): δ 154.9, 148.2, 145.2, 144.6, 143.3, 142.1, 
130.2, 129.6, 126.4, 79.7, 44.7 (br), 42.9, 33.0, 28.6; FT-IR (neat): 1689, 1423, 1164  
cm-1; HRMS (ES+) m/z calcd. for C18H23N3O2Na (M+Na)+ 336.1688, found 336.1686. 
 
 
tert-Butyl 4-(3-(1H-Pyrazol-5-yl)phenyl)piperidine-1-carboxylate (3.31). The title 
compound was obtained as a colorless oil in 65% yield (214 mg) according to method B. 
1H NMR (500 MHz, CDCl3): δ 11.17 (br, 1H), 7.61-7.58 (m, 3H), 7.35-7.32 (m, 1H), 
7.17-7.13 (m, 1H), 6.78-6.61 (m, 1H), 4.25 (br, 2H), 2.83-2.77 (m, 2H), 2.68-2.64 (m, 
1H), 1.83-1.81 (m, 2H), 1.65-1.63 (m, 2H), 1.49 (s, 9H); 13C NMR (125.8 MHz, CDCl3): 
δ 155.1, 148.9, 146.4, 133.4, 132.5, 129.0, 126.4, 124.5, 124.1, 102.6, 79.7, 44.4 (br), 
42.8, 33.2, 28.7; FT-IR (neat): 2930, 1687, 1427, 1169 cm-1; HRMS (ES+) m/z calcd. for 
C19H26N3O2 (M+H)+ 328.2025, found 328.2016. 
 
 
tert-Butyl 4-(4-(1,3,4-Oxadiazol-2-yl)phenyl)piperidine-1-carboxylate (3.32). The title 
compound was obtained as a white solid in 32% yield (105 mg) according to method B. 
BocN
N
H
N
BocN
O N
N
     199 
mp: 146-147 °C. 1H NMR (500 MHz, CDCl3): δ 8.44 (s, 1H), 8.00 (d, J = 8.1 Hz, 2H), 
7.34 (d, J = 7.4 Hz, 2H), 4.26 (br, 2H), 2.81-2.74 (m, 2H), 2.72-2.69 (m, 1H), 1.85-1.82 
(m, 2H), 1.65-1.62 (m, 2H), 1.47 (s, 9H); 13C NMR (125.8 MHz, CDCl3): δ 164.7, 154.8, 
152.7, 150.2, 127.7, 127.4, 121.7, 79.6, 44.7 (br), 42.8, 33.0, 28.6; FT-IR (neat): 2924, 
1670, 1428, 1167 cm-1; HRMS (ES+) m/z calcd. for C18H23N3O3Na (M+Na)+ 352.1637, 
found 352.1637. 
 
 
3-(Tetrahydro-2H-pyran-4-yl)quinoline (3.33). The title compound was obtained as an 
orange solid in 41% yield (87 mg) according to method B. mp: 97-99 °C. 1H NMR (500 
MHz, CDCl3): δ 8.83 (s, 1H), 8.07 (d, J = 8.3 Hz, 1H), 7.93 (s, 1H), 7.78 (d, J = 8.2  Hz, 
1H), 7.68-7.65 (m, 1H), 7.54-7.51 (m, 1H), 4.14-4.12 (m, 2H), 3.61-3.57 (m, 2H), 3.00-
2.95 (m, 1H), 1.96-1.86 (m, 4H); 13C NMR (125.8 MHz, CDCl3): δ 151.1, 147.3, 138.3, 
132.5, 129.3, 129.0, 128.2, 127.7, 126.8, 68.3, 39.2, 33.7; FT-IR (neat): 2951, 2851, 
1494, 1120 cm-1; HRMS (CI+) m/z calcd. for C14H16NO (M+H)+ 214.1232, found 
214.1237. 
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5-(Tetrahydro-2H-pyran-4-yl)-1H-pyrrolo[2,3-b]pyridine (3.34). The title compound 
was obtained as a white solid in 45% yield (91 mg) according to method B. mp: 165-
167 °C. 1H NMR (500 MHz, CDCl3): δ 11.12 (br, 1H), 8.26-8.25 (m, 1H), 7.83-7.82 (m, 
1H), 7.38-7.37 (m, 1H), 6.48-6.47 (m, 1H), 4.12 (dt, J = 11.8, 6.2 Hz, 2H), 3.60-3.56 (m, 
2H), 2.93-2.88 (m, 1H), 1.95-1.82 (m, 4H); 13C NMR (125.8 MHz, CDCl3): δ 148.2, 
142.0, 133.2, 126.9, 126.1, 120.7, 100.3, 68.6, 39.5, 34.7; FT-IR (neat): 2954, 1587, 
1354, 1086 cm-1; HRMS (CI+) m/z calcd. for C12H14N2O (M)+ 202.1106, found 
202.1110. 
 
 
5-(Tetrahydro-2H-pyran-4-yl)benzofuran (3.35). The title compound was obtained as 
a colorless oil in 49% yield (99 mg) according to method B. 1H NMR (500 MHz, CDCl3): 
δ 7.62-7.61 (m, 1H), 7.47-7.45 (m, 2H), 7.19-7.17 (m, 1H), 6.75-6.74 (m, 1H), 4.13-4.10 
(m, 2H), 3.60-3.55 (m, 2H), 2.89-2.84 (m, 1H), 1.90-1.81 (m, 4H); 13C NMR (125.8 
MHz, CDCl3): δ 153.9, 145.4, 140.8, 127.8, 123.6, 118.9, 111.4, 106.7, 68.7, 41.7, 34.7; 
FT-IR (neat): 2936, 2360, 1469, 1128 cm-1; HRMS (ES+) m/z calcd. for C13H14O2 (M)+ 
202.0994, found 202.0995. 
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tert-Butyl 3-(Quinolin-3-yl)azetidine-1-carboxylate (3.36). The title compound was 
obtained as a yellow oil in 30% yield (85 mg) according to method B. 1H NMR (500 
MHz, CDCl3): δ 8.85 (s, 1H), 8.10-8.08 (m, 2H), 7.80 (d, J = 8.2 Hz, 1H), 7.70-7.67 (m, 
1H), 7.56-7.53 (m, 1H), 4.45-4.42 (m, 2H), 4.09-4.06 (m, 2H), 3.95-3.90 (m, 1H), 1.48 
(s, 9H); 13C NMR (125.8 MHz, CDCl3): δ 156.5, 150.3, 147.5, 135.0, 133.1, 129.4, 
129.4, 128.0, 127.7, 127.1, 80.0, 56.7 (br), 31.4, 28.5; FT-IR (neat): 2972, 1698, 1400, 
1140 cm-1; HRMS (ES+) m/z calcd. for C17H21N2O2 (M+H)+ 285.1603, found 285.1613. 
 
 
tert-Butyl 5-(Tetrahydro-2H-pyran-4-yl)-1H-indole-1-carboxylate (3.37). The title 
compound was obtained as a white solid in 73% yield (220 mg) according to method B. 
mp: 86-87 °C. 1H NMR (500 MHz, CDCl3): δ 8.06-8.05 (m, 1H), 7.58-7.57 (m, 1H), 7.40 
(s, 1H), 7.20-7.18 (m, 1H), 6.54-6.53 (m, 1H), 4.11-4.08 (m, 2H), 3.58-3.53 (m, 2H), 
2.87-2.82 (m, 1H), 1.89-1.79 (m, 4H), 1.67 (s, 9H); 13C NMR (125.8 MHz, CDCl3): δ 
149.9, 140.6, 134.1, 131.0, 126.3, 123.6, 118.7, 115.3, 107.4, 83.6, 68.6, 41.6, 34.6, 28.3; 
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FT-IR (neat): 2951, 1724, 1364, 1132 cm-1; HRMS (ES+) m/z calcd. for C18H24NO3 
(M+H)+ 302.1756, found 302.1755. 
 
 
tert-Butyl 5-(Tetrahydro-2H-pyran-3-yl)-1H-indole-1-carboxylate (3.38). The title 
compound was obtained as a colorless oil in 37% yield (112 mg) according to method B. 
1H NMR (500 MHz, CDCl3): δ 8.07-8.05 (m, 1H), 7.58-7.57 (m, 1H), 7.41 (s, 1H), 7.19-
7.17 (m, 1H), 6.53-6.52 (m, 1H), 4.03-4.01 (m, 2H), 3.50-3.41 (m, 2H), 2.97-2.93 (m, 
1H), 2.10-2.09 (m, 1H), 1.82-1.79 (m, 3H), 1.67 (s, 9H); 13C NMR (125.8 MHz, CDCl3): 
δ 149.9, 137.2, 134.2, 131.0, 126.3, 124.0, 119.4, 115.2, 107.3, 83.7, 74.4, 68.4, 43.0, 
31.0, 28.3, 26.5; FT-IR (neat): 2933, 1732, 1368, 1084 cm-1; HRMS (ES+) m/z calcd. for 
C18H23NO3Na (M+Na)+ 324.1576, found 324.1582. 
 
 
tert-Butyl 5-(Tetrahydrofuran-3-yl)-1H-indole-1-carboxylate (3.39). The title 
compound was obtained as a colorless oil in 44% yield (126 mg) according to method B. 
1H NMR (500 MHz, CDCl3): δ 8.08-8.07 (m, 1H), 7.59-7.58 (m, 1H), 7.44 (s, 1H), 7.22-
O
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7.21 (m, 1H), 6.53-6.52 (m, 1H), 4.20-4.16 (m, 1H), 4.12-4.08 (m, 1H), 3.97-3.94 (m, 
1H), 3.80-3.76 (m, 1H), 3.52-3.49 (m, 1H), 2.42-2.39 (m, 1H), 2.08-2.04 (m, 1H), 1.67 
(s, 9H); 13C NMR (125.8 MHz, CDCl3): δ 149.9, 137.2, 134.1, 131.0, 126.4, 123.8, 
119.3, 115.3, 107.3, 83.8, 75.1, 68.7, 45.1, 35.1, 28.1; FT-IR (neat): 2979, 1731, 1471, 
1134 cm-1; HRMS (ES+) m/z calcd. for C17H20NO3 (M-H)- 286.1443, found 286.1444. 
 
 
tert-Butyl 5-(Oxetan-3-yl)-1H-indole-1-carboxylate (3.40). The title compound was 
obtained as a yellow oil in 70% yield (191 mg) according to method B. 1H NMR (500 
MHz, CDCl3): δ 8.14-8.13 (m, 1H), 7.61-7.60 (m, 1H), 7.57 (s, 1H), 7.37-7.35 (m, 1H), 
6.56-6.55 (m, 1H), 5.13-5.10 (m, 2H), 4.84-4.82 (m, 2H), 4.33-4.30 (m, 1H), 1.68 (s, 
9H); 13C NMR (125.8 MHz, CDCl3): δ 149.8, 136.1, 134.5, 131.1, 126.6, 123.2, 119.0, 
115.6, 107.3, 83.8, 79.4, 40.5, 28.3; FT-IR (neat): 2973, 1731, 1368, 1162 cm-1; HRMS 
(ES+) m/z calcd. for C16H18NO3 (M-H)- 272.1287, found 272.1280. 
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tert-Butyl 5-(1-(tert-Butoxycarbonyl)piperidin-4-yl)-1H-indole-1-carboxylate (3.41). 
The title compound was obtained as a colorless oil in 51% yield (204 mg) according to 
method B. 1H NMR (500 MHz, CDCl3): δ 8.06 (br, 1H), 7.58-7.57 (m, 1H), 7.38 (s, 1H), 
7.17-7.16 (m, 1H), 6.53-6.52 (m, 1H), 4.21 (br, 2H), 2.87-2.82 (m, 2H), 2.76-2.71 (m, 
1H), 1.87-1.85 (m, 2H), 1.67 (s, 9H), 1.50 (s, 9H), 1.49-1.46 (m, 2H); 13C NMR (125.8 
MHz, CDCl3): δ 155.0, 149.9, 140.5, 134.0, 130.9, 126.3, 123.5, 118.7, 115.2, 107.4, 
83.7, 79.5, 44.4 (br), 42.8, 33.8, 28.6, 28.3; FT-IR (neat): 1733, 1691, 1365, 1163 cm-1; 
HRMS (ES+) m/z calcd. for C23H32N2O4Na (M+Na)+ 423.2260, found 423.2257. 
 
 
tert-Butyl 5-(1-(tert-Butoxycarbonyl)piperidin-3-yl)-1H-indole-1-carboxylate (3.42). 
The title compound was obtained as a colorless oil in 48% yield (192 mg) according to 
method B. 1H NMR (500 MHz, CDCl3): δ 8.07-8.06 (m, 1H), 7.58-7.57 (m, 1H), 7.41 (s, 
1H), 7.20-7.18 (m, 1H), 6.53-6.52 (m, 1H), 4.17 (br, 2H), 2.78-2.76 (m, 3H), 2.07-2.04 
(m, 1H), 1.79-1.77 (m, 1H), 1.70-1.59 (m, 11H), 1.48 (s, 9H); 13C NMR (125.8 MHz, 
CDCl3): δ 155.0, 149.9, 138.2, 134.2, 130.9, 126.3, 123.8, 119.1, 115.2, 107.3, 83.7, 79.5, 
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51.2 (br), 44.3 (br), 42.7, 32.3, 28.6, 28.3, 25.8; FT-IR (neat): 2977, 1733, 1689, 1367 
cm-1; HRMS (ES+) m/z calcd. for C23H32N2O4Na (M+Na)+ 423.2260, found 423.2256. 
 
 
tert-Butyl 5-(1-(tert-Butoxycarbonyl)pyrrolidin-3-yl)-1H-indole-1-carboxylate (3.43). 
The title compound was obtained as a colorless oil in 38% yield (147 mg) according to 
method B. 1H NMR (500 MHz, CDCl3): δ 8.08-8.06 (m, 1H), 7.58-7.57 (m, 1H), 7.42 (s, 
1H), 7.20-7.18 (m, 1H), 6.53-6.52 (m, 1H), 3.89-3.80 (m, 1H), 3.67-3.57 (m, 1H), 3.43-
3.30 (m, 3H), 2.29-2.28 (m, 1H), 2.04-2.01 (m, 1H), 1.67 (s, 9H), 1.48 (s, 9H); 13C NMR 
(125.8 MHz, CD3OD): δ 155.1, 149.7, 135.8, 134.3, 131.0, 125.9, 123.2, 118.8, 114.8, 
107.1, 83.6, 79.6, 52.8 and 52.3, 46.0 and 45.5, 44.0 and 43.3, 33.2 and 32.4, 27.6, 27.2; 
FT-IR (neat): 2976, 1732, 1693, 1367 cm-1; HRMS (ES+) m/z calcd. for C22H30N2O4Na 
(M+Na)+ 409.2103, found 409.2106. 
 
 
tert-Butyl 5-(1-(tert-Butoxycarbonyl)azetidin-3-yl)-1H-indole-1-carboxylate (3.44). 
The title compound was obtained as a colorless oil in 36% yield (134 mg) according to 
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method B. 1H NMR (500 MHz, CDCl3): δ 8.11-8.10 (m, 1H), 7.60-7.59 (m, 1H), 7.49 (s, 
1H), 7.27-7.26 (m, 1H), 6.54-6.53 (m, 1H), 4.38-4.35 (m, 2H), 4.03-4.00 (m, 2H), 3.83-
3.82 (m, 1H), 1.67 (s, 9H), 1.48 (s, 9H); 13C NMR (125.8 MHz, CDCl3): δ 155.6, 149.7, 
136.8, 134.4, 131.0, 126.6, 123.1, 119.0, 115.5, 107.2, 83.8, 79.5, 57.2 (br), 33.7, 28.6, 
28.3; FT-IR (neat): 2676, 1733, 1699, 1368 cm-1; HRMS (ES+) m/z calcd. for 
C21H28N2O4Na (M+Na)+ 395.1947, found 395.1938. 
 
Procedure for the reductive cross-coupling of alkyl iodides with 3-bromo-2,1-
borazaronaphthalenes .  An oven-dried Biotage 10 mL microwave vial equipped with a 
magnetic stirbar was charged with the 3-bromo-2,1-borazaronaphthalene (0.5 mmol), 
alkyl iodide (0.6 mmol), NiCl2•glyme (0.025 mmol, 5.5 mg), 4,4’-dimethyl-2,2’-
bipyridine (0.025 mmol, 4.6 mg), NaBF4 (0.25 mmol, 27.5 mg), and Mn powder (1.0 
mmol, 55.0 mg).  The vial was sealed with a disposable Teflon septum cap and was 
evacuated and purged with Ar three times. A 2:1 mixture of cyclohexane/DMA (1.67 mL 
cyclohexane, 0.83 mL DMA) and 4-ethylpyridine (0.5 mmol, 54 mg) was added via 
syringe. The reaction was stirred under Ar with conventional heating at 40 °C for 18 h, 
after which the solution was cooled and diluted with 5 mL of EtOAc. The resulting 
mixture was filtered through Celite, which was rinsed with EtOAc (~ 10 mL). The 
solution was concentrated, and the product was isolated by column chromatography, 
eluting with a gradient of EtOAc in hexanes (0 to 10% EtOAc).   
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3-(4-(N-Boc)-Piperidinyl)-2-phenyl-2,1-borazaronaphthalene (3.45).  The title 
compound was obtained as an off-white solid in 78% yield (151 mg). mp 174-174 °C; 1H 
NMR (500 MHz, CDCl3): δ 8.03 (br s, 1H), 7.91 (s, 1H), 7.70-7.65 (m, 3H), 7.50-7.46 
(m, 3H), 7.45-7.41 (m, 1H), 7.30-7.27 (m, 1H), 7.26-7.24 (m, 1H), 4.23 (br, 2H), 3.02-
2.96 (m, 1H), 2.73 (br, 2H), 1.81 (d, J = 11.7 Hz, 2H), 1.66-1.61 (m, 2H), 1.53 (s, 9H); 
13C NMR (125.8 MHz, CDCl3): δ 154.9, 139.6, 138.9, 132.3, 129.1, 128.3, 128.0, 127.8, 
125.3, 121.3, 117.7, 79.2, 44.2, 39.3, 33.2, 28.5; 11B NMR (128.38 MHz, CDCl3) δ 37.9; 
FT-IR (neat): 1664, 1431, 1165 cm-1; HRMS (ES+) m/z calcd. for C24H30BN2O2 (M+H)+ 
389.2400, found 389.2399. 
 
 
3-(4-(N-Boc)-Piperidinyl)-2-(4-fluorophenyl)-2,1-borazaronaphthalene (3.46). The 
title compound was obtained as a white solid in 96% yield (195 mg). mp 169-171 °C; 1H 
NMR (500 MHz, CDCl3): δ 8.00 (br s, 1H), 7.89 (s, 1H), 7.66 (d, J = 7.8 Hz, 1H), 7.63-
7.60 (m, 2H), 7.43-7.40 (m, 1H), 7.30 (d, J = 8.1 Hz, 1H), 7.24-7.20 (m, 1H), 7.19-7.15 
(m, 2H), 4.17 (br, 2H), 2.94-2.90 (m, 1H), 2.69 (br, 2H), 1.80-1.76 (m, 2H), 1.66-1.62 
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(m, 2H), 1.50 (s, 9H); 13C NMR (125.8 MHz, CDCl3): δ 163.2 (d, J = 247 Hz), 154.9, 
139.7, 138.8, 134.1 (d, J = 7.6 Hz), 129.1, 127.8, 125.3, 121.4, 117.7, 115.1 (d, J = 20 
Hz), 79.2, 44.7, 39.4, 33.1, 28.6; 11B NMR (128.38 MHz, CDCl3) δ 34.2; FT-IR (neat): 
3260, 1670, 1420, 1162 cm-1; HRMS (ES+) m/z calcd. for C24H28BN2O2FNa (M+Na)+ 
429.2126, found 429.2118. 
 
 
3-(4-(N-Boc)-Piperidinyl)-2-(3-methoxyphenyl)-2,1-borazaronaphthalene (3.47). The 
title compound was obtained a white solid in 77% yield (161 mg). mp 93-94 °C; 1H NMR 
(500 MHz, CDCl3): δ 8.02 (br s, 1H), 7.90 (s, 1H), 7.66 (d, J = 7.8 Hz, 1H), 7.43-7.40 
(m, 2H), 7.28 (d, J = 8.3 Hz, 1H), 7.24-7.19 (m, 3H), 7.02-6.98 (m, 1H), 4.28 (br, 2H), 
3.88 (s, 3H), 3.02-2.96 (m, 1H), 2.73 (br, 2H), 1.82-1.79 (m, 2H), 1.62-1.60 (m, 2H), 1.51 
(s, 9H); 13C NMR (125.8 MHz, CDCl3): δ 159.1, 154.9, 139.6, 138.8, 129.2, 129.1, 
127.8, 125.3, 124.6, 121.3, 117.8, 117.7, 113.5, 79.2, 55.1, 45.0, 39.3, 33.2, 28.5 ; 11B 
NMR (128.38 MHz, CDCl3) δ 35.4; FT-IR (neat): 1674, 1569, 1422, 1168 cm-1; HRMS 
(ES+) m/z calcd. for C25H32BN2O3 (M+H)+ 419.2506, found 419.2518. 
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3-(4-(N-Boc)-Piperidinyl)-2-(2,4-difluorophenyl)-2,1-borazaronaphthalene (3.48). 
The title compound was obtained as a white solid in 80% yield (170 mg). mp 170-172 
°C; 1H NMR (500 MHz, CDCl3): δ 8.17 (br s, 1H), 7.91 (s, 1H), 7.67 (d, J = 7.8 Hz, 1H), 
7.45-7.40 (m, 2H), 7.30 (d, J = 8.1 Hz, 1H), 7.25-7.22 (m, 1H), 7.00-6.97 (m, 1H), 6.90-
6.87 (m, 1H), 4.18 (br, 2H), 2.73-2.61 (m, 3H), 1.76-1.73 (m, 2H), 1.58-1.55 (m, 2H), 
1.49 (s, 9H); 13C NMR (125.8 MHz, CDCl3): δ 164.8 (dd, J = 256, 13 Hz), 163.6 (dd, J = 
256, 13 Hz), 154.8, 139.9, 138.6, 134.9 (dd, J = 1, 10 Hz), 129.1, 127.8, 125.4, 121.5, 
117.8, 111.3 (dd, J = 20, 4 Hz), 103.5 (dd, J = 29, 5 Hz), 79.2, 44.3, 39.8, 33.1, 28.4.; 
11B NMR (128.38 MHz, CDCl3) δ 33.4; FT-IR (neat): 3276, 1668, 1436, 1167 cm-1; 
HRMS (ES+) m/z calcd. for C24H27BF2N2O2Na (M+Na)+ 447.2031, found 447.2045. 
 
 
3-(4-(N-Boc)-Piperidinyl)-2-(3-carbomethoxyphenyl)-2,1-borazaronaphthalene 
(3.49). The title compound was obtained as a white solid in 74% yield (165 mg). mp 172-
174 °C; 1H NMR (500 MHz, CDCl3): δ 8.32 (br s, 1H), 8.21 (s, 1H), 8.08 (d, J =  7.6 Hz, 
1H), 7.89 (s, 1H), 7.82 (d, J = 6.8 Hz, 1H), 7.65 (d, J = 7.6 Hz, 1H), 7.52-7.50 (m, 1H), 
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7.42-7.39 (m, 1H), 7.34-7.31 (m, 1H), 7.23-7.20 (m, 1H), 4.18 (br, 2H), 3.93 (s, 3H), 
2.90-2.87 (m, 1H), 2.65 (br, 2H), 1.77-1.74 (m, 2H), 1.58-1.55 (m, 2H), 1.48 (s, 9H); 13C 
NMR (125.8 MHz, CDCl3): δ 167.4, 154.8, 139.8, 138.8, 136.8, 136.8, 133.4, 129.6, 
129.3, 129.1, 127.9, 127.9, 125.3, 121.4, 117.8, 79.2, 52.1, 44.5, 39.4, 33.1, 28.4; 11B 
NMR (128.38 MHz, CDCl3) δ 35.0; FT-IR (neat): 3324, 1707, 1682, 1427, 1231, 1167 
cm-1; HRMS (ES+) m/z calcd. for C26H31BN2O4Na (M+Na)+ 469.2275, found 469.2273. 
 
 
3-(4-(N-Boc)-Piperidinyl)-2-(4-dibenzothienyl)-2,1-borazaronaphthalene (3.50). The 
title compound was obtained as an off-white solid in 74% yield (183 mg). mp 107-109°C; 
1H NMR (500 MHz, CDCl3): δ 8.31 (br s, 1H), 8.21 (d, J = 7.6 Hz, 2H), 7.99 (s, 1H), 
7.82 (d, J = 7.6 Hz, 1H), 7.71 (d, J = 7.6 Hz, 1H), 7.59-7.53 (m, 2H), 7.50-7.41 (m, 3H), 
7.29-7.25 (m, 2H), 4.11 (br, 2H), 2.88-2.83 (m, 1H), 2.59-2.54 (m, 2H), 1.80-1.76 (m, 
2H), 1.62-1.59 (m, 2H), 1.45 (s, 9H); 13C NMR (125.8 MHz, CDCl3): δ 155.1, 143.4, 
140.5, 139.7, 138.9, 137.9, 136.0, 134.9, 130.9, 129.4, 128.1, 126.8, 125.8, 124.6, 124.3, 
122.9, 121.8, 121.6, 118.2, 79.4, 44.5, 39.9, 33.3, 28.7; 11B NMR (128.38 MHz, CDCl3) δ 
35.0; FT-IR (neat): 1684, 1424, 1166 cm-1; HRMS (ES+) m/z calcd. for 
C30H31BN2O2NaS (M+Na)+ 517.2097, found 517.2096. 
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3-(4-(N-Boc)-Piperidinyl)-2-(4-dibenzofuranyl)-2,1-borazaronaphthalene (3.51).  The 
title compound was obtained as a white solid in 89% yield (213 mg). mp 54-56 °C; 1H 
NMR (500 MHz, CDCl3): δ 8.47 (br s, 1H), 8.07-8.00 (m, 3H), 7.74-7.68 (m, 2H), 7.57 
(d, J = 7.8 Hz, 1H), 7.50-7.43 (m, 3H), 7.41-7.38 (m, 1H), 7.36-7.34 (m, 1H), 7.28-7.25 
(m, 1H), 4.19 (br, 2H), 3.02-2.99 (m, 1H), 2.64 (br, 2H), 1.92-1.89 (m, 2H), 1.68-1.65 
(m, 2H), 1.49 (s, 9H); 13C NMR (125.8 MHz, CDCl3): δ 158.8, 155.9, 154.9, 140.0, 
138.8, 131.7, 129.1, 127.8, 127.0, 125.5, 124.3, 123.2, 122.7, 122.6, 121.4, 121.0, 120.7, 
117.9, 111.5, 79.1, 44.8, 39.7, 33.2, 28.5; 11B NMR (128.38 MHz, CDCl3) δ 34.4; FT-IR 
(neat): 1684, 1425, 1186, 1168 cm-1; HRMS (ES+) m/z calcd. for C30H32BN2O3 (M+H)+ 
479.2506, found 479.2509. 
 
 
3-(4-(N-Boc)-Piperidinyl)-2-methyl-2,1-borazaronaphthalene (3.52). The title 
compound was obtained as a white solid in 62% yield (101 mg). mp 131-133 °C; 1H 
NMR (500 MHz, CDCl3): δ 7.76 (br s, 1H), 7.64 (s, 1H), 7.56 (d, J = 7.8 Hz, 1H), 7.37-
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7.33 (m, 1H), 7.19 (d, J = 8.1 Hz, 1H), 7.15-7.11 (m, 1H), 4.31 (br, 2H), 2.85 (br, 2H), 
2.75-2.71 (m, 1H), 1.82-1.78 (m, 2H), 1.63-1.60 (m, 2H), 1.53 (s, 9H), 0.79 (s, 3H); 13C 
NMR (125.8 MHz, CDCl3): δ 154.9, 139.1, 137.2, 128.9, 127.2, 125.0, 120.6, 117.1, 
79.2, 44.5, 40.8, 32.5, 28.5; 11B NMR (128.38 MHz, CDCl3) δ 37.0; FT-IR (neat): 3314, 
1672, 1435, 1164 cm-1; HRMS (ES+) m/z calcd. for C19H27BN2O2Na (M+Na)+ 349.2063, 
found 349.2076. 
 
 
3-(4-(N-Boc)-Piperidinyl)-2-cyclobutyl-2,1-borazaronaphthalene (3.53). The title 
compound was obtained as a yellow oil in 37% yield (68 mg). 1H NMR (500 MHz, 
CDCl3): δ 7.75 (br s, 1H), 7.66 (s, 1H), 7.56 (d, J = 7.6 Hz, 1H), 7.38-7.34 (m, 1H), 7.26 
(d, J = 8.3 Hz, 1H), 7.16-7.12 (m, 1H), 4.27 (br, 2H), 2.81 (br, 2H), 2.70-2.64 (m, 2H), 
2.29-2.26 (m, 3H), 2.13-2.10 (m, 2H), 2.01-1.99 (m, 1H), 1.77-1.74 (m, 2H), 1.59-1.54 
(m, 2H), 1.50 (s, 9H); 13C NMR (125.8 MHz, CDCl3): δ 154.9, 138.8, 137.8, 128.8, 
127.3, 125.2, 120.7, 117.3, 79.2, 44.8, 39.9, 32.3, 28.4, 25.7, 22.2; 11B NMR (128.38 
MHz, CDCl3) δ 36.8; FT-IR (neat): 1684, 1674, 1425, 1168 cm-1; HRMS (ES+) m/z 
calcd. for C22H32BN2O2 (M+H)+ 367.2557, found 367.2551. 
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3-(4-(N-Boc)-Piperidinyl)-2-cyclopropyl-2,1-borazaronaphthalene (3.54). The title 
compound was obtained as a white solid in 88% yield (155 mg). mp 199-202 °C; 1H 
NMR (500 MHz, CDCl3): δ 7.62 (s, 1H), 7.54 (d, J = 7.6 Hz, 1H), 7.33-7.29 (m, 1H), 
7.14-7.10 (m, 3H), 4.30 (br, 2H), 2.93-2.86 (m, 3H), 1.94-1.92 (m, 2H), 1.68-1.64 (m, 
2H), 1.52 (s, 9H), 0.92-0.89 (m, 2H), 0.56-0.52 (m, 3H); 13C NMR (125.8 MHz, CDCl3): 
δ 154.9, 138.9, 136.9, 128.8, 127.2, 124.9, 120.5, 117.1, 79.2, 44.6, 40.6, 32.6, 28.5, 6.1; 
11B NMR (128.38 MHz, CDCl3) δ 36.7; FT-IR (neat): 3318, 1670, 1430, 1159, 1122   
cm-1; HRMS (CI) m/z calcd. for C21H29BN2O2 (M)+ 352.2322,  found 352.2321. 
 
 
 
1-Benzyl-3-(4-(N-Boc)-piperidinyl)-2-methyl-2,1-borazaronaphthalene (3.55). The 
title compound was obtained as a light yellow solid in 84% yield (175 mg). mp 47-50 °C; 
1H NMR (500 MHz, CDCl3): δ 7.72 (s, 1H), 7.63 (d, J = 7.8 Hz, 1H), 7.33-7.29 (m, 4H), 
7.27-7.24 (m, 1H), 7.17-7.13 (m, 3H), 5.36 (s, 2H), 4.36 (br, 2H), 2.91-2.85 (m, 3H), 
1.92-1.88 (m, 2H), 1.68-1.65 (m, 2H), 1.57 (s, 9H), 0.90 (s, 3H); 13C NMR (125.8 MHz, 
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CDCl3): δ 154.9, 140.5, 138.4, 137.5, 129.8, 128.7, 127.6, 126.8, 126.3, 125.7, 120.6, 
115.6, 79.3, 51.2, 44.8, 40.3, 32.7, 28.5; 11B NMR (128.38 MHz, CDCl3) δ 39.2;  FT-IR 
(neat): 1689, 1424, 1364, 1230, 1168 cm-1; HRMS (ES+) m/z calcd. for C26H33BN2O2Na 
(M+Na)+ 439.2533, found 439.2530. 
 
 
1-Allyl-3-(4-(N-Boc)-piperidinyl)-2-methyl-2,1-borazaronaphthalene (3.56). The title 
compound was obtained as an off-white solid in 51% yield (93 mg). mp 146-148 °C; 1H 
NMR (500 MHz, CDCl3): δ 7.62-7.58 (m, 2H), 7.42-7.39 (m, 2H), 7.17-7.15 (m, 1H), 
6.08-6.01 (m, 1H), 5.15 (dd, J = 10.5, 1.5 Hz 1H), 4.98 (dd, J = 17.2, 1.3 Hz, 1H), 4.72-
4.69 (m, 2H), 4.31 (br, 2H), 2.86-2.79 (m, 3H), 1.83-1.80 (m, 2H), 1.58-1.52 (m, 2H), 
1.48 (s, 9H), 0.84 (s, 3H); 13C NMR (125.8 MHz, CDCl3): δ 154.9, 140.3, 137.1, 134.3, 
129.7, 127.4, 126.1, 120.3, 115.5, 115.0, 79.2, 49.5, 44.5, 40.3, 32.6, 28.5; 11B NMR 
(128.38 MHz, CDCl3) δ 39.2;  FT-IR (neat): 1671, 1426, 1162, 1120cm-1; HRMS (ES+) 
m/z calcd. for C22H31BN2O2Na (M+Na)+ 389.2376, found 389.2367. 
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1-Allyl-3-(4-(N-Boc)-piperidinyl)-2-phenyl-2,1-borazaronaphthalene (3.57). The title 
compound was obtained as a light yellow oil in 90% yield (193 mg). 1H NMR (500 MHz, 
CDCl3): δ 7.87 (s, 1H), 7.72-7.69 (m, 1H), 7.52-7.42 (m, 7H), 7.28-7.25 (m, 1H), 5.97-
5.94 (m, 1H), 5.16 (d, J = 10.3 Hz, 1H), 4.96 (d, J = 17.4 Hz, 1H), 4.65-4.62 (m, 2H), 
4.17 (br, 2H), 2.57-2.50 (m, 3H), 1.72-1.70 (m, 2H), 1.56-1.48 (m, 11H); 13C NMR 
(125.8 MHz, CDCl3): δ 154.8, 139.8, 139.3, 135.1, 130.1, 129.9, 127.8, 127.6, 127.3, 
127.7, 121.1, 116.2, 115.8, 79.1, 51.1, 44.6, 39.9, 32.9, 28.5; 11B NMR (128.38 MHz, 
CDCl3) δ 37.5; FT-IR (neat): 1689, 1427, 1364, 1168 cm-1; HRMS (ES+) m/z calcd. for 
C27H33BN2O2Na (M+Na)+ 451.2533, found 451.2533. 
 
 
3-(3-(N-Boc)-Azetidinyl)-2-phenyl-2,1-borazaronaphthalene (3.58). The title 
compound was obtained as an off-white solid in 61% yield (110 mg). mp 46-48 °C; 1H 
NMR (500 MHz, CDCl3): δ 8.02 (s, 1H), 7.96 (s, 1H), 7.70-7.67 (m, 1H), 7.57-7.54 (m, 
2H), 7.45-7.41 (m, 4H), 7.30-7.26 (m, 1H), 7.25-7.22 (m, 1H), 4.17-4.14 (m, 2H), 4.12-
4.08 (m, 1H), 3.95 (br, 2H), 1.46 (s, 9H); 13C NMR (125.8 MHz, CDCl3): δ 156.5, 139.9, 
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139.1, 132.2, 129.1, 128.6, 128.2, 128.0, 124.9, 121.4, 117.8, 79.2, 32.2, 28.4, 27.6; 11B 
NMR (128.38 MHz, CDCl3) δ 34.5; FT-IR (neat): 1682, 1410, 1366, 1150 cm-1; HRMS 
(ES+) m/z calcd. for C22H26BN2O2 (M+H)+ 361.2087, found 361.2094. 
 
 
2-Phenyl-3-(4-tetrahydro-2H-pyranyl)-2,1-borazaronaphthalene (3.59). The title 
compound was obtained as a light brown oil in 90% yield (130 mg). 1H NMR (500 MHz, 
CDCl3): δ 8.01 (br s, 1H), 7.96 (s, 1H), 7.72-7.68 (m, 3H), 7.53-7.43 (m, 4H), 7.32-7.24 
(m, 2H), 4.09-4.06 (m, 2H), 3.51-3.46 (m, 2H), 3.14-3.09 (m, 1H), 1.84-1.74 (m, 4H); 
13C NMR (125.8 MHz, CDCl3): δ 139.6, 138.9, 132.2, 129.1, 128.3, 128.0, 127.8, 125.3, 
121.3, 117.7, 117.6, 68.6, 38.4, 34.0; 11B NMR (128.38 MHz, CDCl3) δ 34.5; FT-IR 
(neat): 1734, 1721, 1242 cm-1; HRMS (CI+) m/z calcd. for C19H21BNO (M+H)+ 
290.1716, found 290.1730. 
 
 
2-Phenyl-3-(3-tetrahydrofuranyl)-2,1-borazaronaphthalene (3.60). The title 
compound was obtained as a light brown oil in 48% yield (66 mg). 1H NMR (500 MHz, 
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CDCl3): δ 8.03 (s, 1H), 8.00 (s, 1H), 7.70-7.76 (m, 3H), 7.50-7.44 (m, 4H), 7.30-7.24 (m, 
2H), 4.09-4.04 (m, 2H), 3.94-3.89 (m, 1H), 3.79-3.68 (m, 2H), 2.31-2.25 (m, 1H), 2.07-
2.00 (m, 1H); 13C NMR (125.8 MHz, CDCl3): δ 140.0, 138.9, 132.4, 129.2, 128.4, 128.0, 
127.9, 125.2, 121.3, 117.7, 74.8, 68.2, 42.3, 34.5; 11B NMR (128.38 MHz, CDCl3) δ 
34.5; FT-IR (neat): 1615, 1567, 1429, 1239 cm-1; HRMS (CI+) m/z calcd. for 
C18H19BNO (M+H)+ 276.1560, found 276.1567. 
 
 
3-(3-Oxetanyl)-2-phenyl-2,1-borazaronaphthalene (3.61). The title compound was 
obtained as an off-white solid in 59% yield (77 mg). mp 117-119 °C; 1H NMR (500 
MHz, CDCl3): δ 8.10 (s, 2H), 7.74 (d, J = 7.8 Hz, 1H), 7.60-7.55 (m, 2H), 7.49-7.44 (m, 
4H), 7.32-7.26 (m, 2H), 4.96-4.93 (m, 2H), 4.82-4.79 (m, 2H), 4.65-4.62 (m, 1H); 13C 
NMR (125.8 MHz, CDCl3): δ 139.9, 139.1, 132.2, 129.2, 128.6, 128.1, 125.1, 121.5, 
117.8, 117.8, 78.6, 38.7; 11B NMR (128.38 MHz, CDCl3) δ 34.0; FT-IR (neat): 3286, 
1616, 1574, 1458 cm-1; HRMS (ES+) m/z calcd. for C7H16BNO (M) +  261.1325, found 
261.1326. 
 
B
H
N
O
     218 
 
3-Cyclohexyl-2-phenyl-2,1-borazaronaphthalene (3.62). The title compound was 
obtained as a white solid in 62% yield (89 mg). mp 86-87  °C; 1H NMR (500 MHz, 
CDCl3): δ 7.90 (s, 1H), 7.66-7.62 (m, 3H), 7.46-7.42 (m, 3H), 7.38-7.35 (m, 1H), 7.24-
7.20 (m, 2H), 7.18-7.15 (m, 1H), 2.83-2.80 (m, 1H), 1.86-1.83 (m, 2H), 1.80-1.76 (m, 
2H), 1.72-1.69 (m, 1H), 1.41-1.27 (m, 5H); 13C NMR (125.8 MHz, CDCl3): δ 139.0, 
138.8, 132.5, 129.0, 127.9, 127.4, 125.6, 121.1, 117.7, 117.6, 41.1, 34.6, 27.1, 26.4; 11B 
NMR (128.38 MHz, CDCl3) δ 34.4; FT-IR (neat): 2927, 1613, 1422 cm-1; HRMS (ES+) 
m/z calcd. for C20H22BN (M)+ 287.1845, found 287.1845. 
 
 
3-Butyl-2-phenyl-2,1-borazaronaphthalene (3.63). The title compound was obtained as 
a light brown oil in 70% yield (91 mg). 1H NMR (500 MHz, CDCl3): δ 7.91 (s, 1H), 7.86 
(s, 1H), 7.72-7.69 (m, 2H), 7.65-7.62 (m, 1H), 7.48-7.42 (m, 3H), 7.41-7.38 (m, 1H), 
7.27-7.23 (m, 1H), 7.22-7.18 (m, 1H), 2.77-2.73 (m, 2H), 1.52-1.48 (m, 2H), 1.37-1.32 
(m, 2H), 0.90-0.87 (m, 3H); 13C NMR (125.8 MHz, CDCl3): δ 141.8, 139.0, 132.5, 128.8, 
128.4, 128.0, 127.3, 125.5, 121.1, 117.7, 34.9, 33.5, 22.7, 14.0; 11B NMR (128.38 MHz, 
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CDCl3) δ33.6; FT-IR (neat): 1614, 1566, 1423 cm-1; HRMS (ES+) m/z calcd. for 
C18H20BN (M)+ 261.1689, found 261.1697. 
 
 
4-(2-Phenyl-2,1-borazaronaphthyl)butyl acetate (3.64).  The title compound was 
obtained as a light brown oil in 91% yield (145 mg). 1H NMR (500 MHz, CDCl3): δ 7.99 
(br s, 1H), 7.88 (s, 1H), 7.73-7.70 (m, 2H), 7.67 (d, J = 7.8 Hz, 1H), 7.51-7.40 (m, 4H), 
7.31-7.28 (m, 1H), 7.24-7.21 (m, 1H), 4.04 (t, J = 6.5 Hz, 2H), 2.81 (t, J = 7.5 Hz, 2H), 
2.03 (s, 3H), 1.67-1.62 (m, 2H), 1.61-1.56 (m, 2H); 13C NMR (125.8 MHz, CDCl3): δ 
171.2, 142.1, 139.1, 132.3, 128.8, 128.4, 128.0, 127.5, 125.3, 121.2, 117.7, 64.4, 34.8, 
28.4, 27.3, 21.0; 11B NMR (128.38 MHz, CDCl3) δ 34.6; FT-IR (neat): 1734, 1722, 1615, 
1241 cm-1; HRMS (CI) m/z calcd. for C20H22BNO2 (M)+ 319.1744, found 319.1732. 
 
General procedure for the cross-coupling of nonaromatic heterocyclic tosylates with 
aryl and heteroaryl bromides.  An oven-dried Biotage 10 mL microwave vial equipped 
with a magnetic stirbar was charged with alkyl tosylate (0.5 mmol), NiBr2•glyme (0.025 
mmol, 7.7 mg), 4,4’-di-tert-butyl-2,2’-bipyridine (0.025 mmol, 6.7 mg), KI (0.5 mmol, 
83.0 mg), and Mn powder (1.0 mmol, 55.0 mg).  The vial was sealed with a disposable 
Teflon septum cap and was evacuated and purged with Ar three times. Dimethyl 
acetamide (2.5 mL) and 4-ethylpyridine (0.5 mmol, 54 mg) were added via syringe, 
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followed by the (hetero)aryl bromide (0.5 mmol). In cases where the (hetero)aryl bromide 
was a solid, it was added to the vial along with the other solids. The reaction was stirred 
under Ar at 80 °C for 18 h, after which the solution was cooled and diluted with 5 mL of 
MeCN. The resulting mixture was filtered through a pad of Celite, which was rinsed with 
MeCN (~ 10 mL), and the solution was concentrated.  The resulting residue was diluted 
with H2O (20 mL), extracted with EtOAc (3 x 10 mL), and the combined organic 
portions were washed with H2O (2 x 10 mL) and brine (10 mL). The organic layer was 
dried (NaSO4), after which it was filtered and concentrated.  The product was isolated by 
column chromatography, eluting with a gradient of EtOAc in hexanes (10 to 60% 
EtOAc).  
 
 
tert-Butyl 5-(1-(tert-Butoxycarbonyl)piperidin-4-yl)-1H-indole-1-carboxylate 
(3.65).55 The spectral data is in accordance with those published. The title compound was 
obtained as a colorless oil in 73% yield (146 mg). 1H NMR (500 MHz, CDCl3): δ 8.06 
(br, 1H), 7.58-7.57 (m, 1H), 7.39 (s, 1H), 7.18-7.16 (m, 1H), 6.53-6.52 (d, J = 3.6 Hz, 
1H), 4.27 (br, 2H), 2.86-2.82 (m, 2H), 2.76-2.71 (m, 1H), 1.87-1.85 (m, 2H), 1.69-1.67 
(m, 11H), 1.50 (s, 9H); 13C NMR (125.8 MHz, CDCl3): δ 155.0, 149.8, 140.5, 134.0, 
130.9, 126.2, 123.6, 118.7, 115.3, 107.4, 83.6, 79.4, 44.3 (br), 42.8, 33.8, 28.7, 28.3. 
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tert-Butyl 5-(Tetrahydro-2H-pyran-4-yl)-1H-indole-1-carboxylate (3.66).55 The title 
compound was obtained as a white solid in 69% yield (104 mg). The spectral data is in 
accordance with those published. mp: 82-84 °C (lit. 86-87 °C). 1H NMR (500 MHz, 
CDCl3): δ 8.07-8.06 (m, 1H), 7.58-7.57 (m, 1H), 7.40 (s, 1H), 7.20-7.18 (m, 1H), 6.53-
6.52 (d, J = 3.7 Hz, 1H), 4.11-4.08 (m, 2H), 3.58-3.53 (m, 2H), 2.86-2.83 (m, 1H), 1.92-
1.79 (m, 4H), 1.66 (s, 9H); 13C NMR (125.8 MHz, CDCl3): δ 149.9, 140.6, 134.0, 131.0, 
126.3, 123.5, 118.7, 115.3, 107.4, 83.7, 68.7, 41.7, 34.6, 28.3. 
 
 
tert-Butyl 5-(Tetrahydrofuran-3-yl)-1H-indole-1-carboxylate (3.67).55 The title 
compound was obtained as a colorless oil in 36% yield (52 mg). From the corresponding 
mesylate, the compound was isolated in 28% yield (40 mg). The spectral data is in 
accordance with those published. 1H NMR (500 MHz, CDCl3): δ 8.07-8.06 (m, 1H), 
7.59-7.58 (m, 1H), 7.44 (s, 1H), 7.22-7.20 (d, J = 8.6 Hz, 1H), 6.53-6.52 (m, 1H), 4.20-
4.17 (m, 1H), 4.13-4.08 (m, 1H), 3.97-3.92 (m, 1H), 3.79-3.76 (m, 1H), 3.52-3.49 (m, 
1H), 2.42-2.39 (m, 1H), 2.08-2.04 (m, 1H), 1.67 (s, 9H); 13C NMR (125.8 MHz, CDCl3): 
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δ 149.9, 137.1, 134.1, 131.0, 126.4, 123.8, 119.3, 115.4, 107.3, 83.8, 75.1, 68.7, 45.0, 
35.1, 28.3. 
 
 
tert-Butyl 5-(1-Benzylpiperidin-4-yl)-1H-indole-1-carboxylate (3.68). The title 
compound was obtained as a colorless oil in 66% yield (129 mg). 1H NMR (500 MHz, 
CDCl3): δ 8.09-8.07 (m, 1H), 7.60-7.59 (d, J = 3.4 Hz, 1H), 7.42-7.38 (m, 5H), 7.36-7.34 
(m, 1H), 7.18-7.16 (m, 1H), 6.54-6.53 (d, J = 3.7 Hz, 1H), 5.19 (s, 2H), 4.37 (br, 2H), 
2.94-2.93 (m, 2H), 2.80-2.75 (m, 1H), 1.91-1.89 (m, 2H), 1.71-1.67 (m, 11H); 13C NMR 
(125.8 MHz, CDCl3): δ 155.3, 149.7, 140.0, 136.9, 130.7, 128.4, 127.9, 127.8, 126.1, 
123.3, 118.5, 115.0, 107.1, 83.5, 67.0, 44.7, 42.5, 33.5 (br), 28.1; FT-IR (neat): 1732, 
1698, 1366, 1223 cm-1; HRMS (ES+) m/z calcd. for C25H31N2O2 (M+H)+ 391.2386, 
found 391.2379. 
 
 
tert-Butyl 5-(1-(tert-Butoxycarbonyl)pyrrolidin-3-yl)-1H-indole-1-carboxylate 
(3.69).55 The title compound was obtained as a colorless oil in 52% yield (100 mg). The 
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spectral data is in accordance with those published. 1H NMR (500 MHz, CDCl3): δ 8.08-
8.07 (m, 1H), 7.59-7.58 (m, 1H), 7.42 (s, 1H), 7.20-7.19 (m, 1H), 6.54-6.53 (d, J = 3.5 
Hz, 1H), 3.89-3.80 (m, 1H), 3.67-3.58 (m, 1H), 3.44-3.30 (m, 3H), 2.29-2.28 (m, 1H), 
2.06-2.02 (m, 1H), 1.67 (s, 9H), 1.48 (s, 9H); 13C NMR (125.8 MHz, CD3OD): δ 155.0, 
149.7, 135.7, 134.2, 131.0, 125.9, 123.3, 118.9, 114.9, 107.1, 83.5, 79.5, 52.8 and 52.3, 
46.0 and 45.6, 44.0 and 43.3, 33.2 and 32.4, 27.7, 27.2. 
 
 
tert-Butyl 5-(1-(tert-Butoxycarbonyl)piperidin-3-yl)-1H-indole-1-carboxylate 
(3.70).55 The title compound was obtained as a colorless oil in 24% yield (48 mg). The 
spectral data is in accordance with those published. 1H NMR (500 MHz, CDCl3): δ 8.07-
8.06 (m, 1H), 7.59-7.58 (m, 1H), 7.42 (s, 1H), 7.21-7.19 (m, 1H), 6.54-6.53 (d, J = 3.6 
Hz, 1H), 4.18 (br, 2H), 2.77-2.76 (m, 3H), 2.09-2.05 (m, 1H), 1.80-1.77 (m, 1H), 1.70-
1.59 (m, 11H), 1.48 (s, 9H); 13C NMR (125.8 MHz, CDCl3): δ 155.0, 149.9, 138.2, 134.2, 
130.9, 126.3, 123.8, 119.1, 115.2, 107.3, 83.7, 79.5, 51.2 (br), 44.3 (br), 42.7, 32.4, 28.6, 
28.3, 25.7. 
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tert-Butyl 4-(Quinolin-3-yl)piperidine-1-carboxylate (3.71).55 The title compound was 
obtained as a yellow oil in 74% yield (116 mg). On a 3.0 mmol scale, the product was 
isolated in 81% yield (759 mg). The spectral data is in accordance with those published. 
1H NMR (500 MHz, CDCl3): δ 8.80-8.79 (d, J = 2.2 Hz, 1H), 8.07-8.06 (d, J = 8.5 Hz, 
1H), 7.90 (s, 1H), 7.77-7.75 (d, J = 8.3 Hz, 1H), 7.67-7.64 (m, 1H), 7.53-7.50 (m, 1H), 
4.30 (br, 2H), 2.88-2.83 (m, 3H), 1.94-1.91 (m, 2H), 1.74-1.71 (m, 2H), 1.48 (s, 9H); 13C 
NMR (125.8 MHz, CDCl3): δ 154.9, 151.0, 147.2, 138.3, 132.7, 129.2, 129.0, 128.2, 
127.7, 126.8, 79.7, 44.6 (br), 40.3, 33.0, 28.6. 
 
 
tert-Butyl 4-(2-Methylpyridin-4-yl)piperidine-1-carboxylate (3.72).55 The title 
compound was obtained as a yellow oil in 60% yield (83 mg). The spectral data is in 
accordance with those published. 1H NMR (500 MHz, CDCl3): δ 8.39-8.38 (d, J = 5.1 
Hz, 1H), 6.97 (s, 1H), 6.92-6.91 (d, J = 5.2 Hz, 1H), 4.24 (br, 2H), 2.78-2.76 (m, 2H), 
2.60-2.58 (m, 1H), 2.51 (s, 3H), 1.81-1.77 (m, 2H), 1.62-1.55 (m, 2H), 1.46 (s, 9H); 13C 
NMR (125.8 MHz, CDCl3): δ 158.7, 154.9, 154.8, 149.4, 121.9, 119.5, 79.8, 44.3 (br), 
42.1, 32.4, 28.6, 24.6. 
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tert-Butyl 4-(Benzo[b]thiophen-2-yl)piperidine-1-carboxylate (3.73). The title 
compound was obtained as a white solid in 42% yield (67 mg). mp: 83-84 °C. 1H NMR 
(500 MHz, CDCl3): δ 7.77 (d, J = 7.9 Hz, 1H), 7.68 (d, J = 7.7 Hz, 1H), 7.32-7.26 (m, 
2H), 7.03 (s, 1H), 4.23 (br, 2H), 3.03-3.00 (m, 1H), 2.88-2.82 (m, 2H), 2.07-2.04 (m, 
2H), 1.72-1.66 (m, 2H), 1.49 (s, 9H); 13C NMR (125.8 MHz, CDCl3): δ 154.9, 150.6, 
140.0, 138.8, 124.3, 123.8, 123.1, 122.4, 119.0, 79.7, 44.3 (br), 38.4, 33.8, 28.6; FT-IR 
(neat): 1681, 1428, 1156 cm-1; HRMS (ES+) m/z calcd. for C18H23NO2SNa (M+Na)+ 
340.1347, found 340.1346. 
 
 
5-(Tetrahydro-2H-pyran-4-yl)benzofuran (3.74).55 The title compound was obtained 
as a colorless oil in 49% yield (50 mg). The spectral data is in accordance with those 
published. 1H NMR (500 MHz, CDCl3): δ 7.62-7.61 (m, 1H), 7.47-7.45 (m, 2H), 7.19-
7.17 (d, J = 8.6 Hz, 1H), 6.75-6.74 (m, 1H), 4.13-4.10 (m, 2H), 3.59-3.54 (m, 2H), 2.88-
2.83 (m, 1H), 1.92-1.80 (m, 4H); 13C NMR (125.8 MHz, CDCl3): δ 153.9, 145.4, 140.8, 
127.7, 123.6, 118.9, 111.4, 106.7, 68.7, 41.7, 34.7. 
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2-(4-(Tetrahydro-2H-pyran-4-yl)phenyl)-1,3,4-oxadiazole (3.75). The title compound 
was obtained as a white solid in 62% yield (77 mg). mp: 110-112 °C. 1H NMR (500 
MHz, CDCl3): δ 8.45 (s, 1H), 8.01 (d, J = 8.3  Hz, 2H), 7.36 (d, J =  8.2 Hz, 2H), 4.10-
4.07 (m, 2H), 3.55-3.50 (m, 2H), 2.85-2.79 (m, 1H), 1.87-1.76 (m, 4H); 13C NMR (125.8 
MHz, CDCl3): δ 164.8, 152.7, 150.3, 127.7, 127.5, 121.7, 68.3, 41.7, 33.7; FT-IR (neat): 
1615, 1493, 1086 cm-1; HRMS (ES+) m/z calcd. for C13H15N2O2 (M+H)+ 231.1134, 
found 231.1134. 
 
 
tert-Butyl 4-(4-Acetamidophenyl)piperidine-1-carboxylate (3.76).55 The title 
compound was obtained as a white solid in 38% yield (61 mg). The spectral data is in 
accordance with those published. mp: 171-172 °C (lit. 165-168 °C). 1H NMR (500 MHz, 
CDCl3): δ 7.61 (br, 1H), 7.40 (d, J = 8.1 Hz, 2H), 7.11 (d, J = 8.1 Hz, 2H), 4.21 (br, 2H), 
2.79-2.74 (m, 2H), 2.61-2.56 (m, 1H), 2.14 (s, 3H), 1.78-1.75 (m, 2H), 1.57-1.53 (m, 
2H), 1.47 (s, 9H); 13C NMR (125.8 MHz, CDCl3): δ 168.6, 155.0, 141.9, 136.4, 127.3, 
120.4, 79.7, 44.4 (br), 42.2, 33.4, 28.6, 24.6. 
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tert-Butyl 4-(4-Fluorophenyl)piperidine-1-carboxylate (3.77).55 The title compound 
was obtained as a colorless oil in 65% yield (91 mg). The spectral data is in accordance 
with those published. 1H NMR (500 MHz, CDCl3): δ 7.15-7.13 (m, 2H), 7.00-6.97 (m, 
2H), 4.24 (br, 2H), 2.81-2.74 (m, 2H), 2.64-2.59 (m, 1H), 1.81-1.78 (m, 2H), 1.62-1.55 
(m, 2H), 1.47 (s, 9H); 13C NMR (125.8 MHz, CDCl3): δ 161.5 (d, J = 244.1 Hz), 155.0, 
141.6 (d, J = 3.4 Hz), 128.2 (d, J = 7.7 Hz), 115.3 (d, J = 20.9 Hz), 79.6, 44.4 (br), 42.1, 
33.5, 28.6. 
 
 
tert-Butyl 4-(2-Methoxyphenyl)piperidine-1-carboxylate (3.78).55 The title compound 
was obtained as a white solid in 60% yield (87 mg). mp: 65-66 °C (lit: 63-65 °C). The 
spectral data is in accordance with those published. 1H NMR (500 MHz, CDCl3): δ 7.20-
7.14 (m, 2H), 6.95-6.93 (m, 1H), 6.88-6.86 (m, 1H), 4.24 (br, 2H), 3.83 (s, 3H), 3.12-3.07 
(m, 1H), 2.84-2.81 (m, 2H), 1.82-1.78 (m, 2H), 1.61-1.57 (m, 2H), 1.49 (s, 9H); 13C 
NMR (125.8 MHz, CDCl3): δ 156.9, 155.1, 134.0, 127.2, 126.6, 120.8, 110.5, 79.4, 55.4, 
44.4 (br), 35.5, 32.0, 28.7. 
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1-(4-(Tetrahydro-2H-pyran-4-yl)phenyl)ethan-1-one (3.79).55 The title compound was 
obtained as a white solid in 72% yield (74 mg). mp: 71-73 °C (lit: 75-76 °C). The spectral 
data is in accordance with those published. 1H NMR (500 MHz, CDCl3): δ 7.90 (d, J = 
8.2 Hz, 2H), 7.30 (d, J = 8.1 Hz, 2H), 4.08-4.05 (m, 2H), 3.54-3.49 (m, 2H), 2.83-2.78 
(m, 1H), 2.56 (s, 3H), 1.85-1.73 (m, 4H); 13C NMR (125.8 MHz, CDCl3): δ 197.9, 151.5, 
135.6, 128.9, 127.1, 68.3, 41.7, 33.7, 26.7. 
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Appendix A1. 1H, 13C, 11B, and 19F Spectra Relevant to Chapter 2
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Figure A1.1. 1H NMR (500 MHz, CDCl3) Spectrum of Benzyl 2-(3-Methoxyphenyl)acetate (2.1) 
 
Figure A1.2. 13C NMR (128.5 MHz, CDCl3) Spectrum of Benzyl 2-(3-Methoxyphenyl)acetate (2.1) 
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Figure A1.3.  1H NMR (500 MHz, CDCl3) Spectrum of Benzyl 2-(2-Methoxyphenyl)acetate (2.2) 
 
Figure A1.4. 13C NMR (128.5 MHz, CDCl3) Spectrum of Benzyl 2-(2-Methoxyphenyl)acetate (2.2) 
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Figure A1.5. 1H NMR (500 MHz, CDCl3) Spectrum of Benzyl 2-(o-Tolyl)acetate (2.3) 
 
Figure A1.6. 13C NMR (128.5 MHz, CDCl3) Spectrum of Benzyl 2-(o-Tolyl)acetate (2.3) 
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Figure A1.7. 1H NMR (500 MHz, CDCl3) Spectrum of Benzyl 2-(Quinolin-6-yl)acetate (2.4) 
 
Figure A1.8. 13C NMR (128.5 MHz, CDCl3) Spectrum of Benzyl 2-(Quinolin-6-yl)acetate (2.4) 
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Figure A1.9. 1H NMR (500 MHz, CDCl3) Spectrum of Benzyl 2-(2,3-Dihydrobenzo[1,4]dioxin-6-
yl)acetate (2.5) 
 
Figure A1.10. 13C NMR (128.5 MHz, CDCl3) Spectrum of Benzyl 2-(2,3-Dihydrobenzo[1,4]dioxin-6-
yl)acetate (2.5) 
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Figure A1.11. 1H NMR (500 MHz, CDCl3) Spectrum of Benzyl 2-(3,5-Diisopropylphenyl)acetate (2.6) 
 
Figure A1.12. 13C NMR (128.5 MHz, CDCl3) Spectrum of Benzyl 2-(3,5-Diisopropylphenyl)acetate (2.6) 
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Figure A1.13. 1H NMR (500 MHz, CDCl3) Spectrum of Benzyl 2-(2,4-Difluorophenyl)acetate (2.7) 
 
Figure A1.14. 13C NMR (128.5 MHz, CDCl3) Spectrum of Benzyl 2-(2,4-Difluorophenyl)acetate (2.7) 
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Figure A1.15. 1H NMR (500 MHz, CDCl3) Spectrum of Benzyl 2-(Furan-3-yl)acetate (2.8) 
 
Figure A1.16. 13C NMR (128.5 MHz, CDCl3) Spectrum of Benzyl 2-(Furan-3-yl)acetate (2.8) 
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Figure A1.17. 1H NMR (500 MHz, CDCl3) Spectrum of Benzyl 2-(4-Chlorophenyl)acetate (2.9) 
 
Figure A1.18. 13C NMR (128.5 MHz, CDCl3) Spectrum of Benzyl 2-(4-Chlorophenyl)acetate (2.9) 
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Figure A1.19. 1H NMR (500 MHz, CDCl3) Spectrum of tert-Butyl 2-(p-Tolyl)acetate (2.10) 
 
Figure A1.20. 13C NMR (128.5 MHz, CDCl3) Spectrum of tert-Butyl 2-(p-Tolyl)acetate (2.10) 
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Figure A1.21. 1H NMR (500 MHz, CDCl3) Spectrum of tert-Butyl 2-[2-{(Pent-4-en-1-
yloxy)methyl}phenyl]acetate (2.11) 
 
Figure A1.22. 13C NMR (128.5 MHz, CDCl3) Spectrum of tert-Butyl 2-[2-{(Pent-4-en-1-
yloxy)methyl}phenyl]acetate (2.11) 
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Figure A1.23. 1H NMR (500 MHz, CDCl3) Spectrum of tert-Butyl 2-(3-nitrophenyl)acetate (2.12) 
 
Figure A1.24. 13C NMR (128.5 MHz, CDCl3) Spectrum of tert-Butyl 2-(3-nitrophenyl)acetate (2.12) 
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Figure A1.25. 1H NMR (500 MHz, CDCl3) Spectrum of Methyl 3-{2-(tert-Butoxy)-2-oxoethyl}benzoate 
(2.13) 
 
Figure A1.26. 13C NMR (128.5 MHz, CDCl3) Spectrum of Methyl 3-{2-(tert-Butoxy)-2-
oxoethyl}benzoate (2.13) 
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Figure A1.27. 1H NMR (500 MHz, CDCl3) Spectrum of tert-Butyl 2-(3-Acetylphenyl)acetate (2.14) 
 
Figure A1.28. 13C NMR (128.5 MHz, CDCl3) Spectrum of tert-Butyl 2-(3-Acetylphenyl)acetate (2.14) 
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Figure A1.29. 1H NMR (500 MHz, CDCl3) Spectrum of Methyl 2-(4-Fluorophenyl)acetate (2.15) 
 
Figure A1.30. 13C NMR (128.5 MHz, CDCl3) Spectrum of Methyl 2-(4-Fluorophenyl)acetate (2.15) 
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Figure A1.31. 1H NMR (500 MHz, CDCl3) Spectrum of Methyl 2-(p-Tolyl)acetate (2.16) 
 
Figure A1.32. 13C NMR (128.5 MHz, CDCl3) Spectrum of Methyl 2-(p-Tolyl)acetate (2.16) 
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Figure A1.33. 1H NMR (500 MHz, CDCl3) Spectrum of tert-Butyl 2-(Quinolin-6-yl)acetate (2.17) 
 
Figure A1.34. 13C NMR (128.5 MHz, CDCl3) Spectrum of tert-Butyl 2-(Quinolin-6-yl)acetate (2.17) 
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Figure A1.35. 1H NMR (500 MHz, CDCl3) Spectrum of tert-Butyl 2-(Isoquinolin-5-yl)acetate (2.18) 
 
Figure A1.36. 13C NMR (128.5 MHz, CDCl3) Spectrum of tert-Butyl 2-(Isoquinolin-5-yl)acetate (2.18) 
9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 ppm
1.
38
8
3.
93
5
7.
54
4
7.
56
0
7.
58
7
7.
60
1
7.
75
4
7.
76
6
7.
88
2
7.
89
8
8.
54
3
8.
55
5
9.
23
9
9.
25
2.
06
1.
07
1.
06
1.
03
1.
00
1.
00
1.
00
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
28
.0
9
39
.8
4
81
.5
9
11
7.
13
12
7.
08
12
7.
43
12
9.
06
13
0.
79
13
2.
06
13
5.
03
14
3.
30
15
3.
18
17
0.
37
tBu-O
O
N
!! !! !253!
 
Figure A1.37. 1H NMR (500 MHz, CDCl3) Spectrum of tert-Butyl 2-(Pyridin-3-yl)acetate (2.19) 
 
Figure A1.38. 13C NMR (128.5 MHz, CDCl3) Spectrum of tert-Butyl 2-(Pyridin-3-yl)acetate (2.19) 
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Figure A1.39. 1H NMR (500 MHz, CDCl3) Spectrum of tert-Butyl 2-(2,4-Dimethoxypyrimidin-5-
yl)acetate (2.20) 
 
Figure A1.40. 13C NMR (128.5 MHz, CDCl3) Spectrum of tert-Butyl 2-(2,4-Dimethoxypyrimidin-5-
yl)acetate (2.20) 
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Figure A1.41. 1H NMR (500 MHz, CDCl3) Spectrum of tert-Butyl 2-(Isoquinolin-4-yl)acetate (2.21) 
 
Figure A1.42. 13C NMR (128.5 MHz, CDCl3) Spectrum of tert-Butyl 2-(Isoquinolin-4-yl)acetate (2.21) 
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Figure A1.43. 1H NMR (500 MHz, CDCl3) Spectrum of tert-Butyl 2-(Pyridin-4-yl)acetate (2.22) 
 
Figure A1.44. 13C NMR (128.5 MHz, CDCl3) Spectrum of tert-Butyl 2-(Pyridin-4-yl)acetate (2.22) 
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Figure A1.45. 1H NMR (500 MHz, CDCl3) Spectrum of tert-Butyl 2-(Furan-3-yl)acetate (2.23) 
 
Figure A1.46. 13C NMR (128.5 MHz, CDCl3) Spectrum of tert-Butyl 2-(Furan-3-yl)acetate (2.23) 
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Figure A1.47. 1H NMR (500 MHz, CDCl3) Spectrum of tert-Butyl 2-(2-Acetylthiophen-3-yl)acetate.(2.24) 
 
Figure A1.48. 13C NMR (128.5 MHz, CDCl3) Spectrum of tert-Butyl 2-(2-Acetylthiophen-3-yl)acetate 
(2.24) 
9 8 7 6 5 4 3 2 1 0 ppm
1.
45
2
2.
52
8
3.
96
8
7.
05
0
7.
06
0
7.
43
2
7.
44
2
9.
27
3.
02
2.
03
1.
00
1.
02
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
28
.2
0
29
.5
8
36
.7
9
81
.1
4
12
9.
72
13
2.
30
13
6.
82
14
1.
11
17
0.
04
19
0.
97
tBu-O
O
S
O
!! !! !259!
 
Figure A1.49. 1H NMR (500 MHz, CDCl3) Spectrum of tert-Butyl 2-(Thiophen-2-yl)acetate (2.25) 
 
Figure A1.50. 13C NMR (128.5 MHz, CDCl3) Spectrum of tert-Butyl 2-(Thiophen-2-yl)acetate (2.25) 
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Figure A1.51. 1H NMR (500 MHz, CDCl3) Spectrum of Methyl 2-(Furan-3-yl)acetate (2.26) 
 
Figure A1.52. 13C NMR (128.5 MHz, CDCl3) Spectrum of Methyl 2-(Furan-3-yl)acetate (2.26) 
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Figure A1.53. 1H NMR (500 MHz, CDCl3) Spectrum of 1-Morpholino-2-(p-tolyl)ethan-1-one (2.27) 
 
Figure A1.54. 13C NMR (128.5 MHz, CDCl3) Spectrum of 1-Morpholino-2-(p-tolyl)ethan-1-one (2.27) 
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Figure A1.55. 1H NMR (500 MHz, CDCl3) Spectrum of 1-Morpholino-2-(naphthalen-2-yl)ethan-1-one 
(2.28) 
 
Figure A1.56. 13C NMR (128.5 MHz, CDCl3) Spectrum of 1-Morpholino-2-(naphthalen-2-yl)ethan-1-one 
(2.28) 
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Figure A1.57. 1H NMR (500 MHz, CDCl3) Spectrum of 2-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)-1-
morpholinoethan-1-one (2.29) 
 
Figure A1.58. 13C NMR (128.5 MHz, CDCl3) Spectrum of 2-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)-1-
morpholinoethan-1-one (2.29) 
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Figure A1.59. 1H NMR (500 MHz, CDCl3) Spectrum of 2-(3-Acetylphenyl)-1-morpholinoethan-1-one 
(2.30) 
 
Figure A1.60. 13C NMR (128.5 MHz, CDCl3) Spectrum of 2-(3-Acetylphenyl)-1-morpholinoethan-1-one 
(2.30) 
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Figure A1.61. 1H NMR (500 MHz, CDCl3) Spectrum of 2-(4-Fluorophenyl)-1-morpholinoethan-1-one 
(2.31) 
 
Figure A1.62. 13C NMR (128.5 MHz, CDCl3) Spectrum of 2-(4-Fluorophenyl)-1-morpholinoethan-1-one 
(2.31) 
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Figure A1.63. 1H NMR (500 MHz, CDCl3) Spectrum of 2-(Furan-3-yl)-1-morpholinoethan-1-one (2.32) 
 
Figure A1.64. 13C NMR (128.5 MHz, CDCl3) Spectrum of 2-(Furan-3-yl)-1-morpholinoethan-1-one (2.32) 
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Figure A1.65. 1H NMR (500 MHz, CDCl3) Spectrum of 2-(2-Morpholino-2-oxoethyl)furan-3-carboxylic 
acid (2.33) 
 
Figure A1.66. 13C NMR (128.5 MHz, CDCl3) Spectrum of 2-(2-Morpholino-2-oxoethyl)furan-3-
carboxylic acid (2.33) 
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Figure A1.67. 1H NMR (500 MHz, CDCl3) Spectrum of 1-Morpholino-2-{1-(phenylsulfonyl)-1H-indol-3-
yl}ethan-1-one (2.34) 
 
Figure A1.68. 13C NMR (128.5 MHz, CDCl3) Spectrum of 1-Morpholino-2-{1-(phenylsulfonyl)-1H-indol-
3-yl}ethan-1-one (2.34) 
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Figure A1.69. 1H NMR (500 MHz, CDCl3) Spectrum of 2-(Benzothiophen-2-yl)-1-morpholinoethan-1-one 
(2.35) 
 
Figure A1.70. 13C NMR (128.5 MHz, CDCl3) Spectrum of 2-(Benzothiophen-2-yl)-1-morpholinoethan-1-
one (2.35) 
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Figure A1.71. 1H NMR (500 MHz, CDCl3) Spectrum of 1-(Piperidin-1-yl)-2-(p-tolyl)ethan-1-one (2.36) 
 
Figure A1.72. 13C NMR (128.5 MHz, CDCl3) Spectrum of 1-(Piperidin-1-yl)-2-(p-tolyl)ethan-1-one (2.36) 
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Figure A1.73. 1H NMR (500 MHz, CDCl3) Spectrum of N,N-Diethyl-2-(p-tolyl)acetamide (2.37) 
 
Figure A1.74. 13C NMR (128.5 MHz, CDCl3) Spectrum of N,N-Diethyl-2-(p-tolyl)acetamide (2.37) 
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Figure A1.75. 1H NMR (500 MHz, CDCl3) Spectrum of N-Benzyl-2-(quinolin-6-yl)acetamide (2.38) 
 
Figure A1.76. 13C NMR (128.5 MHz, CDCl3) Spectrum of N-Benzyl-2-(quinolin-6-yl)acetamide (2.38) 
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Figure A1.77. 1H NMR (500 MHz, CDCl3) Spectrum of N-Benzyl-2-(p-tolyl)acetamide (2.39) 
 
Figure A1.78. 13C NMR (128.5 MHz, CDCl3) Spectrum of N-Benzyl-2-(p-tolyl)acetamide (2.39) 
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Figure A1.79. 1H NMR (500 MHz, CDCl3) Spectrum of N-Cyclopropyl-2-(p-tolyl)acetamide (2.40) 
 
Figure A1.80. 13C NMR (128.5 MHz, CDCl3) Spectrum of N-Cyclopropyl-2-(p-tolyl)acetamide (2.40) 
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Figure A1.81. 1H NMR (500 MHz, CDCl3) Spectrum of N-Cyclopropyl-2-(furan-3-yl)acetamide (2.41) 
 
Figure A1.82. 13C NMR (128.5 MHz, CDCl3) Spectrum of N-Cyclopropyl-2-(furan-3-yl)acetamide (2.41) 
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Figure A1.83. 1H NMR (500 MHz, CDCl3) Spectrum of N-Cyclopropyl-2-(naphthalen-1-yl)acetamide 
(2.42) 
 
Figure A1.84. 13C NMR (128.5 MHz, CDCl3) Spectrum of N-Cyclopropyl-2-(naphthalen-1-yl)acetamide 
(2.42) 
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Figure A1.85. 1H NMR (500 MHz, CDCl3) Spectrum of N-Cyclopropyl-2-(isoquinolin-5-yl)acetamide 
(2.43) 
 
Figure A1.86. 13C NMR (128.5 MHz, CDCl3) Spectrum of N-Cyclopropyl-2-(isoquinolin-5-yl)acetamide 
(2.43) 
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Figure A1.87. 1H NMR (500 MHz, CDCl3) spectrum of (E)-Benzyl 4-Phenylbut-3-enoate (2.44) 
 
Figure A1.88. 13C NMR (125.8 MHz, CDCl3) spectrum of (E)-Benzyl 4-Phenylbut-3-enoate (2.44)  
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Figure A1.89. 1H NMR (500 MHz, CDCl3) spectrum of (E)-Benzyl Pent-3-enoate (2.45) 
 
Figure A1.90. 13C NMR (125.8 MHz, CDCl3) spectrum of (E)-Benzyl Pent-3-enoate (2.45) 
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Figure A1.91. 1H NMR (500 MHz, CDCl3) spectrum of (Z)-Benzyl Dodec-3-enoate (2.46) 
 
Figure A1.92. 13C NMR (125.8 MHz, CDCl3) spectrum of (Z)-Benzyl Dodec-3-enoate (2.46) 
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Figure A1.93. 1H NMR (500 MHz, CDCl3) spectrum of (E)-Benzyl Dodec-3-enoate (2.47) 
 
Figure A1.94. 13C NMR (125.8 MHz, CDCl3) spectrum of (E)-Benzyl Dodec-3-enoate (2.47) 
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Figure A1.95. 1H NMR (500 MHz, CDCl3) spectrum of (Z)-Benzyl 6-Phenylhex-3-enoate (2.48) 
 
Figure A1.96. 13C NMR (125.8 MHz, CDCl3) spectrum of (Z)-Benzyl 6-Phenylhex-3-enoate (2.48) 
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Figure A1.97. 1H NMR (500 MHz, CDCl3) spectrum of Benzyl 2-(Cyclohex-1-en-1-yl)acetate (2.49)  
 
Figure A1.98. 13C NMR (125.8 MHz, CDCl3) spectrum of Benzyl 2-(Cyclohex-1-en-1-yl)acetate (2.49) 
BnO
O
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Figure A1.99. 1H NMR (500 MHz, CDCl3) spectrum of (E)-Benzyl 7-Cyanohept-3-enoate (2.50) 
 
Figure A1.100. 13C NMR (125.8 MHz, CDCl3) spectrum of (E)-Benzyl 7-Cyanohept-3-enoate (2.50) 
BnO
O
CN
!! !! !285!
 
Figure A1.101. 1H NMR (500 MHz, CDCl3) spectrum of Benzyl 3-Methylbut-3-enoate (2.51) 
 
Figure A1.102. 13C NMR (125.8 MHz, CDCl3) spectrum of Benzyl 3-Methylbut-3-enoate (2.51)
BnO
O
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Figure A1.103. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl (E)-4-Phenylbut-3-enoate (2.52) 
 
Figure A1.104. 13C NMR (125.8 MHz, CDCl3) spectrum of tert-Butyl (E)-4-Phenylbut-3-enoate (2.52)
6.36.46.56.6 ppm
6.
30
0
6.
31
6
6.
33
1
6.
34
6
6.
47
5
6.
50
7
9 8 7 6 5 4 3 2 1 ppm
1.
50
3.
18
3.
19
6.
30
6.
32
6.
33
6.
35
6.
47
6.
51
7.
25
7.
26
7.
28
7.
31
7.
33
7.
34
7.
39
7.
40
9.
34
2.
04
1.
00
1.
00
1.
04
2.
15
2.
10
200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 ppm
28
.2
7
39
.8
3
80
.9
7
12
2.
65
12
6.
42
12
7.
57
12
8.
66
13
3.
13
13
7.
22
17
1.
09
O
O
!! !! !287!
 
Figure A1.105. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl (E)-5-Phenylpent-3-enoate (2.53) 
 
Figure A1.106. 13C NMR (125.8 MHz, CDCl3) spectrum of tert-Butyl (E)-5-Phenylpent-3-enoate (2.53) 
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Figure A1.107. 1H NMR (500 MHz, CDCl3) spectrum of Isopropyl (E)-5-Phenylpent-3-enoate (2.54) 
 
Figure A1.108. 13C NMR (125.8 MHz, CDCl3) spectrum of Isopropyl (E)-5-Phenylpent-3-enoate (2.54) 
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Figure A1.109. 1H NMR (500 MHz, CDCl3) spectrum of Benzyl (E)-8-Chlorooct-3-enoate (2.55). 
 
Figure A1.110. 13C NMR (125.8 MHz, CDCl3) spectrum of Benzyl (E)-8-Chlorooct-3-enoate (2.55). 
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Figure A1.111. 1H NMR (500 MHz, CDCl3) spectrum of Benzyl (E)-5-(Benzyl(methyl)amino)pent-3-
enoate (2.56) 
 
Figure A1.112. 13C NMR (125.8 MHz, CDCl3) spectrum of Benzyl (E)-5-(Benzyl(methyl)amino)pent-3-
enoate (2.56) 
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Figure A1.113. 1H NMR (500 MHz, CDCl3) spectrum of Benzyl (E)-5-(Benzyloxy)pent-3-enoate (2.57) 
 
Figure A1.114. 13C NMR (125.8 MHz, CDCl3) spectrum of Benzyl (E)-5-(Benzyloxy)pent-3-enoate (2.57) 
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Figure A1.115. 1H NMR (500 MHz, CDCl3) spectrum of Benzyl (E)-6-((Tetrahydropyran-2-yl)oxy)hex-3-
enoate (2.58) 
 
Figure A1.116. 13C NMR (125.8 MHz, CDCl3) spectrum of Benzyl (E)-6-((Tetrahydropyran-2-yl)oxy)hex-
3-enoate (2.58) 
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Figure A1.117. 1H NMR (500 MHz, CDCl3) spectrum of (Z)-Benzyl Pent-3-enoate (2.59) 
 
Figure A1.118. 13C NMR (125.8 MHz, CDCl3) spectrum of (Z)-Benzyl Pent-3-enoate (2.59) 
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Figure A1.119. 1H NMR (500 MHz, CDCl3) spectrum of (Z)-Benzyl 4-Phenylbut-3-enoate (2.60) 
 
Figure A1.120. 13C NMR (125.8 MHz, CDCl3) spectrum of (Z)-Benzyl 4-Phenylbut-3-enoate (2.60) 
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Figure A1.121. 1H NMR (500 MHz, CDCl3) spectrum of (E)-N-Benzyl 4-Phenylbut-3-enamide (2.61) 
 
Figure A1.122. 13C NMR (125.8 MHz, CDCl3) spectrum of (E)-N-Benzyl 4-Phenylbut-3-enamide (2.61) 
BnHN
O
Ph
!! !! !296!
 
Figure A1.123. 1H NMR (500 MHz, CDCl3) spectrum of (E)-N-Benzylpent-3-enamide (2.62) 
Figure A1.124. 13C NMR (125.8 MHz, CDCl3) spectrum of (E)-N-Benzylpent-3-enamide (2.62) 
BnHN
O
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Figure A1.125. 1H NMR (500 MHz, CDCl3) spectrum of (E)-N-Benzyldodec-3-enamide (2.63) 
 
Figure A1.126. 13C NMR (125.8 MHz, CDCl3) spectrum of (E)-N-Benzyldodec-3-enamide (2.63) 
BnHN
O
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!! !! !298!
 
Figure A1.127. 1H NMR (500 MHz, CDCl3) spectrum of N-Benzylbut-3-enamide (2.64) 
 
Figure A1.128. 13C NMR (125.8 MHz, CDCl3) spectrum of N-Benzylbut-3-enamide (2.64) 
BnHN
O
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Figure A1.129. 1H NMR (500 MHz, CDCl3) spectrum of (E)-N-Benzyl 5-Phenylpent-3-enamide (2.65) 
 
Figure A1.130. 13C NMR (125.8 MHz, CDCl3) spectrum of (E)-N-Benzyl 5-Phenylpent-3-enamide (2.65) 
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Figure A1.131. 1H NMR (500 MHz, CDCl3) spectrum of (Z)-N-Benzylpent-3-enamide (2.66)
Figure A1.132. 13C NMR (125.8 MHz, CDCl3) spectrum of (Z)-N-Benzylpent-3-enamide (2.66) 
BnHN
O
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Figure A1.133. 1H NMR (500 MHz, CDCl3) spectrum of (E)-1-(Piperidin-1-yl)pent-3-en-1-one (2.67) 
 
Figure A1.134. 13C NMR (125.8 MHz, CDCl3) spectrum of (E)-1-(Piperidin-1-yl)pent-3-en-1-one (2.67) 
N
O
Me
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Figure A1.135. 1H NMR (500 MHz, CDCl3) spectrum of (E)-N-Isopropylpent-3-enamide (2.68) 
 
Figure A1.136. 13C NMR (125.8 MHz, CDCl3) spectrum of (E)-N-Isopropylpent-3-enamide (2.68)  
N
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O
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Figure A1.137. 1H NMR (500 MHz, CDCl3) spectrum of (E)-Pent-3-enamide (2.69) 
 
Figure A1.138. 13C NMR (125.8 MHz, CDCl3) spectrum of (E)-Pent-3-enamide (2.69) 
H2N
O
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Figure A1.139. 1H NMR (500 MHz, CDCl3) spectrum of (E)-1-Morpholinopent-3-en-1-one (2.70)
Figure A1.140. 13C NMR (125.8 MHz, CDCl3) spectrum of (E)-1-Morpholinopent-3-en-1-one (2.70) 
5.505.555.60 ppm
5.
54
3
5.
54
8
9 8 7 6 5 4 3 2 1 ppm
1.
69
1.
70
3.
06
3.
45
3.
46
3.
61
3.
61
3.
65
3.
66
5.
54
5.
55
3.
22
1.
96
1.
99
2.
00
4.
00
1.
90
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
18
.0
9
37
.5
4
42
.0
1
46
.2
8
66
.7
3
66
.9
4
12
3.
66
12
8.
86
17
0.
27
O
N
O
!! !! !305!
 
Figure A1.141. 1H NMR (500 MHz, CDCl3) spectrum of (E)-N-Cyclopropyl Pent-3-enamide (2.71) 
 
Figure A1.142. 13C NMR (125.8 MHz, CDCl3) spectrum of (E)-N-Cyclopropyl Pent-3-enamide (2.71) 
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Figure A1.143. 1H NMR (500 MHz, CDCl3) spectrum of (E)-1-Morpholino-5-phenylpent-3-en-1-one 
(2.72)
 
Figure A1.144. 13C NMR (125.8 MHz, CDCl3) spectrum of  (E)-1-Morpholino-5-phenylpent-3-en-1-one 
(2.72) 
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Figure A1.145. 1H NMR (500 MHz, CDCl3) spectrum of (E)-N-Cyclopropyl 5-Phenylpent-3-enamide 
(2.73)
 
Figure A1.146. 13C NMR (125.8 MHz, CDCl3) spectrum of (E)-N-Cyclopropyl 5-Phenylpent-3-enamide 
(2.73) 
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Figure A1.147. 1H NMR (500 MHz, CDCl3) spectrum of (E)-1-Morpholino-4-phenylbut-3-en-1-one (2.74)
 
Figure A1.148. 13C NMR (125.8 MHz, CDCl3) spectrum of (E)-1-Morpholino-4-phenylbut-3-en-1-one 
(2.74) 
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Figure A1.149. 1H NMR (500 MHz, CDCl3) spectrum of N-Cyclopropyl 2-(4,4-Difluorocyclohex-1-en-1-
yl)acetamide (2.75) 
 
Figure A1.150. 13C NMR (125.8 MHz, CDCl3) spectrum of N-Cyclopropyl 2-(4,4-Difluorocyclohex-1-en-
1-yl)acetamide (2.75) 
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Figure A1.151. 1H NMR (500 MHz, acetone-d6) spectrum of  (2.76) 
 
Figure A1.152. 13C NMR (125.8 MHz, acetone-d6) spectrum of Potassium (Z)-Dec-1-en-1-
yltrifluoroborate (2.76) 
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Figure A1.153. 1H NMR (500 MHz, acetone-d6) spectrum of Potassium (E)-(6-Chlorohex-1-en-1-
yl)trifluoroborate (2.77) 
 
Figure A1.154. 13C NMR (125.8 MHz, acetone-d6) spectrum of Potassium (E)-(6-Chlorohex-1-en-1-
yl)trifluoroborate (2.77) 
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Figure A1.155. 11B NMR: (128.4 MHz, acetone-d6) spectrum of Potassium (E)-(6-Chlorohex-1-en-1-
yl)trifluoroborate (2.77) 
 
Figure A1.156. 19F NMR: (470.8 MHz, acetone-d6) spectrum of Potassium (E)-(6-Chlorohex-1-en-1-
yl)trifluoroborate (2.77) 
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Figure A1.157. 1H NMR (500 MHz, acetone-d6) spectrum of Potassium (E)-N-Benzyl-N-methyl-3-
(trifluoroborato)prop-2-en-1-amine (2.78) 
 
Figure A1.158. 13C NMR (125.8 MHz, acetone-d6) spectrum of Potassium (E)-N-Benzyl-N-methyl-3-
(trifluoroborato)prop-2-en-1-amine (2.78) 
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Figure A1.159. 11B NMR: (128.4 MHz, acetone-d6) spectrum of Potassium (E)-N-Benzyl-N-methyl-3-
(trifluoroborato)prop-2-en-1-amine (2.78) 
 
Figure A1.160. 19F NMR: (470.8 MHz, acetone-d6) spectrum of Potassium (E)-N-Benzyl-N-methyl-3-
(trifluoroborato)prop-2-en-1-amine (2.78) 
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Figure A1.161. 1H NMR (500 MHz, acetone-d6) spectrum of Potassium (E) -(3-(Benzyloxy)prop-1-en-1-
yl)trifluoroborate (2.79) 
 
Figure A1.162. 13C NMR (125.8 MHz, acetone-d6) spectrum of Potassium (E) -(3-(Benzyloxy)prop-1-en-
1-yl)trifluoroborate (2.79) 
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Figure A1.163. 11B NMR: (128.4 MHz, acetone-d6) spectrum of Potassium (E) -(3-(Benzyloxy)prop-1-en-
1-yl)trifluoroborate (2.79) 
 
Figure A1.164. 19F NMR: (470.8 MHz, acetone-d6) spectrum of Potassium (E) -(3-(Benzyloxy)prop-1-en-
1-yl)trifluoroborate (2.79) 
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Figure A1.165. 1H NMR (500 MHz, acetone-d6) spectrum of Potassium (E)-(3-((Tetrahydropyran-2-
yl)oxy)prop-1-en-1-yl)trifluoroborate (2.80) 
 
Figure A1.166. 13C NMR (125.8 MHz, acetone-d6) spectrum of Potassium (E)-(3-((Tetrahydropyran-2-
yl)oxy)prop-1-en-1-yl)trifluoroborate (2.80) 
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Figure A1.167. 11B NMR: (128.4 MHz, acetone-d6) spectrum of Potassium (E)-(3-((Tetrahydropyran-2-
yl)oxy)prop-1-en-1-yl)trifluoroborate (2.80) 
 
Figure A1.168. 19F NMR: (470.8 MHz, acetone-d6) spectrum of Potassium (E)-(3-((Tetrahydropyran-2-
yl)oxy)prop-1-en-1-yl)trifluoroborate (2.80) 
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Figure A1.169. 1H NMR (500 MHz, CDCl3) spectrum of N-Benzyl-4-phenylbut-3-ynamide (2.81) 
 
Figure A1.170. 13C NMR (125.8 MHz, CDCl3) spectrum of N-Benzyl-4-phenylbut-3-ynamide (2.81) 
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Figure A1.171. 1H NMR (500 MHz, CDCl3) spectrum of N-Benzyloct-3-ynamide (2.82) 
 
Figure A1.172. 13C NMR (125.8 MHz, CDCl3) spectrum of N-Benzyloct-3-ynamide (2.82) 
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Figure A1.173. 1H NMR (500 MHz, CDCl3) spectrum of N-Benzyl-4-cyclohexylbut-3-ynamide (2.83) 
 
 
Figure A1.174. 13C NMR (125.8 MHz, CDCl3) spectrum of N-Benzyl-4-cyclohexylbut-3-ynamide (2.83) 
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Figure A1.175. 1H NMR (500 MHz, CDCl3) spectrum of N-Benzyl-4-cyclopropylbut-3-ynamide (2.84) 
 
Figure A1.176. 13C NMR (125.8 MHz, CDCl3) spectrum of N-Benzyl-4-cyclopropylbut-3-ynamide (2.84) 
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Figure A1.177. 1H NMR (500 MHz, CDCl3) spectrum of N-Benzyl-5-phenylpent-3-ynamide (2.85) 
 
Figure A1.178. 13C NMR (125.8 MHz, CDCl3) spectrum of N-Benzyl-5-phenylpent-3-ynamide (2.85) 
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Figure A1.179. 1H NMR (500 MHz, CDCl3) spectrum of 4-([1,1'-Biphenyl]-4-yl)-N-Benzylbut-3-ynamide 
(2.86). 
 
Figure A1.180. 13C NMR (125.8 MHz, CDCl3) spectrum of 4-([1,1'-Biphenyl]-4-yl)-N-Benzylbut-3-
ynamide (2.86). 
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Figure A1.181. 1H NMR (500 MHz, CDCl3) spectrum of N-Benzyl-8-(benzyloxy)oct-3-ynamide (2.87) 
 
Figure A1.182. 13C NMR (125.8 MHz, CDCl3) spectrum of N-Benzyl-8-(benzyloxy)oct-3-ynamide (2.87) 
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Figure A1.183. 1H NMR (500 MHz, CDCl3) spectrum of 1-Morpholino-4-phenylbut-3-yn-1-one (2.88) 
 
Figure A1.184. 13C NMR (125.8 MHz, CDCl3) spectrum of 1-Morpholino-4-phenylbut-3-yn-1-one (2.88) 
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Figure A1.185. 1H NMR (500 MHz, CDCl3) spectrum of N,N-Diethyl-4-phenylbut-3-ynamide (2.89) 
 
Figure A1.186. 13C NMR (125.8 MHz, CDCl3) spectrum of N,N-Diethyl-4-phenylbut-3-ynamide (2.89) 
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Figure A1.187. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl 4-Phenylbut-3-ynoate (2.90) 
 
Figure A1.188. 13C NMR (125.8 MHz, CDCl3) spectrum of tert-Butyl 4-Phenylbut-3-ynoate (2.90) 
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Figure A1.189. 1H NMR (500 MHz, CDCl3) spectrum of Isopropyl 4-phenylbut-3-ynoate (2.91) 
 
Figure A1.190. 13C NMR (125.8 MHz, CDCl3) spectrum of Isopropyl 4-phenylbut-3-ynoate (2.91) 
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Figure A1.191. 1H NMR (500 MHz, CDCl3) spectrum of N-Cyclopropyl-7-phenylhept-3-ynamide (2.92) 
 
Figure A1.192. 13C NMR (125.8 MHz, CDCl3) spectrum of N-Cyclopropyl-7-phenylhept-3-ynamide (2.92) 
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Figure A1.193. 1H NMR (500 MHz, CDCl3) spectrum of N-Cyclopropyloct-3-ynamide (2.93) 
 
Figure A1.194. 13C NMR (125.8 MHz, CDCl3) spectrum of N-Cyclopropyloct-3-ynamide (2.93) 
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Figure A1.195. 1H NMR (500 MHz, CDCl3) spectrum of 7-Chloro-N-cyclopropylhept-3-ynamide (2.94) 
 
Figure A1.196. 13C NMR (125.8 MHz, CDCl3) spectrum of 7-Chloro-N-cyclopropylhept-3-ynamide (2.94) 
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Figure A1.197. 1H NMR (500 MHz, CDCl3) spectrum of N,4-Dicyclopropylbut-3-ynamide (2.95) 
 
Figure A1.198. 13C NMR (125.8 MHz, CDCl3) spectrum of N,4-Dicyclopropylbut-3-ynamide (2.95) 
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Figure A1.199. 1H NMR (500 MHz, CDCl3) spectrum of Benzyl oct-3-ynoate (2.96)
 
Figure A1.200. 13C NMR (125.8 MHz, CDCl3) spectrum of Benzyl oct-3-ynoate (2.96) 
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Figure A1.201. 1H NMR (500 MHz, CDCl3) spectrum of Isopropyl 7-phenylhept-3-ynoate (2.97) 
 
Figure A1.202. 13C NMR (125.8 MHz, CDCl3) spectrum of Isopropyl 7-phenylhept-3-ynoate (2.97) 
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Figure A1.203. 1H NMR (500 MHz, DMSO) spectrum of Potassium (3-phenylprop-1-yn-1-
yl)trifluoroborate (2.98) 
 
Figure A1.204. 13C NMR (125.8 MHz, DMSO) spectrum of Potassium (3-phenylprop-1-yn-1-
yl)trifluoroborate (2.98) 
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Figure A1.205. 11B NMR (128.4 MHz, DMSO) spectrum of Potassium (3-phenylprop-1-yn-1-
yl)trifluoroborate (2.98) 
 
Figure A1.206. 19F NMR (470.8 MHz, DMSO) spectrum of Potassium (3-phenylprop-1-yn-1-
yl)trifluoroborate (2.98)  
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Figure A2.1. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl 4-(4-Methoxyphenyl)piperidine-1-
carboxylate (3.1). 
 
Figure A2.2. 13C NMR (125.8 MHz, CDCl3) spectrum of tert-Butyl 4-(4-Methoxyphenyl)piperidine-1-
carboxylate (3.1). 
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Figure A2.3. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl 4-(3-Methoxyphenyl)piperidine-1-
carboxylate (3.2). 
 
Figure A2.4. 13C NMR (125.8 MHz, CDCl3) spectrum of tert-Butyl 4-(3-Methoxyphenyl)piperidine-1-
carboxylate (3.2). 
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Figure A2.5. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl 4-(2-Methoxyphenyl)piperidine-1-
carboxylate (3.3). 
 
Figure A2.6. 13C NMR (125.8 MHz, CDCl3) spectrum of tert-Butyl 4-(2-Methoxyphenyl)piperidine-1-
carboxylate (3.3). 
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Figure A2.7. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl 4-(4-Fluorophenyl)piperidine-1-
carboxylate (3.4). 
 
Figure A2.8. 13C NMR (125.8 MHz, CDCl3) spectrum of tert-Butyl 4-(4-Fluorophenyl)piperidine-1-
carboxylate (3.4). 
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Figure A2.9. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl 4-(4-Acetamidophenyl)piperidine-1-
carboxylate (3.5). 
 
Figure A2.10. 13C NMR (125.8 MHz, CDCl3) spectrum of tert-Butyl 4-(4-Acetamidophenyl)piperidine-1-
carboxylate (3.5). 
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Figure A2.11. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl 4-(4-Acetylphenyl)piperidine-1-
carboxylate (3.6). 
 
Figure A2.12. 13C NMR (125.8 MHz, CDCl3) spectrum of tert-Butyl 4-(4-Acetylphenyl)piperidine-1-
carboxylate (3.6). 
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Figure A2.13. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl 4-(Benzofuran-5-yl)piperidine-1-
carboxylate (3.7). 
 
Figure A2.14. 13C NMR (125.8 MHz, CDCl3) spectrum of tert-Butyl 4-(Benzofuran-5-yl)piperidine-1-
carboxylate (3.7). 
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Figure A2.15. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl 4-(Pyridin-3-yl)piperidine-1-
carboxylate (3.8). 
 
Figure A2.16. 13C NMR (125.8 MHz, CDCl3) spectrum of tert-Butyl 4-(Pyridin-3-yl)piperidine-1-
carboxylate (3.8). 
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Figure A2.17. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl 4-(2-Methylpyridin-3-yl)piperidine-1-
carboxylate (3.9). 
 
Figure A2.18. 13C NMR (125.8 MHz, CDCl3) spectrum of tert-Butyl 4-(2-Methylpyridin-3-yl)piperidine-
1-carboxylate (3.9). 
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Figure A2.19. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl 4-(5-Methylpyridin-2-yl)piperidine-1-
carboxylate (3.10). 
 
Figure A2.20. 13C NMR (125.8 MHz, CDCl3) spectrum of tert-Butyl 4-(5-Methylpyridin-2-yl)piperidine-
1-carboxylate (3.10). 
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Figure A2.21. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl 4-(2-Methylpyridin-4-yl)piperidine-1-
carboxylate (3.11). 
 
Figure A2.22. 13C NMR (125.8 MHz, CDCl3) spectrum of tert-Butyl 4-(2-Methylpyridin-4-yl)piperidine-
1-carboxylate (3.11). 
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Figure A2.23. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl 4-(5-Methoxypyridin-3-yl)piperidine-1-
carboxylate (3.12). 
 
Figure A2.24. 13C NMR (125.8 MHz, CD3OD) spectrum of tert-Butyl 4-(5-Methoxypyridin-3-
yl)piperidine-1-carboxylate (3.12). 
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Figure A2.25. 1H NMR (500 MHz, CDCl3) spectrum of 4-(4-Methoxyphenyl)tetrahydro-2H-pyran (3.13). 
 
Figure A2.26. 13C NMR (125.8 MHz, CDCl3) spectrum of 4-(4-Methoxyphenyl)tetrahydro-2H-pyran 
(3.13). 
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Figure A2.27. 1H NMR (500 MHz, CDCl3) spectrum of 4-(3-Methoxyphenyl)tetrahydro-2H-pyran (3.14). 
 
Figure A2.28. 13C NMR (125.8 MHz, CDCl3) spectrum of 4-(3-Methoxyphenyl)tetrahydro-2H-pyran 
(3.14). 
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Figure A2.29. 1H NMR (500 MHz, CDCl3) spectrum of 4-(2-Methoxyphenyl)tetrahydro-2H-pyran (3.15). 
 
Figure A2.30. 13C NMR (125.8 MHz, CDCl3) spectrum of 4-(2-Methoxyphenyl)tetrahydro-2H-pyran 
(3.15). 
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Figure A2.31. 1H NMR (500 MHz, CDCl3) spectrum of 1-(4-(Tetrahydro-2H-pyran-4-yl)phenyl)ethan-1-
one (3.16). 
 
Figure A2.32. 13C NMR (125.8 MHz, CDCl3) spectrum of 1-(4-(Tetrahydro-2H-pyran-4-yl)phenyl)ethan-
1-one (3.16). 
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Figure A2.33. 1H NMR (500 MHz, CDCl3) spectrum of 4-(o-Tolyl)tetrahydro-2H-pyran (3.17). 
 
Figure A2.34. 13C NMR (125.8 MHz, CDCl3) spectrum of 4-(o-Tolyl)tetrahydro-2H-pyran (3.17). 
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Figure A2.35. 1H NMR (500 MHz, CDCl3) spectrum of 4-(4-(Trifluoromethyl)phenyl)tetrahydro-2H-pyran 
(3.18). 
 
Figure A2.36. 13C NMR (125.8 MHz, CDCl3) spectrum of 4-(4-(Trifluoromethyl)phenyl)tetrahydro-2H-
pyran (3.18). 
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Figure A2.37. 1H NMR (500 MHz, acetone-d6) spectrum of 4-(Tetrahydro-2H-pyran-4-
yl)benzenesulfonamide (3.19). 
 
Figure A2.38. 13C NMR (125.8 MHz, acetone-d6) spectrum of 4-(Tetrahydro-2H-pyran-4-
yl)benzenesulfonamide (3.19). 
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Figure A2.39. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl 3-(4-Methoxyphenyl)piperidine-1-
carboxylate (3.20). 
 
Figure A2.40. 13C NMR (125.8 MHz, CDCl3) spectrum of tert-Butyl 3-(4-Methoxyphenyl)piperidine-1-
carboxylate (3.20). 
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Figure A2.41. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl 3-(4-Methoxyphenyl)pyrrolidine-1-
carboxylate (3.21). 
 
Figure A2.42. 13C NMR (125.8 MHz, CDCl3) spectrum of tert-Butyl 3-(4-Methoxyphenyl)pyrrolidine-1-
carboxylate (3.21). 
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Figure A2.43. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl 3-(4-Methoxyphenyl)azetidine-1-
carboxylate (3.22). 
 
Figure A2.44. 13C NMR (125.8 MHz, CDCl3) spectrum of tert-Butyl 3-(4-Methoxyphenyl)azetidine-1-
carboxylate (3.22). 
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Figure A2.45. 1H NMR (500 MHz, CDCl3) spectrum of 3-(4-Methoxyphenyl)tetrahydro-2H-pyran (3.23). 
 
Figure A2.46. 13C NMR (125.8 MHz, CDCl3) spectrum of 3-(4-Methoxyphenyl)tetrahydro-2H-pyran 
(3.23). 
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Figure A2.47. 1H NMR (500 MHz, CDCl3) spectrum of 3-(4-Methoxyphenyl)tetrahydrofuran (3.24). 
 
Figure A2.48. 13C NMR (125.8 MHz, CDCl3) spectrum of 3-(4-Methoxyphenyl)tetrahydrofuran (3.24). 
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Figure A2.49. 1H NMR (500 MHz, CDCl3) spectrum of 3-(4-Methoxyphenyl)oxetane (3.25). 
 
Figure A2.50. 13C NMR (125.8 MHz, CDCl3) spectrum of 3-(4-Methoxyphenyl)oxetane (3.25). 
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Figure A2.51. 1H NMR (500 MHz, CDCl3) spectrum of 1-(4-(Tetrahydrofuran-3-yl)phenyl)ethan-1-one 
(3.26). 
 
Figure A2.52. 13C NMR (125.8 MHz, CDCl3) spectrum of 1-(4-(Tetrahydrofuran-3-yl)phenyl)ethan-1-one 
(3.26). 
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Figure A2.53. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl 4-(Quinolin-3-yl)piperidine-1-
carboxylate (3.27). 
 
Figure A2.54. 13C NMR (125.8 MHz, CDCl3) spectrum of tert-Butyl 4-(Quinolin-3-yl)piperidine-1-
carboxylate (3.27). 
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Figure A2.55. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl 4-(1H-Indol-5-yl)piperidine-1-
carboxylate (3.28). 
 
Figure A2.56. 13C NMR (125.8 MHz, CDCl3) spectrum of tert-Butyl 4-(1H-Indol-5-yl)piperidine-1-
carboxylate (3.28). 
-112 11 10 9 8 7 6 5 4 3 2 1 0 ppm
1.
50
1.
50
1.
68
1.
68
1.
70
1.
71
1.
73
1.
73
1.
86
1.
88
2.
70
2.
71
2.
71
2.
72
2.
73
2.
74
2.
75
2.
76
2.
76
2.
83
4.
26
6.
50
6.
50
6.
51
7.
04
7.
04
7.
06
7.
06
7.
18
7.
18
7.
19
7.
32
7.
34
7.
46
8.
23
9.
62
2.
22
2.
10
1.
23
1.
97
2.
01
1.
02
1.
07
1.
06
1.
06
1.
06
1.
00
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
28
.7
2
34
.0
8
42
.9
9
44
.7
6
79
.6
1
10
2.
35
11
1.
21
11
8.
24
12
1.
47
12
4.
81
12
8.
21
13
4.
85
13
7.
44
15
5.
21
BocN
N
H
! 367! !
 
Figure A2.57. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl 4-(Isoquinolin-4-yl)piperidine-1-
carboxylate (3.29). 
 
Figure A2.58. 13C NMR (125.8 MHz, CDCl3) spectrum of tert-Butyl 4-(Isoquinolin-4-yl)piperidine-1-
carboxylate (3.29). 
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Figure A2.59. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl 4-(Quinoxalin-6-yl)piperidine-1-
carboxylate (3.30). 
 
Figure A2.60. 13C NMR (125.8 MHz, CDCl3) spectrum of tert-Butyl 4-(Quinoxalin-6-yl)piperidine-1-
carboxylate (3.30). 
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Figure A2.61. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl 4-(3-(1H-Pyrazol-5-
yl)phenyl)piperidine-1-carboxylate (3.31). 
 
Figure A2.62. 13C NMR (125.8 MHz, CDCl3) spectrum of tert-Butyl 4-(3-(1H-Pyrazol-5-
yl)phenyl)piperidine-1-carboxylate (3.31). 
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Figure A2.63. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl 4-(4-(1,3,4-Oxadiazol-2-
yl)phenyl)piperidine-1-carboxylate (3.32). 
 
Figure A2.64. 13C NMR (125.8 MHz, CDCl3) spectrum of tert-Butyl 4-(4-(1,3,4-Oxadiazol-2-
yl)phenyl)piperidine-1-carboxylate (3.32). 
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Figure A2.65. 1H NMR (500 MHz, CDCl3) spectrum of 3-(Tetrahydro-2H-pyran-4-yl)quinoline (3.33). 
 
Figure A2.66 13C NMR (125.8 MHz, CDCl3) spectrum of 3-(Tetrahydro-2H-pyran-4-yl)quinoline (3.33). 
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Figure A2.67. 1H NMR (500 MHz, CDCl3) spectrum of 5-(Tetrahydro-2H-pyran-4-yl)-1H-pyrrolo[2,3-
b]pyridine (3.34). 
 
Figure A2.68. 13C NMR (125.8 MHz, CDCl3) spectrum of 5-(Tetrahydro-2H-pyran-4-yl)-1H-pyrrolo[2,3-
b]pyridine (3.34). 
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Figure A2.69. 1H NMR (500 MHz, CDCl3) spectrum of 5-(Tetrahydro-2H-pyran-4-yl)benzofuran (3.35). 
 
Figure A2.70. 13C NMR (125.8 MHz, CDCl3) spectrum of 5-(Tetrahydro-2H-pyran-4-yl)benzofuran (3.35). 
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Figure A2.71. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl 3-(Quinolin-3-yl)azetidine-1-
carboxylate (3.36). 
 
Figure A2.72. 13C NMR (125.8 MHz, CDCl3) spectrum of tert-Butyl 3-(Quinolin-3-yl)azetidine-1-
carboxylate (3.36). 
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Figure A2.73. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl 5-(Tetrahydro-2H-pyran-4-yl)-1H-
indole-1-carboxylate (3.37). 
 
Figure A2.74. 13C NMR (125.8 MHz, CDCl3) spectrum tert-Butyl 5-(Tetrahydro-2H-pyran-4-yl)-1H-
indole-1-carboxylate (3.37). 
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Figure A2.75. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl 5-(Tetrahydro-2H-pyran-3-yl)-1H-
indole-1-carboxylate (3.38). 
 
Figure A2.76. 13C NMR (125.8 MHz, CDCl3) spectrum of tert-Butyl 5-(Tetrahydro-2H-pyran-3-yl)-1H-
indole-1-carboxylate (3.38). 
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Figure A2.77. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl 5-(Tetrahydrofuran-3-yl)-1H-indole-1-
carboxylate (3.39). 
 
Figure A2.78. 13C NMR (125.8 MHz, CDCl3) spectrum of tert-Butyl 5-(Tetrahydrofuran-3-yl)-1H-indole-
1-carboxylate (3.39). 
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Figure A2.79. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl 5-(Oxetan-3-yl)-1H-indole-1-
carboxylate (3.40). 
 
Figure A2.80. 13C NMR (125.8 MHz, CDCl3) spectrum of tert-Butyl 5-(Oxetan-3-yl)-1H-indole-1-
carboxylate (3.40). 
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Figure A2.81. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl 5-(1-(tert-Butoxycarbonyl)piperidin-4-
yl)-1H-indole-1-carboxylate (3.41). 
 
Figure A2.82. 13C NMR (125.8 MHz, CDCl3) spectrum of tert-Butyl 5-(1-(tert-Butoxycarbonyl)piperidin-
4-yl)-1H-indole-1-carboxylate (3.41). 
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Figure A2.83. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl 5-(1-(tert-Butoxycarbonyl)piperidin-3-
yl)-1H-indole-1-carboxylate (3.42). 
 
Figure A2.84. 13C NMR (125.8 MHz, CDCl3) spectrum of tert-Butyl 5-(1-(tert-Butoxycarbonyl)piperidin-
3-yl)-1H-indole-1-carboxylate (3.42). 
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Figure A2.85. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl 5-(1-(tert-Butoxycarbonyl)pyrrolidin-3-
yl)-1H-indole-1-carboxylate (3.43). 
 
Figure A2.86. 13C NMR (125.8 MHz, CDCl3) spectrum of tert-Butyl 5-(1-(tert-Butoxycarbonyl)pyrrolidin-
3-yl)-1H-indole-1-carboxylate (3.43). 
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Figure A2.87. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl 5-(1-(tert-Butoxycarbonyl)azetidin-3-
yl)-1H-indole-1-carboxylate (3.44). 
 
Figure A2.88. 13C NMR (125.8 MHz, CDCl3) spectrum of tert-Butyl 5-(1-(tert-Butoxycarbonyl)azetidin-3-
yl)-1H-indole-1-carboxylate (3.44). 
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Figure A2.89. 1H NMR (500 MHz, CDCl3) of 3-(4-(N-Boc)-piperidinyl)-2-phenyl-2,1-
borazaronaphthalene (3.45) 
Figure A2.90. 13C NMR (125.8 MHz, CDCl3) of 3-(4-(N-Boc)-piperidinyl)-2-phenyl-2,1-
borazaronaphthalene (3.45) 
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Figure A2.91. 11B NMR (128.38 MHz, CDCl3) of 3-(4-(N-Boc)-piperidinyl)-2-phenyl-2,1-
borazaronaphthalene (3.45) 
Figure A2.92. 1H NMR (500 MHz, CDCl3) of 3-(4-(N-Boc)-piperidinyl)-2-(4-fluorophenyl)-2,1-
borazaronaphthalene (3.46) 
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Figure A2.93. 13C NMR (125.8 MHz, CDCl3) of 3-(4-(N-Boc)-piperidinyl)-2-(4-fluorophenyl)-2,1-
borazaronaphthalene (3.46) 
Figure A2.94. 11B NMR (128.38 MHz, CDCl3) of 3-(4-(N-Boc)-piperidinyl)-2-(4-fluorophenyl)-2,1-
borazaronaphthalene (3.46) 
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Figure A2.95. 1H NMR (500 MHz, CDCl3) of 3-(4-(N-Boc)-piperidinyl)-2-(3-methoxyphenyl)-2,1-
borazaronaphthalene (3.47) 
Figure A2.96. 13C NMR (125.8 MHz, CDCl3) of 3-(4-(N-Boc)-piperidinyl)-2-(3-methoxyphenyl)-2,1-
borazaronaphthalene (3.47) 
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Figure A2.97. 11B NMR (128.38 MHz, CDCl3) of 3-(4-(N-Boc)-piperidinyl)-2-(3-methoxyphenyl)-2,1-
borazaronaphthalene (3.47) 
Figure A2.98. 1H NMR (500 MHz, CDCl3) of 3-(4-(N-Boc)-piperidinyl)-2-(2,4-difluorophenyl)-2,1-
borazaronaphthalene (3.48) 
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Figure A2.99. 13C NMR (125.8 MHz, CDCl3) of 3-(4-(N-Boc)-piperidinyl)-2-(2,4-difluorophenyl)-2,1-
borazaronaphthalene (3.48) 
 
Figure A2.100. 11B NMR (128.38 MHz, CDCl3) of 3-(4-(N-Boc)-piperidinyl)-2-(2,4-difluorophenyl)-2,1-
borazaronaphthalene (3.48)
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Figure A2.101. 1H NMR (500 MHz, CDCl3) of 3-(4-(N-Boc)-piperidinyl)-2-(3-carbomethoxyphenyl)-2,1-
borazaronaphthalene (3.49) 
Figure A2.102. 13C NMR (125.8 MHz, CDCl3) of 3-(4-(N-Boc)-piperidinyl)-2-(3-carbomethoxyphenyl)-
2,1-borazaronaphthalene (3.49) 
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Figure A2.103. 11B NMR (128.38 MHz, CDCl3) of 3-(4-(N-Boc)-piperidinyl)-2-(3-carbomethoxyphenyl)-
2,1-borazaronaphthalene (3.49) 
Figure A2.104. 1H NMR (500 MHz, CDCl3) of 3-(4-(N-Boc)-piperidinyl)-2-(4-dibenzothienyl)-2,1-
borazaronaphthalene (3.50)
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Figure A2.105. 13C NMR (125.8 MHz, CDCl3) of 3-(4-(N-Boc)-piperidinyl)-2-(4-dibenzothienyl)-2,1-
borazaronaphthalene (3.50) 
Figure A2.106. 11B NMR (128.38 MHz, CDCl3) of 3-(4-(N-Boc)-piperidinyl)-2-(4-dibenzothienyl)-2,1-
borazaronaphthalene (3.50) 
B
H
N
N
Boc
S
! 392! !
Figure A2.107. 1H NMR (500 MHz, CDCl3) of 3-(4-(N-Boc)-piperidinyl)-2-(4-dibenzofuranyl)-2,1-
borazaronaphthalene (3.51) 
Figure A2.108. 13C NMR (125.8 MHz, CDCl3) of 3-(4-(N-Boc)-piperidinyl)-2-(4-dibenzofuranyl)-2,1-
borazaronaphthalene (3.51) 
B
H
N
N
Boc
O
! 393! !
Figure A2.109. 11B NMR (128.38 MHz, CDCl3) of 3-(4-(N-Boc)-piperidinyl)-2-(4-dibenzofuranyl)-2,1-
borazaronaphthalene (3.51) 
Figure A2.110. 1H NMR (500 MHz, CDCl3) of 3-(4-(N-Boc)-piperidinyl)-2-methyl-2,1-
borazaronaphthalene (3.52) 
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Figure A2.111. 13C NMR (125.8 MHz, CDCl3) of 3-(4-(N-Boc)-piperidinyl)-2-methyl-2,1-
borazaronaphthalene (3.52) 
Figure A2.112. 11B NMR (128.38 MHz, CDCl3) of 3-(4-(N-Boc)-piperidinyl)-2-methyl-2,1-
borazaronaphthalene (3.52) 
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Figure A2.113. 1H NMR (500 MHz, CDCl3) of 3-(4-(N-Boc)-piperidinyl)-2-cyclobutyl-2,1-
borazaronaphthalene (3.53) 
Figure A2.114. 13C NMR (125.8 MHz, CDCl3) of 3-(4-(N-Boc)-piperidinyl)-2-cyclobutyl-2,1-
borazaronaphthalene (3.53) 
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Figure A2.115. 11B NMR (128.38 MHz, CDCl3) of 3-(4-(N-Boc)-piperidinyl)-2-cyclobutyl-2,1-
borazaronaphthalene (3.53) 
Figure A2.116. 1H NMR (500 MHz, CDCl3) of 3-(4-(N-Boc)-piperidinyl)-2-cyclopropyl-2,1-
borazaronaphthalene (3.54) 
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Figure A2.117. 13C NMR (125.8 MHz, CDCl3) of 3-(4-(N-Boc)-piperidinyl)-2-cyclopropyl-2,1-
borazaronaphthalene (3.54) 
Figure A2.118. 11B NMR (128.38 MHz, CDCl3) of 3-(4-(N-Boc)-piperidinyl)-2-cyclopropyl-2,1-
borazaronaphthalene (3.54)
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Figure A2.119. 1H NMR (500 MHz, CDCl3) of 1-Benzyl-3-(4-(N-Boc)-piperidinyl)-2-methyl-2,1-
borazaronaphthalene (3.55)
Figure A2.120. 13C NMR (125.8 MHz, CDCl3) of 1-Benzyl-3-(4-(N-Boc)-piperidinyl)-2-methyl-2,1-
borazaronaphthalene (3.55) 
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Figure A2.121. 11B NMR (128.38 MHz, CDCl3) of 1-Benzyl-3-(4-(N-Boc)-piperidinyl)-2-methyl-2,1-
borazaronaphthalene (3.55) 
Figure A2.122. 1H NMR (500 MHz, CDCl3) of 1-Allyl-3-(4-(N-Boc)-piperidinyl)-2-methyl-2,1-
borazaronaphthalene (3.56) 
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Figure A2.123. 13C NMR (125.8 MHz, CDCl3) of 1-Allyl-3-(4-(N-Boc)-piperidinyl)-2-methyl-2,1-
borazaronaphthalene (3.56) 
Figure A2.124. 11B NMR (128.38 MHz, CDCl3) of 1-Allyl-3-(4-(N-Boc)-piperidinyl)-2-methyl-2,1-
borazaronaphthalene (3.56) 
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Figure A2.125. 1H NMR (500 MHz, CDCl3) of 1-Allyl-3-(4-(N-Boc)--piperidinyl)-2-phenyl-2,1-
borazaronaphthalene (3.57) 
Figure A2.126. 13C NMR (125.8 MHz, CDCl3) of 1-Allyl-3-(4-(N-Boc)-piperidinyl)-2-phenyl-2,1-
borazaronaphthalene (3.57) 
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Figure A2.127. 11B NMR (128.38 MHz, CDCl3) of 1-Allyl-3-(4-(N-Boc)-piperidinyl)-2-phenyl-2,1-
borazaronaphthalene (3.57) 
Figure A2.128. 1H NMR (500 MHz, CDCl3) of 3-(3-(N-Boc)-azetindyl)-2-phenyl-2,1-borazaronaphthalene 
(3.58) 
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Figure A2.129. 13C NMR (125.8 MHz, CDCl3) of 3-(3-(N-Boc)-azetidinyl)-2-phenyl-2,1-
borazaronaphthalene (3.58) 
Figure A2.130. 11B NMR (128.38 MHz, CDCl3) of 3-(3-(N-Boc)-azetidinyl)-2-phenyl-2,1-
borazaronaphthalene (3.58) 
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Figure A2.131. 1H NMR (500 MHz, CDCl3) of 2-Phenyl-3-(4-tetrahydro-2H-pyranyl)-2,1-
borazaronaphthalene (3.59) 
Figure A2.132. 13C NMR (125.8 MHz, CDCl3) of 2-Phenyl-3-(4-tetrahydro-2H-pyranyl)-2,1-
borazaronaphthalene (3.59) 
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Figure A2.133. 11B NMR (128.38 MHz, CDCl3) of 2-Phenyl-3-(4-tetrahydro-2H-pyranyl)-2,1-
borazaronaphthalene (3.59) 
Figure A2.134. 1H NMR (500 MHz, CDCl3) of 2-Phenyl-3-(3-tetrahydrofuranyl)-2,1-borazaronaphthalene 
(3.60) 
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Figure A2.135. 13C NMR (125.8 MHz, CDCl3) of 2-Phenyl-3-(3-tetrahydrofuranyl)-2,1-
borazaronaphthalene (3.60) 
Figure A2.136. 11B NMR (128.38 MHz, CDCl3) of 2-Phenyl-3-(3-tetrahydrofuranyl)-2,1-
borazaronaphthalene (3.60) 
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Figure A2.137. 1H NMR (500 MHz, CDCl3) of 3-(3-Oxetanyl)-2-phenyl-2,1-borazaronaphthalene (3.61) 
Figure A2.138. 13C NMR (125.8 MHz, CDCl3) of 3-(3-Oxetanyl)-2-phenyl-2,1-borazaronaphthalene (3.61) 
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Figure A2.139. 11B NMR (128.38 MHz, CDCl3) of 3-(3-Oxetanyl)-2-phenyl-2,1-borazaronaphthalene 
(3.61) 
 
Figure A2.140. 1H NMR (500 MHz, CDCl3) of 3-Cyclohexyl-2-phenyl-2,1-borazaronaphthalene (3.62) 
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Figure A2.141. 13C NMR (125.8 MHz, CDCl3) of 3-Cyclohexyl-2-phenyl-2,1-borazaronaphthalene (3.62) 
Figure A2.142. 11B NMR (128.38 MHz, CDCl3) of 3-Cyclohexyl-2-phenyl-2,1-borazaronaphthalene (3.62) 
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Figure A2.143. 1H NMR (500 MHz, CDCl3) of 3-Butyl-2-phenyl-2,1-borazaronaphthalene (3.63) 
 
Figure A2.144. 13C NMR (125.8 MHz, CDCl3) of 3-Butyl-2-phenyl-2,1-borazaronaphthalene (3.63) 
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Figure A2.145. 11B NMR (128.38 MHz, CDCl3) of 3-Butyl-2-phenyl-2,1-borazaronaphthalene (3.63) 
 
Figure A2.146. 1H NMR (500 MHz, CDCl3) of 4-(2-Phenyl-2,1-borazaronaphthalene)butyl acetate (3.64) 
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Figure A2.147. 13C NMR (125.8 MHz, CDCl3) of 4-(2-Phenyl-2,1-borazaronaphthalene)butyl acetate 
(3.64) 
Figure A2.148. 11B NMR (128.38 MHz, CDCl3) of 4-(2-Phenyl-2,1-borazaronaphthalene)butyl acetate 
(3.64) 
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Figure A2.149. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl 5-(1-(tert-Butoxycarbonyl)piperidin-4-
yl)-1H-indole-1-carboxylate (3.65). 
Figure A2.150. 13C NMR (125.8 MHz, CDCl3) spectrum of  tert-Butyl 5-(1-(tert-
Butoxycarbonyl)piperidin-4-yl)-1H-indole-1-carboxylate (3.65). 
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Figure A2.151. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl 5-(Tetrahydro-2H-pyran-4-yl)-1H-
indole-1-carboxylate (3.66). 
 
Figure A2.152. 13C NMR (125.8 MHz, CDCl3) spectrum of  tert-Butyl 5-(Tetrahydro-2H-pyran-4-yl)-1H-
indole-1-carboxylate (3.66). 
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Figure A2.153, 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl 5-(Tetrahydrofuran-3-yl)-1H-indole-1-
carboxylate (3.67). 
 
Figure A2.154, 13C NMR (125.8 MHz, CDCl3) spectrum of tert-Butyl 5-(Tetrahydrofuran-3-yl)-1H-indole-
1-carboxylate (3.67). 
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Figure A2.155. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl 5-(1-Benzylpiperidin-4-yl)-1H-indole-
1-carboxylate (3.68). 
 
Figure A2.156. 13C NMR (125.8 MHz, CDCl3) spectrum of tert-Butyl 5-(1-Benzylpiperidin-4-yl)-1H-
indole-1-carboxylate (3.68). 
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Figure A2.157. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl 5-(1-(tert-Butoxycarbonyl)pyrrolidin-
3-yl)-1H-indole-1-carboxylate (3.69). 
 
Figure A2.158. 13C NMR (125.8 MHz, CD3OD) spectrum of  tert-Butyl 5-(1-(tert-
Butoxycarbonyl)pyrrolidin-3-yl)-1H-indole-1-carboxylate (3.69). 
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Figure A2.159. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl 5-(1-(tert-Butoxycarbonyl)piperidin-3-
yl)-1H-indole-1-carboxylate (3.70). 
 
Figure A2.160. 13C NMR (125.8 MHz, CDCl3) spectrum of tert-Butyl 5-(1-(tert-
Butoxycarbonyl)piperidin-3-yl)-1H-indole-1-carboxylate (3.70). 
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Figure A2.161. 1H NMR (500 MHz, CDCl3) spectrum of  tert-Butyl 4-(Quinolin-3-yl)piperidine-1-
carboxylate (3.71). 
 
Figure A2.162. 13C NMR (125.8 MHz, CDCl3) spectrum of tert-Butyl 4-(Quinolin-3-yl)piperidine-1-
carboxylate (3.71). 
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Figure A2.163. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl 4-(2-Methylpyridin-4-yl)piperidine-1-
carboxylate (3.72). 
 
Figure A2.164. 13C NMR (125.8 MHz, CDCl3) spectrum of tert-Butyl 4-(2-Methylpyridin-4-yl)piperidine-
1-carboxylate (3.72). 
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Figure A2.165. 1H NMR (500 MHz, CDCl3) spectrum of  tert-Butyl 4-(Benzo[b]thiophen-2-yl)piperidine-
1-carboxylate (3.73). 
 
Figure A2.166. 13C NMR (125.8 MHz, CDCl3) spectrum of tert-Butyl 4-(Benzo[b]thiophen-2-
yl)piperidine-1-carboxylate (3.73). 
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Figure A2.167. 1H NMR (500 MHz, CDCl3) spectrum of 5-(Tetrahydro-2H-pyran-4-yl)benzofuran (3.74). 
 
Figure A2.168. 13C NMR (125.8 MHz, CDCl3) spectrum of 5-(Tetrahydro-2H-pyran-4-yl)benzofuran 
(3.74). 
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Figure A2.169. 1H NMR (500 MHz, CDCl3) spectrum of 2-(4-(Tetrahydro-2H-pyran-4-yl)phenyl)-1,3,4-
oxadiazole (3.75). 
 
Figure A2.170. 13C NMR (125.8 MHz, CDCl3) spectrum of 2-(4-(Tetrahydro-2H-pyran-4-yl)phenyl)-
1,3,4-oxadiazole (3.75). 
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Figure A2.171. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl 4-(4-Acetamidophenyl)piperidine-1-
carboxylate (3.76). 
 
Figure A2.172. 13C NMR (125.8 MHz, CDCl3) spectrum of tert-Butyl 4-(4-Acetamidophenyl)piperidine-1-
carboxylate (3.76). 
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Figure A2.173. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl 4-(4-Fluorophenyl)piperidine-1-
carboxylate (3.77). 
 
Figure A2.174. 13C NMR (125.8 MHz, CDCl3) spectrum of tert-Butyl 4-(4-Fluorophenyl)piperidine-1-
carboxylate (3.77). 
-112 11 10 9 8 7 6 5 4 3 2 1 0 ppm
1.
48
1.
56
1.
59
1.
62
1.
78
1.
81
2.
62
2.
79
4.
24
6.
99
7.
15
9.
21
2.
49
2.
05
0.
98
2.
05
2.
00
1.
94
2.
00
210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 ppm
28
.6
1
33
.4
8
42
.1
2
44
.4
1
79
.5
9
11
5.
26
11
5.
42
12
8.
21
12
8.
27
14
1.
59
14
1.
62
15
4.
96
16
0.
55
16
2.
49
BocN
F
! 426! !
 
Figure A2.175. 1H NMR (500 MHz, CDCl3) spectrum of tert-Butyl 4-(2-Methoxyphenyl)piperidine-1-
carboxylate (3.78). 
 
Figure A2.176. 13C NMR (125.8 MHz, CDCl3) spectrum of tert-Butyl 4-(2-Methoxyphenyl)piperidine-1-
carboxylate (3.78). 
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Figure A2.177. 1H NMR (500 MHz, CDCl3) spectrum of 1-(4-(Tetrahydro-2H-pyran-4-yl)phenyl)ethan-1-
one (3.79). 
 
Figure A2.178. 13C NMR (125.8 MHz, CDCl3) spectrum of 1-(4-(Tetrahydro-2H-pyran-4-yl)phenyl)ethan-
1-one (3.79)  
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